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Abstract 
 
Micro-RNAs (miRNAs) are a class of non-coding RNA which post-transcriptionally regulate 
gene expression. Epstein-Barr Virus (EBV) can transform resting B-cells in vitro to establish 
continuously proliferating lymphoblastoid cell lines (LCLs) and is aetiologically linked to 
certain lymphomas. Little is known about the contribution of miRNAs to the transformation 
of B cells. We initially examined the regulation of the oncogenic miR-155, which is highly 
expressed in Hodgkin’s lymphomas but was reportedly absent in Burkitt’s lymphoma. We 
found that miR-155 was up-regulated by EBV-LMP1 expression, and that a reported defect of 
miR-155 processing in Burkitt’s lymphoma was a misinterpretation of data.  Next, to identify 
cellular miRNAs and genes modulated during EBV-induced transformation, we compared the 
expression profiles of resting B cells and B cells either infected with EBV or stimulated to 
proliferate with CD40L and IL4. This revealed that a large proportion of miRNAs and genes 
differentially regulated by EBV and not by CD40L/IL4 were modulated by EBV interaction 
with its CD21 receptor complex, but these changes were maintained or amplified in LCLs; 
and included a set of tumours suppressor genes selectively down-regulated by EBV. In 
addition, bioinformatics analysis indicated that EBV modulates the expression of multiple 
miRNAs predicted to target the same cellular genes.  
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1. Introduction 
 
1.1 Epstein-Barr virus (EBV) history 
Epstein-Barr virus was identified in 1958 following the observation by surgeon Dennis 
Burkitt that a common childhood cancer in equatorial Africa was endemic to areas with 
specific climatic conditions and geographical locations [1]. This led him to hypothesise that 
the cancer may be caused by an insect-borne vector [2]. Using electron microscopy it was 
subsequently shown by Epstein, Anchong and Barr, that herpesvirus-like particles existed in a 
cell line established from a Burkitt lymphoma (BL) biopsy [3]; and formal identification of a 
new herpesvirus followed in 1965 [4]. Whilst this discovery was consistent with the 
hypothesis of an insect-borne infectious agent, it later transpired that it was not EBV itself 
that was carried by the insect but another co-factor in the development of BL, the malaria 
plasmodium falciparum parasite [5, 6]. Serological assays against the viral capsid antigen 
(VCA) were developed and indicated that greater than 90% of the adult population had 
antibodies against EBV and that the virus was associated with infectious mononucleosis (IM) 
[7, 8], which is now known to be a clinical manifestation of primary EBV infection. The 
growth transforming properties of EBV were identified after the virus was shown to induce 
proliferation in peripheral blood leukocytes in vitro and induce tumours in non-human 
primates [9, 10].  Thus, EBV was the first virus associated with the pathogenesis of a human 
cancer, establishing it as a ubiquitous oncogenic herpesvirus.  
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1.2 Classification of EBV 
EBV (also known as human herpesvirus 4 (HHV4)) is a member of the Herpesviradae family 
[11]. This viral family is sub-divided into alpha, beta and gamma members based on genome 
homology. EBV is a member of the gamma sub-family which is further divided into two 
genera: gamma 1, also known as lymphocryptoviruses (LCV), and gamma 2, also known as 
rhadinoviruses. EBV is the prototype LCV and the only human virus of this genus.  LCVs are 
exclusively found in primate species and are predominantly B lymphotropic. 
 
1.3 EBV structure 
EBV has a glycoprotein (gp)-rich envelope which surrounds a nucleocapsid composed of 162 
capsomers and a protein tegument. The nucleocapsid encases a 184 kilobase pair (kbp) linear, 
double-stranded DNA genome wrapped around a toroid-shaped protein core [4, 12]. The 
genome is divided into short and long, largely unique sequence domains (US and UL) by 
reiterated 3kbp internal direct repeats (IR1) [13, 14]. The ends of the linear genome are 
flanked by 4-12 copies of tandem, reiterated, 500bp direct repeats called terminal repeats 
(TRs), which enable circularisation of the viral DNA into episomes [15-17]. The number of 
TRs can be an indicator of clonality as the precise number of TRs is determined during viral 
replication; therefore all EBV latently infected progeny cells will contain the same number of 
TRs as the originally infected parental cell [18].  
EBV was the first herpesvirus to have its genome cloned and sequenced [19-21]. This was 
achieved using BamHI (and EcoR1) restriction fragments from the B95.8 EBV strain, which 
consequently defined the nomenclature used to describe the viral genome [19]. BamHI 
fragments were assigned a letter from A-Z in descending order of size. Open reading frames  
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Figure 1.1: Schematic map of the EBV genome divided into BamHI digest fragments. 
Arrows represent the latent promoters, filled boxes represent the genes encoding the latent 
proteins and EBERS. Grey boxes represent the terminal repeats (TRs) 
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(ORFs) were stated relative to their BamHI fragment, direction of transcription and position 
relative to other ORFs located on the same fragment. For example: BHRF1 is located on the 
BamHI H fragment, in the first rightward open reading frame. 
All EBV strains have essentially the same genome organisation and most of the sequences are 
highly conserved. However, the two main subtypes of EBV, type 1 and type 2, differ 
primarily in the genes encoding the nuclear antigens (EBNAs) –LP, 2, 3A, 3B and 3C [22, 
23]. The origins of the sequence variations between type 1 and type 2 EBV in EBNA2 and the 
EBNA3A, B and C antigens remains a mystery, with predicted differences in amino acid 
sequences of 47%, 16%, 20% and 28% respectively [24]. The two EBV subtypes can be 
further subdivided into different EBV strains according to local changes at polymorphic sites, 
such as the number of repeat sequences in several of the latent genes [25]. Many of the local 
polymorphisms distinguish between EBV strains of different geographical origin, consistent 
with a slow evolutionary drift of the virus in physically separated human populations.  Type 1 
EBV is epidemiologically dominant, except in areas endemic for BL (equatorial Africa and 
New Guinea) where infection with type 2 EBV is almost as prevalent as type 1 [26-31]. 
 
1.4 EBV tissue tropism 
EBV is a B lymphotropic virus and its ability to effectively target B cells is determined by the 
expression of the C3d complement component receptor, CD21; this is the major viral receptor 
and it is widely expressed on B cells but its expression is lost upon terminal differentiation 
[32-35]. Thus, EBV is able to bind to and infect B cells at most stages of development with 
the exception of plasma cells. Infection of B cells is generally ‘non-productive’ for lytic virus 
replication, or ‘latent’, although lytic infection can occur in B cells [36]. There is also 
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evidence of rare lytic replication in mucosal epithelial cells of non-immuno-compromised 
patients [37]. The ability of EBV to infect CD21-negative epithelial cells is evident from the 
association of EBV with nasopharyngeal carcinoma (NPC) [38] and is supported by in vitro 
experiments which have demonstrated that EBV bound to the surface of B cells can 
efficiently infect epithelial cells by a process termed transfer infection [39, 40]. In addition, it 
is apparent from the broad range of malignancies associated with EBV that the virus is 
capable of infecting other cell types, including T cells [41] and natural killer (NK) cells [42, 
43]. The degree to which CD21 negative epithelial, NK and T cells are normally infected in 
vivo, in the healthy immunocompetent host, and what role, if any, they play in the course of 
EBV infection and persistence is not clear.    
 
1.5 Alternate patterns of latent infection 
There are four well characterised patterns of EBV latent gene expression, latency III, II, I and 
0. Figure 1.2 is adapted from Fields Virology [44] and shows the distinct patterns of viral 
gene expression observed during latency. The four latency states of EBV are not prescriptive 
as EBV latent gene expression in tumours can be variable and may not strictly adhere to any 
of the four categories of viral latency [45, 46] .  
1.5.1 Latency III 
Infection of resting B cells in vitro results in a pattern of viral latent gene expression termed 
latency III. This pattern of viral gene expression involves the expression of 9 or more latent 
genes encoding: each of six nuclear antigens, EBNAs 1, 2, -LP, 3A, 3B and 3C from the viral 
promoters Cp or Wp; the three latent membrane proteins (LMPs) 1, 2A and 2B are expressed 
from their own promoters. In addition, the RNA polymerase III-driven non-coding  
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Figure 1.2: Schematic diagram of EBV latent transcription in different forms of latency. 
Adapted from Fields et al 2001 [44]. Boxes represent EBV latent ORFs; shaded boxes 
represent ORFs which are translated into viral protein; open boxes represent non-coding viral 
RNAs. A linear EBV genome is shown above with the relative positions of the latent genes 
and TRs marked.  
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EBER RNAs are expressed [47] along with the EBV encoded miRNAs: the BamHI A 
rightward transcripts (BARTs) and the BHRF1 miRNAs [48]. The latency III pattern of gene 
expression is also known as the growth-transforming programme (more details in section 
1.9.2) as it transforms resting B cells into proliferating blasts (‘lymphoblastoid’) with a 
phenotype similar to that of B cells proliferating in response to antigen. The latency III 
transcripts are also detected in the tonsils of patients with IM, suggesting that this pattern of 
viral latent gene expression also occurs during primary infection in vivo [49]. 
1.5.2 Latency II 
Latency II is a restricted pattern of viral latent gene expression in which the following latent 
genes are expressed: EBNA1 along with the EBERS, as well as the BARTs and BART 
miRNAs. Variable expression of the LMPs 1, 2A and 2B are also seen from EBNA2 
independent promoters in the BamHI N region of the genome [50-53]. The viral promoters Cp 
and Wp are silent in latency II infected cells and selective expression of EBNA1 initiates from 
an alternative viral promoter Qp, located downstream of the BamHI Q fragment [54]. Latency 
II was originally identified in the epithelial tumour NPC [55, 56] and was subsequently also 
found to be expressed in the Reed-Sternberg cells (HRS) of EBV positive Hodgkin’s 
Lymphoma (HL) [57] . A latency II pattern of EBV gene expression has also been detected in 
the tonsillar GC B cells of IM patients [58], suggesting it may play a role in primary infection. 
1.5.3 Latency I 
Latency I is a restricted form of viral latency first identified in BL [59], in which only 
EBNA1, EBERs and the BART miRNAs are known to be expressed [60]. The EBNA 
promoters Cp and Wp are silent, as in latency II, and the LMP promoters are also silent and 
gene expression is initiated from the Q promoter (Qp) [54]. Latency I has also been detected 
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in replicating peripheral blood memory B cells from IM patients, suggesting that this latency 
state may be important for viral persistence in vivo [61]. 
1.5.4 Latency 0 
It is believed that EBV persists in the memory B cell compartment in normal carriers in a 
form of viral latency termed latency 0. In this form of latency, latent gene expression is 
restricted to only the EBERs and the BARTs [44, 62]. 
 
1.6 EBV latent gene products 
1.6.1 EBNA1 
EBNA1 is encoded by the BKRF1 ORF. All EBNA1 mRNAs have been shown to contain an 
IRES (Internal Ribosome Entry Site) in the U exon. This IRES allows efficient translation of 
EBNA1 irrespective of which viral promoter is used to initiate EBNA1 transcription. 
Consequently, the varying 5’UTRs of EBNA1 generated from alternate promoter usage (Y3-
U-K from Cp and Wp, and Q-U-K from Qp) do not affect the efficiency of EBNA1 protein 
expression [63]. 
EBNA1 is the only latent protein to be expressed in all EBV-associated malignancies. 
EBNA1 is essential for EBV episome maintenance which it mediates through diffuse 
association with mitotic chromosomes [64]. EBNA1 is also expressed during the lytic cycle; 
lytic EBNA1 mRNAs initiate directly from the lytic F promoter, located just up-stream of Qp.  
EBNA1 is believed to exist as a dimer which binds to the latent origin of replication (oriP) to 
initiate DNA replication [65]. The oriP contains two distinct binding sites for EBNA1: the 
family of repeats (FR), which consist of 20 copies of a 30bp EBNA1 binding repeat; and a 
dyad symmetry (DS) region, which contains 4 overlapping EBNA1 binding sites [66, 67]. On 
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binding EBNA1 dimers, DNA replication initiates from within DS and terminates within FR 
[68]. Binding of EBNA1 to FR may also enhance transcription from Cp and Wp, and have a 
long range effect on the transcription of the LMPs [69-71]. Conversely, EBNA1 binding to 
two low affinity sites down-stream of the Qp promoter results in decreased transcription, 
suggesting that EBNA1 negatively regulates its own transcription during latency I and II [72, 
73]. 
In the prototype B95.8 strain the EBNA1 protein is 641aa in length and contains a glycine-
alanine (gly-ala) rich region within the amino terminal which varies in length among different 
EBV isolates. This gly-ala repeat inhibits proteasomal degradation, thereby preventing 
presentation by the major histocompatibility complex (MHC) class I and evading the host 
immune response [74, 75]. EBNA1 is non-essential for growth-transformation although 
transformation efficiency is significantly reduced (>1000 fold) in the absence of EBNA1, 
presumably due to the essential role EBNA1 plays in maintenance of the EBV episome [76]. 
The contribution of EBNA1 to the pathogenesis of EBV associated tumours is also ill defined; 
there are conflicting reports regarding the ability of EBNA1 to increase the incidence of 
lymphoma in transgenic mice with constitutive EBNA1 expression in B cells [77-79]. 
EBNA1 has also been identified as a possible enhancer of cell survival [80], possibly due to 
its ability to prevent p53 stabilisation though binding to the p53 binding partner ubiquitin 
specific peptidase (USP) 7 [81]. 
1.6.2 EBNA2 
EBNA2 is encoded within the BYRF1 ORF. It was the EBNA2 deleted non-transforming 
virus, P3HR1 which first demonstrated the essential role of EBNA2 in EBV-mediated growth 
transformation [82]. EBNA2 contains a number of important structural features: a negatively 
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charged amino terminus which may play a role in homodimerisation; a polyproline repeat 
region of variable size; a highly type divergent central region; a RBP-Jқ interaction domain; a 
highly conserved, imperfect Arg-Gly repeat which can serve as nuclear localisation signal 
(NLS); a negatively charged transactivation domain; and a C-termianl Lys-Arg-Pro-Arg NLS. 
Only the negatively charged N terminal domain and the imperfect Arg-Gly repeat are 
conserved between type I and type II viruses. It is proposed that the sequence differences in 
EBNA2 are the cause of the reduced transformation efficiency of the type 2 viruses relative to 
the type 1 viruses [82, 83].  
The essential role of EBNA2 in B cell transformation is due to its ability to act as a potent 
transcriptional activator of viral and cellular genes. Three of the EBNA2 structural elements, 
the RBP-Jқ binding domain, the acidic activation domain and the homotypic association 
domains have been identified as essential for the transformation and transcriptional properties 
of EBNA2. The RBP-Jқ binding domain mediates promoter modulation in a similar manner 
to the critical development protein, Notch 2 and thus EBNA2 can be described a functional 
orthologue of an activated Notch receptor. RBP-Jқ, either alone or with the ski-interacting 
protein (SKIP), tethers EBNA2 to its response elements up-stream of viral and cellular 
promoters. EBNA2 has been shown to activate the viral promoter Cp and the promoters of the 
LMPs. In resting cells, RBP-Jқ is thought to repress promoters through an interaction with a 
histone deacetylase complex (HDAC) co-receptor complex. The binding of EBNA2 to RBP-
Jқ replaces the repressive interactions and through its transactivation domain, recruits 
activators of transcription. Cellular genes which EBNA2 has been able to transactivate 
include CD21, CD23, c-fgr, cMyc, RUNX3 and EBII/BLR2 [84-88]. 
The acidic activation domain contains a homologous sequence to the herpes simplex virus 
(HSV)-encoded transcriptional activator protein, VP16. Both EBNA2 and VP16 bind a range 
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of transcriptional activators including p300/CBP, TFIIE and p100 [89, 90]. The scaffolding 
protein p100 is complexed with the acidic domain of EBNA2 in LCLs and mediates 
EBNA2’s transactivation of genes through the interaction of p100 with c-myb and PIM-1 [91, 
92].  EBNA2 dependent activation is likely to involve chromatin remodelling and histone 
acetylation, as evidenced by the interaction of EBNA2 with p300/CBP and SWI/SNF [93-95]. 
Finally, either of the regions bordering the polyproline repeat can mediate homotypic 
association which is pivotal to EBNA2’s ability to form complexes that can recruit 
transcription factors [96]. Deletion of both of these regions results in a null transforming 
phenotype [97]. 
 
1.6.3 EBNA-LP   
The EBNA-LP ORFs are located within the 5’UTR of all Wp and Cp initiated transcripts and 
are only translated when W0 or C2 exons splice to an alternate splice acceptor, W1’, creating 
an AUG translation initiation codon  [98]. EBNA-LP is transcribed from Cp or Wp initiated 
C1, C2 or W0 exons, followed by a variable number of W2W1 repeats and unique Y1 and Y2 
exons. The size of EBNA-LP varies between different EBV isolates which show differing 
numbers of repeat domains [99]. EBNA-LP is one of the first latent proteins to be expressed 
during primary B cell infection, along with EBNA2 [47]. The expression of EBNA-LP is not 
believed to be essential for transformation, as recombinants expressing a truncated protein 
lacking the unique C-terminus retain some transforming capabilities [100, 101]. Experiments 
performed with recombinants with mutated EBNA-LP ORFs are required to confirm the role 
of EBNA-LP in the transformation of B cells by EBV. The major function of EBNA-LP 
appears to be as a co-activator of EBNA2 mediated transcription of viral and cellular genes 
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[102]. EBNA-LP enhances EBNA2 mediated transactivation of the LMPs and Cp [103] and 
co-transfection of EBNA2 and EBNA-LP can induce G0 to G1 transition in primary B cells 
[104]. EBNA-LP is a phosphorylated protein with serine 35 in the W2 exon serving as the 
major phosphorylation site for this protein. Substitution of serine 35 reduced EBNA-LP’s 
ability to induce LMP1 following co-transfection with EBNA2 into Akata cells, indicating 
that the phosphorylation of EBNA-LP is critical for its function as co-activator of EBNA2 
[105]. The phosphorylation of EBNA-LP may be required to control its activity depending on 
the requirements of the cell as its phosphorylation is cell-cycle specific, with phosphorylation 
increasing in G2 and being maximal in the G2/M phase [106]. In vitro assays have indicated 
that EBNA-LP phosphorylation can be mediated by casein II kinase, p34cdc2 and DNA-PK 
[105, 107]. 
EBNA-LP is highly associated with the nuclear matrix fraction of the cell and has been 
detected in both ND10 bodies (also known as nuclear bodies) and spread throughout the 
nucleus [99]. Immunofluorescence studies have shown that EBNA-LP co-localises with 
promyelocytic leukaemia protein (PML), retinoblastoma protein (Rb) and heat shock proteins 
(Hsp72/73) in the nucleus [108-110]. However, a cytoplasmic localisation for a proportion of 
EBNA-LP molecules has also been reported [111]. Studies in cell-free systems have also 
indicated an association between EBNA-LP and the tumour suppressor proteins, Rb and p53 
[112]. However, this association has not been shown in LCLs and it has also been reported 
that the transfection of EBNA-LP does not affect Rb or p53 function, therefore the biological 
significance of these interactions is questionable [113]. 
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1.6.4 EBNA3 family 
The ORFs for the EBNA3 family of proteins are tandemly arranged in the BamHI E fragment 
of the viral genome and all three proteins share a number of structural features: hydrophilic N- 
terminus; a type divergent region; a region of short sequences rich in negatively and 
positively charged aa residues; and a proline rich C-terminus containing repeated polypeptide 
domains [44]. The genes encoding the three proteins are postulated to have arisen as a result 
of gene duplication during virus evolution [114, 115]. The type 1 and type 2 EBNA3A, B and 
C proteins share 84%, 80% and 72% aa sequence homology respectively, however, this does 
not appear to have any correlation with the transformation efficiency of the virus [116, 117]. 
The EBNA3 proteins are transcribed from either the Cp or Wp viral promoters. The ORFs for 
each of the EBNA3 genes consists of a unique, short 5’ exon and a unique, long 3’ exon 
(BERF1, BERF2b and BERF4) [117, 118]. Despite only a few copies of the EBNA3 mRNAs 
per cell, the stability of these proteins results in their intranuclear accumulation [115, 119, 
120]. The EBNA3 proteins are highly immunogenic and provide a major target for CD8 
positive cytotoxic T-lymphocytes (CTLs) [121, 122]. 
The EBNA3 family of proteins are believed to act predominantly as a set of transcriptional 
activators and repressors and similar to EBNA2, the EBNA3s can regulate the transcription of 
cellular and viral genes [123-125]. An important function for the EBNA3s is likely to be the 
modulation of EBNA2 and Notch activity through competition for the transcriptional 
repressor RBP-Jқ [126]. Consistent with this, over-expression of EBNA3A in an LCL results 
in dissociation of EBNA2 from RBP-Jқ and consequent down-regulation of CD21, CD23, 
cMyc and G0/G1 cell-cycle arrest [127]. EBNA3C expression in LCLs reduces DNA binding 
by RBP-Jқ and represses the viral Cp and LMP1 promoters in an RBP-Jқ dependent manner 
[123, 128]. EBNA3C and EBNA3A can also repress cellular gene promoters independently of 
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RBP-Jқ when tethered to DNA via the DNA binding domain of the yeast GAL4 protein [129, 
130]. Additionally, the EBNA3 proteins have also been shown to modulate the expression of 
a number of cellular genes. EBNA3B expression in EBV negative DG75-BL caused an 
increase in the expression of vimetin, CD40 and Bcl-2, but a down-regulation in CD77 [131]. 
EBNA3C expression in EBV-negative BJAB B cell line induced an up-regulation of the EBV 
receptor, CD21 [132].  
Only EBNA3A and EBNA3C are essential for transformation, and this may be attributed to 
the pro-survival properties of these two genes [133, 134]. However, a recent report suggests 
that EBNA3A deficient LCLs can be produced from EBNA3A deleted EBV but these cells 
are more sensitive to apoptosis and show reduced proliferation rates, suggesting that 
EBNA3A may be important but not critical for transformation [135]. The EBNA3s have been 
shown to have an anti-apoptotic function in vitro, with EBNA3A and EBNA3C capable of 
down-regulating the expression of the pro-apoptotic protein Bim [136]. Using a recombinant 
virus it has been shown that the proliferation and survival of LCLs is dependent on EBNA3A 
expression [137]. Accordingly, cell lines generated from Wp-restricted BL, which express the 
EBNA3s in the absence of EBNA2 or LMPs, are significantly more resistant to apoptosis than 
latency I BL cell lines [138], although the relative contributions of the EBNA3 proteins and 
the vBCL2 protein, BHRF1, which is also highly expressed in Wp BLs, remains unclear 
[139]. The pro-survival properties of the EBNA3s suggest that they may contribute to the 
oncogenicity of EBV infected cells. Indeed, EBNA3C has been reported to cooperate with 
oncogenic Ras in the transformation of rat embryo fibroblasts [140], and deregulates many 
cell cycle control pathways in EBV infected cells [141, 142]. 
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1.6.5 LMP1 
LMP1 is an integral membrane protein encoded by the BNLF1 ORF. LMP1 is localised to the 
cell membrane, often in lipid rafts. EBNA2 can transactivate the LMP1 promoter and this is 
dependent on the interaction of EBNA2 with RBP-Jқ and PU.1 [143]. LMP1 consists of three 
domains: a short N-terminal, cytoplasmic, hydrophilic domain, 17aa residues in length; a 
hydrophobic transmembrane (TM) domain constituting 6 α helical, hydrophobic TM loops. 
The TM domain enables self aggregation and is essential for the signalling of LMP1 [144]; a 
C-terminal cytoplasmic tail which mediates signalling. The C-terminus contains two 
transformation effector sites: TES1, which is essential for transformation, and TES2 which 
significantly enhances transformation [145-147]. The C-terminus can also be divided into two 
C-terminal activating regions, CTAR1 and CTAR2 which overlap with TES1 and TES2 
respectively [148]. CTAR1 and CTAR2 associate with proteins such as tumour necrosis 
factor (TNF) associated factors (TRAFs) and TNF receptor associated death domain 
(TRADDs) to induce signalling through a number of pathways, particularly NfқB and AP-1 
[146, 149]. 
LMP1 mimics a constitutively active CD40 receptor [150, 151]. This has been demonstrated 
using a mouse model where expression of LMP1 in CD40 null mice partially restored the 
wild type (wt) phenotype [152]. Additionally, a CD40-LMP1 fusion protein, where the 
cytoplasmic tail of LMP1 was fused to CD40, prevented constitutive activation of LMP1 and 
produced a LMP1 protein dependent on CD40L stimulated for activation. The LMP1 
signalling induced in vivo by CD40L completely substituted for CD40 [153]. The functional 
redundancy between LMP1 and CD40 can also be demonstrated in vitro, using LCLs 
generated with a recombinant EBV with inducible LMP1 expression. Upon removal of LMP1 
expression, the LCLs stop proliferating and this inhibition of proliferation can be reversed by 
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treating the LCLs with CD40L [154]. Furthermore, LMP1 and CD40 up-regulate a similar 
repertoire of activation associated antigens and adhesion molecules in B cells such as CD21, 
CD23, CD40 and ICAM1 [155]. 
LMP1 is essential for B cell transformation and proliferation; furthermore, it can transform rat 
fibroblasts in vitro, and its expression in mice predisposes them to lymphoma [145, 154, 156-
160]. Thus, LMP1 can be classified as a viral oncogene. Conversely, high expression of 
LMP1 can induce growth inhibition and apoptosis [161, 162]. Therefore, regulation of LMP1 
expression is critical to cell survival and proliferation, which may explain why three EBV 
encoded BART miRNAs can down-regulate the expression of this crucial gene [163].  
The cellular signalling pathways modulated by LMP1 are essential for its transforming and 
oncogenic properties. The p16
INK4a
-RB pathway plays a critical role in preventing 
inappropriate cell proliferation and is often targeted by viral oncoproteins. Unlike other DNA 
tumour virus oncoproteins, such as papillomavirus E7 or adenovirus E1 [164-166], LMP1 
does not bind directly to pRb but instead inhibits the transcription of p16
INK4a
 by preventing 
the nuclear import of its transcription factor, Ets2 [167, 168]. Activation of NFқB is 
predominantly mediated by CTAR2 and is important for the survival of EBV transformed 
cells as inhibition of NFқB causes apoptosis. CTAR2 is also important in LMP1 mediated 
activation of the c-Jun N-terminal kinase (JNK) pathway, leading to activation of AP-1. 
Signalling through CTAR1 and CTAR2 can also induce p38 mitogen-activated protein kinase 
(MAPK) activation and this activation is essential for LMP1’s ability to transform Rat-1 cells 
[169].   
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1.6.6 LMP2A/B 
The LMP2 gene encodes two isoforms termed LMP2A and LMP2B. These two proteins are 
transcribed from spatially distinct promoters, 3kb apart in the EBV genome [170-173]. The 
transcripts each have a unique first exon but then share 8 common exons which encode the 12 
TM domains and the C-terminus. Exon 1 of LMP2A contains an N-terminal cytoplasmic 
domain which mediates the signalling functions of this protein. LMP2B lacks this exon and 
therefore the signalling capabilities attributed to it. The first exon of LMP2B is non-coding 
and translation initiates at a methionine codon within exon 2 [170]. 
LMP2A and LMP2B are not essential for transformation of primary B cells [174-178], 
however, there is conflicting evidence which suggests LMP2A expression may enhance 
transformation [179, 180]. LMP2A can provide B cells with pro-survival and anti-
differentiation signals and can cooperate with LMP1 to enhance the B cell survival signalling 
mediated by NFқB [181, 182]. LMP2A has also been shown to protect BL and gastric 
carcinoma cell lines from TGF-β and BCR cross-linking induced apoptosis [183, 184]. 
Additionally, LMP2A expression enabled surface Ig negative B cells to escape from the bone 
marrow and colonise peripheral lymphoid organs [185, 186].  
The N-terminal domain of LMP2A is able to interact with the B lymphocyte Src family 
tyrosine kinases, particularly Lyn [187, 188]. Binding of Lyn results in the phosphorylation of 
LMP2A, the recruitment of Syk and activation of PI3K, Btk, BLNK and Akt [189, 190]. The 
signalling through Lyn and Syk has been shown to repress B cell entry into the lytic cycle 
after cross-linking CD19, MHC class II or the BCR [191, 192]. This indicates that one of the 
functions of LMP2A in latent infection is to prevent lytic activation of the virus.  
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Relatively little is known regarding the function of LMP2B, partly due to the technical 
problems involved in studying this isoform, such as the absence of a specific antibody. It is 
presumed that LMP2B must function in a different manner from LMP2A due to the lack of 
the signalling N-terminal cytoplasmic domain. Evidence suggests that the main function of 
LMP2B may be to antagonise LMP2A. Over-expression of LMP2B resulted in the co-
localisation of LMP2A and LMP2B and prevented LMP2A mediated inhibition of lytic 
reactivation after BCR cross-linking [193, 194]. Co-localisation of LMP2A and LMP2B at the 
plasma membrane has been shown to disrupt the self association of LMP2A [195], suggesting 
a direct role for LMP2B in the modulation of LMP2A function.      
1.6.7 EBERS 
The EBV encoded RNAs, EBER1 and EBER2, are small non-polyadenylated RNAs 166 and 
172 nucleotides in length respectively. The genes encoding the EBERs are situated adjacent to 
one another in the BamHI C region of the genome. EBER1 is transcribed by RNA 
polymerases II and III, whereas EBER2 is transcribed exclusively by RNA polymerase III 
[196, 197]. The EBERs are the most abundant EBV RNAs in the cell but they are not 
expressed equally in LCLs, with EBER1 having an approximately 10 fold greater level of 
expression than EBER2 [196, 197]. The EBERs are located in the nucleus where they are 
found in ribonucleoprotein (RNP) particles complexed to cellular proteins [198]. Despite the 
fact that the EBERs only share 54% sequence homology, they are predicted to have similar 
secondary structures and therefore may function in a similar manner. The EBERs have similar 
primary and secondary structures to the Adenovirus non-coding viral associated (VA) RNAs 
and the cellular U6 RNAs, hence these RNAs may provide clues to the function of the EBERs 
[199, 200]. VA RNAs have been shown to enhance adenoviral lytic replication due to their 
ability to promote translation of viral mRNAs [201]. The EBERs can functionally substitute 
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for VA RNAs in late stage Adenovirus 5 lytic cycle [202, 203]. Like VA RNAs, the EBERs 
can bind to and inhibit the interferon induced protein kinase PKR in vitro, providing one 
possible mechanism thorough which EBERs may function [204]. 
The expression of EBERs in all forms of latency suggests an important role for these RNAs in 
transformation; nevertheless, recombinant viruses have clearly demonstrated that the EBERs 
are not essential for transformation. The data regarding the contribution of the EBERs to 
transformation is conflicting. Originally it was demonstrated using an EBER knockout EBV 
that loss of the EBERs had no effect on transformation efficiency or LCL phenotype [205]. 
However, subsequent reports revealed impaired growth rates and transformation efficiency 
with EBER knockout or EBER2-only knockout EBV [206, 207]. 
There is increasing evidence to suggest that the EBERs may contribute to the oncogenicity of 
EBV. EBER expression in EBV negative B cell lines has been reported to increase the 
malignant phenotype of cells by decreasing their susceptibility to apoptosis, up-regulating 
Bcl-2, and enabling the cell lines to cause tumours in severe combined immunodeficiency 
(SCID) mice [208-212]. Additionally, it has been proposed that the EBERs may offer a 
growth advantage to BL cells through their ability to up-regulated IL10, which may act as an 
autocrine growth factor and suppress cytotoxic T cells [213, 214].  
1.6.8 EBV miRNAs 
EBV has been reported to encode at least 42 viral miRNAs, although new miRNAs may still 
be discovered as prediction and detection methods improve. The first EBV miRNAs to be 
discovered were the three BHRF1 miRNAs (BHRF1-1, -2 and -3) which flank the BHRF1 
ORF and these miRNAs are found exclusively in B cells with latency III or Wp-restricted 
types of latent infection and, in the case of miR-BHRF1-2 and miR-BHRF1-3 only, during 
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lytic cycle [215, 216]. The remaining EBV miRNAs are located within the introns of the 
BART region and are consequently called the BART miRNAs. The BART miRNAs are 
located in two clusters (cluster 1 and 2). The B95.8 strain of EBV has a deletion in the BART 
region, leaving only 5 of the BART miRNAs in the genome. This deletion has no apparent 
effect on the transformation efficiency of this strain, suggesting that most of the BART 
miRNAs are non-essential for transformation. Conversely, the high degree of evolutionary 
conservation between the miRNAs of EBV and those of the rhesus LCV indicate that they 
have an important function at some stage of the EBV life cycle.   
There have only been a limited number of EBV miRNAs targets identified, hence the role of 
these miRNAs in transformation and the pathogenesis of EBV remains to be elucidated. The 
EBV miRNA targets which have been identified include cellular as well as viral targets, 
indicating a potential for these miRNAs to control a wide variety of processes. The viral 
targets of the EBV miRNAs include LMP1, LMP2A and the EBV lytic cycle polymerase 
BALF5 [163, 217, 218]. Interestingly, BALF5 is targeted by miR-BART-2 which is located 
in an anti-sense position relative to the 3’UTR of BALF5 and represents the first example of a 
viral antisense miRNA [219]. An antisense miRNA will have 100% complimentarity to its 
target gene and will therefore cause mRNA cleavage in a siRNA-like mechanism, which is 
believed to a very efficient method of gene repression.  
Two cellular gene targets of EBV miRNAs have so far been identified: p53 up-regulated 
modulator of apoptosis (PUMA) and CXCL11, an interferon (IFN)-inducible T cell attracting 
chemokine, targeted by miR-BART-5 and miR-BHRF1-3 respectively [220, 221]. Although 
the data is still limited, a role for EBV miRNAs in protecting EBV infected cells from 
apoptosis and evading immune surveillance is beginning to emerge. This strongly suggests 
that EBV miRNAs may contribute to the pathogenesis of the virus. This is supported by the 
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high expression of a number of the EBV miRNAs found in primary tumour biopsies including 
NPC, BL, PEL, gastric carcinoma and AIDS-DLBCL [220, 222-224].  
 
1.6.9 Other EBV latent transcripts 
1.6.9.1 BARTs 
The BARTs are a family of differentially spliced complimentary-strand transcripts which 
encode mRNAs for putative RK-BARF0, A73 and RPMS1 proteins. The introns from this 
region also encode a number of miRNAs, as discussed in section 1.6.8, and these miRNAs are 
currently the main known function of the BARTs. Recombinant virus experiments have 
shown that the BARTs are not essential for transformation and the BART coding region in the 
B95.8 strain of EBV has a deletion of the BART coding region without any apparent function 
consequence on transformation. The BART transcripts are expressed in all forms of latent and 
lytic infection and have been detected in tumour samples but their function remains elusive 
[51, 225-230]. Although the BARTs encode mRNAs, the proteins produced from these 
mRNAs have not been detected in EBV infected cells in vivo or in vitro [231]. Despite this, 
experimentally generated proteins from these mRNAs have been implicated in the modulation 
of numerous cellular pathways including notch signalling [230]. The significance of these 
interactions cannot be evaluated until the expression of these proteins in EBV infected cells 
has been determined.  
1.6.9.2 BHRF1 and BALF1 
BHRF1 and BALF1 are both homologues of the anti-apoptotic protein Bcl-2 [232-234]. They 
are also both lytic cycle antigens, however, the expression of either BHRF1 or BALF1 has 
also been reported in NPC, BL cell lines and LCLs [139, 233]. Using recombinant viruses it 
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has been demonstrated that BHRF1 is not essential for transformation [235, 236], yet 
inactivation of both BHRF1 and BALF1 eliminates the transforming capacities of EBV [237]. 
This suggests that there is a degree of functional redundancy between these two Bcl-2 
homologues and highlights the potential importance of anti-apoptotic stimuli during the 
transformation of primary B cells.   
1.7 EBV lytic cycle 
The EBV lytic life cycle can be sub-divided into immediate early (IE), early and late lytic 
cycle by the expression of distinct lytic genes. BZLF1 and BRLF1 are two IE lytic proteins 
which function as transcription factors, activating their own, and one another’s promoters (Zp 
and Rp) to amplify lytic induction stimuli [238-242]. The BZLF1 protein is a viral homolog 
of c-Jun and c-Fos, and activates expression of early lytic genes through binding to AP-1 or 
Z-response elements (ZRE) [243, 244]. The lytic cycle is believed to be induced in vivo when 
plasma cells encounter antigen and differentiate [245]. In vitro, the lytic cycle can be induced 
in an EBV positive cell line by a range of stimuli, including surface Ig cross-linking, phorbol 
ester simulation, sodium butyrate treatment or in some instances, ectopic BZLF1 expression 
[246-250].  
Early lytic cycle genes are defined as those which are transcribed prior to viral DNA 
replication and include the EBV DNA polymerase, BALF5, and the major DNA binding 
protein, BALF2 [251, 252]. The expression of early lytic cycle proteins results in the 
replication of EBV genomes by rolling circle replication [253]. During early lytic cycle, EBV 
also expresses the Bcl-2 structural homologs, BHRF1 and BALF [234, 254, 255]. The 
expression of these genes during early lytic cycle is thought to protect cells from apoptosis 
during the lytic cycle in vivo [237, 255].  
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Late lytic cycle genes are expressed following viral DNA replication and mainly include viral 
structural proteins, such as capsid proteins, glycoproteins, and tegument proteins [251, 252]. 
The few non-structural genes expressed during late lytic cycle include BCRF1 which encodes 
for viral IL10, providing growth and survival signals to the cell [256-260]. In addition, IL10 
has been shown to aid immune evasion by negatively regulating macrophage, T cell and NK 
cell function [261-264]; this is important for EBV lytic replication as many viral lytic genes 
are highly immunogenic [265-267].   
 
1.8 EBV infection and persistence in vivo 
Primary EBV infection generally occurs at an early age and is usually asymptomatic. 
However, if EBV infection occurs in adolescence or later, it can result in IM [268-270]. 
Primary EBV infection and lytic replication occurs within the B cells of the oropharynx [271, 
272]. These infected tonsillar B cells in IM patients are heterogeneous in both morphology 
and viral antigen expression [273, 274]. Most cells express a latency III pattern of EBV gene 
expression, however, 2 smaller subsets of infected cells have been identified: one, which 
expresses only EBNA2 in the absence of LMP1 and a second group which displays a HL-
morphology and expresses LMP1 in absence of EBNA2 [275]. Virus replication in the 
oropharynx and virus-driven proliferation and expansion of the B cell pool elicits a strong 
CTL response. Large numbers of CD8
+
 CTLs are produced to bring the infection under 
control, leading to hyperactivation of the immune response and the symptoms of IM [276, 
277]. Despite the strong CTL response, EBV is not completely cleared and EBV remains 
detectable as infectious virus in throat washings and as a latent infection in the B cell pool 
[278, 279]. 
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EBV persists in vivo within memory B cells in a very restricted form of viral latency termed 
latency 0 (section 1.5.4), where only the EBERs and BARTs may be expressed [280]. The 
mechanism by which EBV gains entry into the memory B cell pool is still controversial but 
the most widely accepted model is the GC model (figure 1.3). The GC model predicts that  
 
 
Figure 1.3: Diagram representing the germinal centre model of EBV persistence in vivo. This 
figure is adapted from Thorley-Lawson 2004 [281].   
 
EBV infection of naïve B cells will drive the B cells to differentiate, mirroring the activation 
of naïve B cells by antigen [281]. Initial infection will result in expression of EBV’s growth 
transforming programme (latency III) which will drive the naïve B cells to differentiate into 
GC B cells. As the B cell differentiates, EBV latent gene expression is down-modulated, with 
GC B cells expressing a latency II pattern of gene expression (called the default program). 
The LMPs then mimic the signals a B cell would normally receive in a GC, allowing the 
infected GC B cell to differentiate into a memory B cell, where EBV gene expression is 
further down-modulated to latency 0, also called the ‘latency program’ [281]. Thereafter, only 
when the memory B cells divide will EBNA1 be expressed to allow maintenance of the viral 
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episome. This model is based upon the observations of EBV gene expression found in vivo 
[58, 61, 62, 280, 282-286], and the similarity between antigen-activated B cell blasts and 
EBV infected B cell blasts [155, 287]. However, the mechanism by which EBV may drive 
naïve B cell differentiation is not known.  
The alternative model for EBV infection and persistence in vivo is the direct infection model, 
where memory B cells are predicted to be directly infected by EBV, with no participation in 
the GC reaction [274, 275]. The direct infection model is supported by the persistence of EBV 
in X-linked lymphoproliferative (XLP) patients (these patients cannot form functional GCs), 
indicating that EBV can colonise a host without a need to transit a GC reaction [288].  Both 
models predict that once latently infected, the memory B cells have the potential to 
differentiate in response to antigen to produce plasma cells. These plasma cells are the site for 
vial lytic replication and they tend to localise near mucosal surfaces such as the oropharynx 
[36, 289]. Only a minority of plasma cells complete the lytic cycle and this occasional lytic 
replication and subsequent infection of new B cells serves to replenish the reservoir of 
infected B cells and maintain a lifelong EBV infection [245, 282].  
 
1.9 EBV associated B cell malignancies 
1.9.1 PTLD 
Immunosuppression of transplant recipients to prevent graft versus host disease can cause the 
development of post-transplant lymphproliferative disorder (PTLD). PTLD represents a group 
of heterogeneous, abnormal B cell proliferations which are classified into three histological 
types: i) early lesions, which are usually of polyclonal or oligoclonal origin and are 
consistently EBV positive; ii) polymorphic lesions which may be polyclonal or monoclonal in 
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origin and are almost always EBV positive; iii) monomorphic lesions, these are monoclonal in 
origin and the most common subtype is diffuse large B cell lymphoma. (reviewed in  [290]). 
In PTLD tumour biopsy material, EBV positive cells often only constitute a modest 
proportion of the tumour mass, with an extensive lymphoid infiltrate [291]. There is evidence 
to suggest that this infiltrate is necessary for the establishment of these tumours, possibly by 
supplying essential growth factors [292].  
PTLD incidence varies with different types of organ transplant, with intestinal and heart/lung 
being the most common and bone marrow transplants being the least common [293]. Greater 
than 50% of PTLDs are associated with primary infection, therefore EBV seronegativity of 
the recipient is a risk factor for the development of PTLD; this may explain why paediatric 
recipients are at a greater risk of developing PTLD than adults [294, 295]. The onset of PTLD 
in an EBV negative recipient is usually within the first year post-transplant and these lesions 
respond well to withdrawal of immunosuppression [296, 297]. The onset of PTLD in EBV 
positive recipients is usually >1 year post-transplant and can be many years later [298].  
Most early onset PTLD lesions display a latency III pattern of EBV gene expression, 
consistent with the outgrowth of growth transformed B cells in the absence of a cytotoxic T 
lymphocyte (CTL) response. Interestingly, antibody staining of PTLD sections has revealed a 
degree of heterogeneity in the EBV latent gene expression, similar to the varied EBV 
expression seen in the B cells of IM-tonsils [282].  
Late onset PTLDs present with a much greater heterogeneity in EBV gene expression, with 
latency I and II and III patterns of gene expression all reported. Furthermore, the development 
of monomorphic lesions is likely to involve additional genetic changes and this is supported 
by the detection of mutations in p53, c-myc, N-ras and bcl-6 in tumour biopsies [299-303]. 
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These cellular gene expression changes may explain the greater heterogeneity of EBV gene 
expression seen in late onset and monomorphic tumours, as they may no longer require the 
EBV latent antigens to drive proliferation and protect from apoptosis.  
The treatment of PTLD usually involves the reduction of immunosuppression in combination 
with the monoclonal CD20 antibody drug rituximab or antiviral drugs which prevent lytic 
replication such as acyclovir. However, the efficacy of acyclovir is limited as EBV is usually 
present in a latent rather than a lytic state.  If the reduction of immunosuppression fails then 
irradiation, chemotherapy and surgical resection can be used [304]. Additionally, T cell 
immunotherapy directed against EBV antigens is a very effective treatment for PTLD, is non-
toxic to the patient and carries a lower risk of damage or loss of the transplanted organ [305, 
306]. However, T cell immunotherapy is not a widely used treatment for PTLD, primarily due 
to the cost of providing such a tailored treatment.      
1.9.2 Hodgkin’s Lymphoma 
There are two subtypes of HL, classical HL (cHL) and nodular lymphocyte-predominant HL 
(NLPHL), the latter of which only accounts for approximately 5% of HL. NLPHL is rarely 
associated with EBV, whereas cHL is associated with EBV in approximately 40% of cases in 
the west, although this can be up to 90% in Central and South America [307, 308]. HL is one 
of the most frequent cancers is the western world with an incidence of approximately 3 per 
100,000 per year [308]. The tumours of cHL are characterised by the mononucleated Hodgkin 
cells and the unusual, multi-nucleated Reed-Sternberg cells (HRS cells). The HRS cells are 
only a small percentage of the tumour mass (~1%) with the remaining mass being comprised 
of reactive infiltrate. There is evidence to suggest that this reactive infiltrate is not only 
attracted by the HRS cells, but also necessary for their survival [309-312].  
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HRS cells are believed to be of B cell origin and are characterised by a dramatic down-
regulation of B cell markers which originally hindered the identification of the cellular origin 
of HRS cells.  Sequencing revealed that the HRS cells contained rearranged and somatically 
mutated immunoglobulin variable (IgV) genes, with some cells showing clearly destructive 
mutations which ought to have caused apoptosis in the germinal centre [313]. This led to the 
hypothesis that HRS cells originate from crippled germinal centre (GC) cells which somehow 
escape apoptosis [314]. Indeed, one of the postulated roles for EBV in the development of HL 
is to rescue germinal centre cells with crippling IgG mutations from apoptosis. EBV expresses 
a latency II pattern of gene expression in HRS cells and it is likely to be to the LMPs which 
are responsible for the rescue of GC B cells from apoptosis [53, 273, 315, 316]. Signalling 
through the CD40 and the BCR are two major physiological survival and selection signals for 
GC B cells [317]. As discussed in sections 1.6.5 and 1.6.6, LMP1 can mimic many of the 
signals normally supplied by an activated CD40 receptor and LMP2A can deliver BCR-like 
survival signals [152, 185]. This hypothesis is supported by two observations: firstly, 
comparison of clonal IgV region sequences in HL cases with the EBV status of the tumour 
revealed that almost all tumours with crippling mutations were EBV positive [318]; secondly, 
EBV can rescue GC B cells with crippling mutations from apoptosis in vitro.[319-321]. 
1.9.3 Burkitt Lymphoma 
The form of BL originally described by Denis Burkitt in 1958 is now called endemic BL 
(eBL) and it occurs with high incidence in areas of equatorial Africa and Papua New Guinea 
where malaria is holoendemic [1, 2]. eBL has almost a 100% association with EBV and each 
tumour cell carries monoclonal EBV episomes [3]. In contrast, sporadic BL, which is a 
histologically identical tumour, occurs at lower incidence in other parts of the world; this is 
also a paediatric tumour although it presents more frequently in the abdomen rather than the 
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jaw. The association of sporadic BL with EBV varies with location and ranges from 15-85% 
[322].  AIDS-associated BL was discovered in the 1980’s and has identical histology and 
similar sites of presentation as the sporadic form, however, it only presents in HIV positive 
adults. The association of AIDS-associated BL with EBV is approximately 30-40% and the 
lymphoma usually presents early in disease progression when patients are still relatively 
immunocompetent [323].  
BL is characterised by a c-myc translocation to the Ig locus were it is constitutively 
expressed. The most common translocation which occurs is to the heavy chain Ig locus (8:14) 
and this is found in approximately 80% of patients. The alternative translocation is termed the 
‘variant’ translocation and places c-myc under the control of the IgL, қ or γ loci [322, 324]. c-
myc is a proto-oncogene and a transcriptional regulator involved in proliferation, 
differentiation and apoptosis [325]. It is c-myc which drives the proliferation of BL cells, 
however, it also makes the cells sensitive to apoptosis [326-329]. It is this sensitivity to 
apoptosis which led to the hypothesis that EBV is required to counteract the sensitivity to 
apoptosis induced by constitutive c-myc expression. EBV gene expression in BL is typically 
latency I [51, 59], therefore the essential EBV encoded growth-transforming proteins are 
absent. It is unlikely that EBV, in such a restricted form of latency, is contributing 
substantially to the proliferation of the BL cells, thus, an anti-apoptotic role is more likely. 
This is supported by the observation that EBV loss clones are more sensitive to apoptosis than 
EBV positive clones [330]. Additionally, EBV loss clones are more radily generated from late 
passage BL cell lines (>2 years old) than early passage lines, indicating that cellular gene 
expression changes are required to enable the cells to tolerate loss of the virus. As discussed 
in sections 1.6.1 and 1.6.7, EBER expression in BL has been associated with apoptosis 
resistance and EBNA1 has been implicated in the destabilisation of p53 [81, 213].  
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1.10 Growth transformation of B cell in vitro 
Infection of resting B cells in vitro with EBV results in the growth transformation of the 
resting B cell into proliferating B cell blasts (LCLs) which phenotypically resemble B cells 
proliferating in response to antigen. Infection of B cells in vitro to produce LCLs has been a 
valuable model for studying the transforming capacities of the virus for many years.  
1.10.1 Primary infection of B cells in vitro  
Infection of B cells involves the binding of EBV, via its most abundant glycoprotein, gp350, 
to the C3d complement receptor, CD21, at the B cell suface [35, 331]. Thereafter, a second 
EBV glycoprotein gp42 forms part of a trimeric complex with gp85/gp25 and binds HLA 
class II, initiating viral fusion with the cell membrane [332-334]. EBV binding to CD21 can 
activate resting B cells and this may be important for subsequent viral gene expression. For 
example, CD21 signalling in B cells has been shown to induce NFқB activation and IL6 
production in a protein kinase C dependent manner [335-339]. 
EBV episomes appear within the nuclei of infected B cells approximately 16 hours post 
infection [47]. The Wp promoter initiates transcription and through differential splicing 
produces EBNA2 and EBNA-LP, which are detectable 12-24 hours post-infection [47, 340, 
341]. EBNA-LP enhances the transcriptional changes initiated by EBNA2 which causes an 
up-regulation of the B cell activation marker CD23 and a G0-G1 cell-cycle transition, as 
marked by the induction of cyclin D2. In addition, EBNA2 activates Cp which consequently 
becomes the dominant promoter for EBNA transcription 24-48 hours post-infection, whilst 
Wp-initiated transcription declines [47, 341-343]. The Cp generated mRNA transcripts are 
highly spliced; via alternative RNA splicing these Cp transcripts can produce expression of all 
the EBNAs: 1, 2, -LP, 3A, 3B and 3C [63, 344] (figure 1.4, adapted from Qu and Rowe 1992   
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[345]). It has been reported that EBNA1 binding to oriP also enhances Cp mediated 
transcription of the EBNAs [69]. Conversely, the EBNA3s may inhibit EBNA2 mediated 
transactivation [126]. EBNA2 and EBNA-LP also activate the LMP promoters, with LMP1 
expression rising approximately 5 days post-infection [341, 346].  
1.10.2 Growth transformation 
The growth transforming programme of EBV (latency III) involves the expression of 9 latent 
genes, only 4 of which are essential for transformation: LMP1, EBNA3C, EBNA3A and 
EBNA2 [82, 133, 159, 160]. An additional two latent genes are important for growth 
transformation: EBNA1 and EBNA-LP. EBNA1 is non-essential for growth transformation 
but is essential for maintenance of the EBV genome in the proliferating blasts [76]. EBNA-LP 
is also non-essential for transformation, although the transformation efficiency is significantly 
reduced in B cells infected with an EBNA-LP mutant EBV relative to wild type virus [101]. 
The latent proteins of EBV produce changes in cellular gene expression which enable 
progression through the cell-cycle and increase cell survival (see section 1.6). Cellular gene 
expression changes are essential for transformation as EBV hijacks the cells normal signalling 
pathways to mimic antigen stimulation, thus producing a latently infected proliferating B cell 
blast (reviewed [347]). These cellular gene expression changes include the modulation of well 
characterised tumour suppressor genes and oncogenes, such as MDM2/p53, Bcl2 and Bim 
[81, 136]. The modulation of cellular genes during transformation which are known to 
contribute to the development of cancer may predispose the B cells to further genetic 
alterations, allowing the progression from transformed B blast to tumour cell.   
The process of transformation is distinct from the process of immortalisation. Early stage 
passage LCLs are unable to form colonies in soft agar or produce tumours in nude mice. 
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However, late passage LCLs (typically passage >180) which have survived a so called 
‘proliferative crisis’ are able to form colonies in soft agar, produce tumours in nude mice, 
show high expression of telomerase and have genetic aberrations [348]. Therefore, the 
process of transformation by EBV is not sufficient to produce a cell line with a tumourogenic 
phenotype, further cellular gene expression changes are required. This point is supported by 
the fact that some LCLs do not survive the proliferative crisis, presumably because they have 
not attained the cellular gene expression changes necessary for immortalisation.  
Transformation in vivo is likely to occur during primary infection as patients with IM show 
detectable latency III lymphoblastoid like cells in lymphoid tissues [275]. Patients with early 
stage PTLD also have detectable latency III lymphoblastoid B cells in the lymphoid tissue 
[349]. Late stage PTLD, which often presents with a much more pronounced tumour 
phenotype, is associated with tumours which contain genetic aberrations. It is therefore likely 
that early passage LCLs are a good model for B cells during primary infection (IM) and early 
stage PTLD, whilst late passage LCLs more closely resemble late stage PTLD.   
It is clear that EBV latent gene expression is not sufficient to produce LCLs with full 
tumourogenic potential, despite the fact that LMP1 alone can transform rat fibroblasts. 
However, the cellular gene expression changes which are required for transformation are not 
fully characterised and the link between transformation and immortalisation of LCLs is not 
understood. The profiling of cellular gene expression changes which occur during 
transformation will provide insight into the mechanism of EBV induced growth 
transformation. These gene expression changes may also be important for EBV associated 
tumourogenesis, pre-disposing the B cells to further genetic aberrations which enable 
immortalisation to occur. miRNAs are post-transcriptional regulators of gene expression and 
the extent to which EBV modulates the expression of the host cellular miRNA system was not 
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known at the outset of this thesis. The relationship between EBV and cellular miRNA 
expression during EBV-mediated growth transformation of resting B cells may prove to be a 
novel method which EBV utilises to alter cellular gene expression during transformation and 
tumourogenesis.  
1.11 The discovery of microRNAs  
miRNAs are members of the RNA interference pathway (RNAi) which mediate post-
transcriptional gene regulation of target genes, and were first identified in Caenorhabditisis 
elegans (C. elegans) by Rosalin Lee et al and Bruce Wightman et al in 1993 [350, 351]. The 
lin-4 gene had previously been shown to control the protein expression of LIN-14 post-
transcriptionally and the 3’UTR of lin-14 was also shown to be necessary for this negative 
regulation [352]. Cloning of the C.elegans lin-4 gene revealed that it was non-protein coding, 
although it did contain two RNAs (one 61nt and the other 21nt in length), which both 
contained a sequence complimentary to a repeat sequence in the lin-14 3’UTR [350]. A 
reporter gene containing the section of the lin-14 3’UTR with complimentary binding sites for 
the lin-4 RNAs revealed that the lin-4 RNAs were able to repress protein expression from 
these sites [351]. These experiments were the first examples of miRNA expression and gave 
the first insights into miRNA mode of action. However, it was not until the year 2000 when 
Reinhart et al [353] discovered let-7a, whose expression was conserved from worms to 
mammals [354], that the importance of miRNAs was realised. 
 
1.12 The biogenesis of miRNAs 
miRNAs are predominantly transcribed in the nucleus by RNA polymerase II as a large 
capped and polyadenylated primary transcript termed a pri-miRNA [355, 356]; however, rare 
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instances of miRNAs transcribed by RNA polymerase III have been reported [357]. The 
majority of miRNAs are localised in intergenic regions, although approximately 25% are 
localised in known protein coding genes either within introns or exons [358]. Pri-miRNAs can 
be transcribed from their own promoters [355, 356] and are often located in close proximity 
where they are transcribed as single polycistronic primary transcripts, also termed ‘pri-
miRNA clusters’ [358, 359].  
pri-miRNAs are processed in the nucleus by the RNase III enzyme, Drosha, to form an 
approximately 80nt long stem-loop containing transcript termed a pre-miRNA [360]. Drosha 
forms a complex, often termed the ‘microprocessor complex’, with the DiGeorge syndrome 
critical region gene 8 (DGCR8) protein [361-363]. DGCR8 is believed to enhance Drosha 
substrate recognition [362]; the double-stranded stem and 3’ overhang, but not the hairpin 
loop, are critical for pre-miRNA recognition [364, 365]. Drosha processing of intronic pri-
miRNAs occurs co-transcriptionally and does not inhibit RNA splicing, as a continuous intron 
is not required for splicing [366, 367]. However, the regulation of exonic pri-miRNA Drosha 
processing remains to be determined. Interestingly, splicing can substitute for Drosha 
processing in a small number of instances if the miRNAs released by splicing are an 
appropriate size to form a hairpin resembling a pre-miRNA. These miRNAs which can 
circumvent Drosha processing are called ‘mirtrons’, and following nuclear export by Exportin 
5, they are processed normally in the cytoplasm by Dicer-1 [368-370]. 
The pre-miRNA is exported from the nucleus to the cytoplasm by Exportin 5 in a complex 
with Ran-GTP [371]. A RNA stem of >16 bases and a short 3’ overhang are the structural 
requirements for Exportin 5 mediated pre-miRNA recognition [372, 373]. The mechanism 
regulating the export of the pre-miRNAs from the nucleus remains to be elucidated, and 
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whether or not nuclear export is used by a cell as a means of controlling mature miRNA 
expression is still debated [374-376].  
Once in the cytoplasm, pre-miRNAs are taken up by the RISC loading complex (RLC) 
composed of, the RNase III enzyme Dicer-1; the double stranded RNA domain binding 
proteins Tar RNA binding protein (TRBP) and protein activator of PKR (PACT); and the 
argonaute-2 (Ago-2) protein [377-380]. TRBP and PACT are non-essential for Dicer-1 
mediated pre-miRNA cleavage but they facilitate miRNA processing by stabilising Dicer-1 
and recruiting Ago-2 [379, 381].  
Once the RLC has formed, the pre-miRNA is bound and processed by one of two possible 
mechanisms: (i) the pre-miRNA is cleaved by Dicer-1 to produce the mature miRNA duplex, 
which is subsequently loaded into the RISC complex (figure 1.5), or (ii) the pre-miRNA is 
cleaved by Ago-2 to produce an Ago2-cleaved-pre-miRNA (ac-pre-miRNA). ac-pre-miRNAs 
contain a nick in the 3’arm of the hairpin which is postulated to facilitate passenger strand 
dissociation of 5’ miRNAs which do not contain mis-match regions in the centre of the 
miRNA duplex. The ac-pre-miRNAs are then processed by Dicer-1 to produce the mature 
miRNA duplex, which is subsequently loaded into the RSC complex, as in (i) [382].  
Dicer-1 cleaves the hairpin loop of the pre-miRNA or ac-pre-miRNA to produce an 
approximately 22nt long mature miRNA duplex with a 2nt 3’ overhang [383-386]. Unlike 
Drosha, Dicer-1 was believed to be essential for the biogenesis of all miRNAs [387, 388]; 
however, recent work by Bosse et al [389] suggests that a subset of miRNAs may be cleaved 
in a Ago-2-dependent, Dicer-1-independent manner.   
Once the pre-miRNA has been cleaved by Dicer-1, the RLC dissociates and the mature 
miRNA duplex is unwound by a helicase and loaded into the miRNA RNA-induced silencing  
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Microprocessor complex: 
Drosha and DGCR8 
     RLC:  
Dicer-1, Ago2, TRBP and 
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mi 
Figure 1.5: Simplififed diagram representing miRNA biogenesis  
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complex (miRSC). Multiple helicases have been associated with the miRNA biogenesis 
machinery. However, whether one universal helicase or multiple helicases are responsible for 
miRNA unwinding is still not clear [390-393]. Which strand of the miRNA duplex is selected 
for miRISC loading (the guide strand), and which strand is degraded (the passenger strand), is  
thought to be determined by the asymmetry of the miRNA duplex. The miRNA with the least 
stable base pair at its 5’ end is usually the guide strand incorporated into the miRISC [394, 
395]. The selection of the guide strand is not 100% efficient, and low levels of the passenger 
strand can be detected in the miRISC, the passenger strand miRNAs are termed the minor 
miRNA (miRNA*) species [396]. It is not yet clear whether miRNA* species contribute to 
gene regulation or simply represent an irrelevant by-product of miRNA processing [396, 397].   
 
1.13 Regulation of miRNA biogenesis  
The expression of pri-miRNA and mature miRNA transcripts have often been observed to 
show no correlation in vitro or in vivo [375, 398-401]. This led to the hypothesis that the 
processing of miRNAs could be regulated as a means of controlling mature miRNA 
expression and function [359, 399]. The control of miRNA processing has been a rapidly 
expanding field throughout the course of this research and has revealed that miRNA post-
transcriptional regulation is an important determinant of miRNA function. 
Numerous methods can be employed to modulate the miRNA biogenesis pathway, and the 
most significant three methods will be described briefly: (i) regulation of Drosha and Dicer-1 
expression; (ii) cellular localisation and; (iii) ADAR editing.  
(i) Drosha and Dicer-1 expression: The biogenesis of miRNAs can be affected by the 
expression of the two RNase III enzymes responsible for miRNA processing. Mouse models 
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have demonstrated that a loss or increase of either Drosha or Dicer-1 expression, results in a 
corresponding, non-specific increase or decrease in global miRNA expression respectively 
[402]. A global decrease in miRNA expression is associated with cancer and has been shown 
to enhance tumour development [398, 402]; moreover, the expression of Dicer-1 and Drosha 
has been reported to be altered in several cancers [403, 404]. In addition to expression 
regulation, the processing efficiency of Drosha has been shown to be enhanced by p53 
binding. In many cancers, mutations are commonly found in the transcriptional domain of 
p53, which have been shown to reduce or prevent the ability of p53 to enhance the processing 
of pri-miRNAs. This is postulated to be another tumour suppressive function of p53 [405], 
and may represent another mechanism by which miRNA expression is regulated post-
transcriptionally.  
(ii) Sub-cellular localisation: miRNAs are processed initially by Drosha in the nucleus, 
followed by Dicer-1 in the cytoplasm; thus, for miRNA processing to occur, the pri-miRNA 
and pre-miRNA transcripts need to be localised in the nucleus and cytoplasm respectively. 
The sub-cellular localisation of miRNA precursors has not been extensively examined. 
Nevertheless, isolated reports have observed certain pri-miRNAs predominantly located in the 
cytoplasmic, rather than the nuclear cell fraction [406, 407], where they will not have access 
to Drosha for processing. Pre-miRNAs have also been shown to accumulate in the nucleus 
where they cannot be further processed by Dicer-1, although the cause of the pre-miRNA 
accumulation remains to be determined [398]. Collectively, these observations suggest that 
the sub-cellular localisation of miRNA precursors may be a method by which mature miRNA 
expression is modulated; this is significant because it may partially explain the tissue specific 
expression of selected miRNAs observed in vivo [408-410]. Furthermore, it is not only 
miRNA processing which may be modulated by sub-cellular localisation. Mature miR-29b 
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has been shown to contain a hexanucleotide motif at its 3’ terminus, which acts as a NLS, 
causing an accumulation of miR-29b in the nucleus. This raises the possibility that the 
localisation of mature miRNAs may also be regulated as a means of controlling miRNA 
function [411].  
(iii) ADAR editing: The enzyme, adenosine deaminase acting on RNA (ADAR), promotes 
the hydrolytic deamination of adenosine residues to inosine on dsRNA substrates [412, 413]. 
ADAR editing of pri-miRNAs and pre-miRNAs has been demonstrated in vivo [414, 415]. 
ADAR editing can alter the secondary structure of pri-miRNAs and pre-miRNAs [416], 
which is essential for Drosha and Dicer-1 recognition, and therefore subsequent miRNA 
processing. Indeed, ADAR editing has been shown to prevent Drosha or Dicer-1 recognition 
and processing of various miRNAs [416, 417]. Additionally, ADAR editing of pre-miR-367 
was shown to be specifically localised to the proximal 5’ ‘seed’ region of the miRNA. This 
resulted in altered miR-367 target recognition, demonstrating for the first time that ADAR 
editing can also affect the target specificity of miRNAs [418]. 
A picture is emerging of a highly complex system whereby the expression of miRNAs can be 
regulated by a host of cellular factors and conditions. A mechanism of miRNA transfer from 
one cell to another via exosomes has also recently been proposed, providing another possible 
mechanism whereby mature miRNA expression could be controlled [419-421]. Additional 
mechanisms by which miRNA biogenesis may be regulated include miRNA sequestration 
[422], miRNA biogenesis inhibitors [423] and even control by the cytoskeleton [424]. These 
mechanisms are currently less well characterised, but they demonstrate the complexity of the 
miRNA expression system and how limited our current knowledge still is. 
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1.14 Mode of action of miRNAs 
Following transcription, mRNAs are assembled into messenger ribonucleoprotein (mRNP) 
particles and exported into the cytoplasm for translation. The fate of these mRNAs is often 
determined by cis-acting elements in the 3’UTR of the mRNA, such as miRNA binding sites 
and AU rich elements, which can respond to the requirements of the cell [425, 426].  Delayed 
translation results in mRNA accumulation in cytoplasmic processing bodies (P-bodies), which 
are also the site of mRNA degradation [427, 428]. Whether a mRNA is degraded or released 
for translation is believed to be governed, at least in part, by the cis-acting elements in the 
mRNAs 3’UTR [429, 430]. The role of miRNAs in the control of mRNA fate has been the 
focus of much of the current research in the field, and clues to the mechanism of miRNA 
mediated gene silencing are emerging.  
miRNA inhibition of gene expression is mediated by the miRISC, which is primarily 
composed of Ago proteins and the mature miRNA [431-433]. Ago proteins are ubiquitously 
expressed proteins, defined by their piwi-argonaute-zwille (PAZ) and PIWI domains which 
bind miRNAs at the 3’ and 5’ terminus respectively [434, 435]. There are 8 Ago genes in 
humans, which encode 4 Ago proteins (Ago 1-4) and 4 PIWI proteins [436]. All four of the 
Ago proteins mediate translational repression, whereas only the Ago-2 protein contains 
intrinsic slicer activity [432, 437-439].  
mRNA cleavage is believed to only be initiated when there is perfect complementarity 
between a miRNA and its mRNA target [440, 441]. This is exemplified by plants where, 
unlike mammals, miRNAs typically have 100% complementarity with target mRNAs and 
induce Ago-2 mediated mRNA cleavage and degradation [442-444]. However, perfect 
complementarity between a miRNA and its target mRNA is not always sufficient to induce 
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mRNA cleavage, suggesting that there may be additional requirements for a miRISC to 
catalyse cleavage [445]. miRNAs in mammals typically show imperfect complementarity to 
target mRNAs and they therefore function primarily through other mechanisms of 
translational repression. 
miRNA mediated gene repression and the mechanisms which regulate it are poorly 
understood. Recent research has revealed some mechanistic detail; however, most models are 
still contested, with no preferred model yet being identified. It is clear that miRNAs can 
induce translational repression, mRNA destabilisation or both. It was originally thought that 
translational repression was the primary mode of action of miRNAs, but more recent work has 
suggested that miRNA induced mRNA destabilisation is also important for miRNA mediated 
gene repression in mammals [446].  
(ii) Translational repression: The majority of literature regarding the mode of miRNA 
mediated translation repression has focused on determining whether inhibition occurs during 
translational initiation or post-translational initiation. Although there is currently greater 
evidence to suggest that inhibition occurs at the stage of translation initiation, a mechanism 
whereby miRNAs mediate inhibition post-initiation, instead of or as well as at the stage of 
initiation, cannot be discounted. 
miRNAs cannot mediate translational inhibition of target mRNAs containing an IRES, 
suggesting that translational inhibition is inhibited in a 5’cap dependent manner [447]. Further 
studies have also demonstrated a dependence on the 5’cap and the poly(A) tail for 
translational inhibition [448-450].  
In C.elegans, lin14 and lin28 mRNAs have been shown to associate with fewer polysomes 
following translational repression by the let7a and lin4 miRNAs; suggesting that translational 
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initiation was inhibited [451], although this observation is contrary to previous reports [452, 
453]. Moreover, there is evidence to suggest that miRNAs may inhibit the association of 
target mRNAs with ribosomes, preventing the initiation of translation [454, 455]. Finally, a 
possible interaction between Ago-2 (as part of the miRISC) and the 5’cap of target mRNAs 
has been reported, preventing the binding of translation initiation factor eIf-4E, thereby 
inhibiting translation initiation [454].  
Collectively, these data demonstrate that the mechanism by which miRNAs mediated 
translational repression is still largely obscure; however, current research suggests that 
miRNAs may inhibit the initiation of translation or they may employ multiple mechanisms to 
exert their effect. 
(iii) mRNA destabilisation: It is accepted that miRNAs mediate gene silencing through both 
inhibition of translation and increasing mRNA destabilisation [448, 456-460]. By 
destabilising the mRNA, miRNAs indirectly enhance the mRNA degradation of target genes. 
It is worth noting that this increased mRNA destabilisation and subsequent mRNA 
degradation is distinct from the mRNA cleavage and degradation caused by RNAi which is 
only induced when a miRNA has perfect complementarity to a mRNA.  
Degradation of target mRNAs is known to require deadenylation of mRNA targets prior to 5’ 
decapping [461]. It has been shown that miRNAs mediate deadenylation of target genes 
through a mechanism that is still uncertain [460, 462-464]. Different degrees of mRNA 
destabilisation apply to different mRNAs, as demonstrated by miRNA inhibition and ectopic 
expression studies [458, 459, 465, 466]; although the majority of genes only show small 
decreases in mRNA and protein expression, consistent with a fine-tuning role for the majority 
of miRNAs. 
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The Ago proteins, the poly(A) binding protein (PABP) and the processing body (P-body) 
associated protein, GW182, are all required for miRNA mediated deadenylation [461, 463, 
464]. Knockdown of GW182 has been shown to abrogate miRNA mediated inhibition of 
translation and mRNA deadenylation, suggesting a critical role for this protein in all aspects 
of miRNA mediated gene silencing [467]. All Ago proteins can interact directly with GW182 
[468], indicating that GW182 may be recruited to target mRNAs by Ago proteins in the 
miRISC.  
GW182 has been shown to directly interact with the deadenylation complex, CAF1-CCR4-
NOT1 [469] and PABP. These interactions are postulated to facilitate the recruitment of the 
proteins required for deadenylation to the miRISC. The current model for miRNA mediated 
deadenylation therefore involves the miRISC functioning as scaffold proteins for 
deadenylation facilitating proteins.   
Following deadenylation, mRNAs will be decapped and then degraded. Components of the 
mRNA degradation machinery are concentrated in P-bodies, and reports have linked P-bodies 
to miRNA mediated gene silencing as they have been shown to contain Ago proteins and 
mRNAs targeted by miRNAs for translational repression [470-472]. Interestingly, one report 
has even suggested that miRNA target genes can be temporarily stored in P-bodies and 
released following cellular stress [473]. Based upon these results, a model for miRNA 
mediated gene silencing involves the targeting of mRNAs to P-bodies, which increases the 
mRNAs association with the mRNA degradation machinery, causing mRNA degradation. 
However, the role of P-bodies in miRNA mediated gene silencing is still contested; numerous 
reports indicate that P-bodies may be a consequence, rather than a cause, of miRNA mediated 
mRNA degradation [467, 474, 475].  Further investigation into this area is required before the 
role of P bodies in miRNA gene silencing can be resolved. 
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The sequence of translational repression and deadenylation are also contested, and it is 
possible that a cyclic model of translational repression and deadenylation will explain the 
conflicting observations [476]. 
(iii) Alternative modes of miRNA action: miRNAs are believed to predominantly function 
through binding to target sequences in the 3’UTR of mRNAs with imperfect complementarity 
to induce translational repression; however, more recently, alternative modes of miRNA 
action have been observed. miRNA binding sites have been identified and validated in the 
5’UTRs [477] and protein coding regions of genes [478]. These sites have been shown to 
induce efficient translational repression of target genes, despite their localisation. Whether 
these examples represent a common mode of action for miRNAs is not clear, as these results 
are contrary to those of Gu et al [479], who demonstrated that miRNA sequences were no 
longer effective at repressing translation following modification of the stop codon to extend 
the coding sequence through the miRNA binding sites.  
Additionally, there have been many reports of miRNA mediated up-regulation of gene 
expression [480-483]. miR-10a has been reported to enhance the translation of a ribosomal 
protein through non-canonical binding to the 5’UTR, indicating that the mode of action of this 
miRNA may be influenced by the position of the binding site and/or the degree of 
complementarity with the mRNA [481]. There are several reports of miRNAs using non-
canonical binding sites in mRNAs to mediate translational repression, and the extent to which 
miRNAs utilise such sites warrants further investigation [353, 484-486]. Interestingly, 
miRNAs have been reported to repress gene expression in actively proliferating cells but to 
up-regulate gene expression in cells arrested in G0/G1 [480, 487]. Vasudevan et al [480] 
suggested that the switch from an inhibitory to an activating miRISC may be caused by the 
association of Ago-2 with different proteins; Ago-2 was found to associate with Fragile X 
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mental retardation protein 1 (FXR1) in ‘activating’ but not ‘repressing’ miRISCs. Cellular 
proliferation has also been linked to a loss of miRNA mediated translation inhibition, by the 
observation that mitogen stimulated lymphocytes express shorter 3’UTRs than resting 
lymphocytes, and that these short 3’UTRs lack conserved miRNA binding sites [488].  
Collectively these data suggest that miRNA mediated gene regulation is complex and may be 
influenced by the requirements of the cell. It has been postulated that miRNAs may merely 
act as guides for the miRISC, and that the protein constituents of the miRISC, influenced by 
the cellular environment, determine the consequence of the miRNA:mRNA interaction; be 
that translational repression, mRNA destabilisation or even the activation of translation. 
 
1.15 miRNA target site specificity and prediction 
One of the major challenges for miRNA research in mammals has been the bioinformatic 
prediction of miRNA target genes. In plants, miRNA target prediction has proved to be very 
effective, as plant miRNAs have near perfect complimentarity to the mRNA target site [489, 
490]. In contrast, mammalian miRNAs bind with imperfect complimentarity to target 
mRNAs, making the prediction of miRNA target genes very complex. Investigations into the 
rules which dictate miRNA mediated translational repression have yielded a partial 
understanding of miRNA:mRNA interaction and have enabled the development of a host of 
miRNA prediction programs which are constantly being refined as new experimental 
evidence regarding miRNA:mRNA interactions becomes available [491-498].  
(i) The principles of miRNA binding: Watson-Crick base pairing between the target mRNA 
and nucleotides 2-7 at the 5’ termini of the miRNA is considered crucial for determining 
miRNA binding and translational repression, and this 6nt sequence is called the miRNA 
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‘seed’ sequence [499]. There is much data to support the requirement of contiguous base 
pairing of the miRNA seed sequence to its target, mostly from mutational studies [500-502].  
The importance of the miRNA seed sequence for miRNA function was first identified 
computationaly following the discovery that only the miRNA seed sequences are conserved 
across different species [459, 503]. Studies showing that mutuation of the miRNA seed 
sequence abolished miRNA function provided conclusive evidence that miRNAs function 
predominantly through seed sequence recognition [478] Collectively, there is strong evidence 
that the miRNA seed sequence is a significant factor in determining miRNA mediated 
translational repression. However, as previously discussed, miRNA targets have been 
identified which do not demonstrate conventional miRNA:mRNA binding in the seed 
sequence [353, 481, 484-486], suggesting that additional factors which influence miRNA 
binding are yet to be identified. 
The 3’ portion of the miRNA can also enhance the repression of miRNA targets which 
already contain a strong 5’ pairing [499, 501, 504, 505], although strong 3’ pairing cannot 
compensate for a weak 5’ miRNA:mRNA pairing interaction [501].  
The presence of multiple miRNA binding sites, either for the same miRNA or multiple 
miRNAs, is generally required for efficient translational repression of mRNA targets [441, 
499, 504, 506]. This is in contrast to miRNA induced cleavage of target mRNAs with 100% 
complementarity binding sites, where only one miRNA target site is usually sufficient [441, 
506].  
(ii) miRNA target prediction programs: Predicting miRNA target genes has proved 
challenging due to the variability of miRNA target sites. Numerous miRNA target prediction 
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programs have been developed and there are three key principles which are used to identify 
miRNA target genes:  
(a) sequence matching, where most miRNA target prediction programs devise a scoring 
system based on the degree of miRNA:mRNA  complementarity. Pairing in the seed region of 
the miRNA will be given a greater weight for matches, or penalty for mis-matches, than the 
rest of the miRNA as this region is considered the most important determinant of miRNA 
action. The programs usually encompass a set of rules defined by mutational studies. For 
example, Enright et al [491] state that there can be no mis-matches at positions 2 or 4, fewer 
than 5 mis-matches between positions 3 and 12, and there must be at least one mis-match 
between positions 5 and the 3’ terminus of the miRNA. Each program may define a slightly 
different set of parameters and rules, resulting in a different predicted gene list. 
(b) Thermodynamic calculations are employed by most miRNA prediction programs which 
requires the calculation of the free energy for each predicted miRNA target interaction to be 
estimated. The free energy is calculated using an algorithm to generate all suboptimal 
secondary RNA structures between the minimum free energy and an arbitrary upper limit 
[491, 507]. A limitation of this form of analysis is that the proteins which facilitate the 
miRNA:mRNA interaction are not yet defined, and the contribution of these proteins to the 
free energy therefore cannot be calculated. With the current literature suggesting that the 
protein components of the miRISC can alter under different cellular conditions [487], the 
contribution of these proteins to the miRNA:mRNA interactions may be significant, and may 
even explain the reported change in miRNA function observed under different cellular 
conditions [480].  
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(c) Evolutionary conservation of the predicted miRNA target site is the final common 
principle upon which miRNA target predictions are based. Some target prediction programs 
(such as Target Scan [492]) allow the user to view highly conserved and/or low and non-
conserved miRNA target genes. Other programs, such as miRanda [491], account for the 
degree of evolutionary conservation in the overall target site score value. Placing a different 
emphasis on evolutionary conservation may produce significant differences in the number of 
gene targets predicted. Additionally, discounting a predicted target site because it is not 
evolutionary conserved may not be an effective method for identifying miRNA target sites in 
humans, as it is reasonable to assume that some miRNA:mRNA interactions will be species 
specific. Likewise, it possible that some miRNA target sites in mRNAs will be evolutionary 
selected against as the resulting interaction is detrimental for gene expression. 
1.16 The function of miRNAs in mammals 
The discovery of miRNAs in 1993 prompted the re-evaluation of how cellular processes are 
regulated. Subsequent investigations have revealed that miRNAs are important regulators of a 
host of cellular processes, including the regulation of the immune response [508, 509], 
apoptosis [510], proliferation [511] and cellular differentiation [512]. The majority of the 
1048 currently identified mature miRNAs in the human genome [513] have no known 
function, therefore, the true extent of miRNA mediated gene regulation in humans remains 
uncertain. Computational analyses predict that approximately 30-90% of known protein 
coding genes in humans are regulated by miRNAs [514, 515], suggesting that miRNAs have 
the potential to influence the expression of a significant portion of the cellular proteome.   
(i) Cellular differentiation and immune regulation: The apparent tissue specific expression 
of miRNAs suggested that miRNAs may have important roles in the regulation of cellular 
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differentiation. This hypothesis was supported by the observation that embryonic 
development was accompanied by a significant increase in cellular miRNA expression [516]. 
Additionally, mouse embryonic stem cells which are Dicer-1 deficient, and therefore cannot 
produce mature miRNAs, are defective in differentiation [387]. The disruption of miRNA 
expression has been shown to affect the differentiation of a wide variety of cell types, 
including neuronal cells [459, 517, 518], epithelial cells [519], myoblasts [520], adipocytes 
[521] and lymphocytes [512, 522]. The modulation of lymphocyte differentiation by miRNAs 
is one of the ways by which miRNAs modulate immune function. 
miRNAs have been shown to regulate the lineage differentiation of B and T cells; Dicer-1 
deficient mice show defects in T cell differentiation [388, 523]. More specifically, miR-181a 
expression can affect the differentiation of B and T lymphocytes [512, 524]. Mouse studies 
demonstrated that over-expression of miR-181a facilitated B cell differentiation and resulted 
in a 2 fold reduction in the number of circulating T lymphocytes, whilst also disrupting the 
distribution of CD4
+
 and CD8
+
 T cells [512, 525]. Furthermore, the two miRNAs processed 
from the miR-142 gene (miR-142-3p and miR-142-5p) were shown to substantially alter the 
lineage differentiation of haematopoietic progenitor bone marrow cells from mice [512]. The 
expression of miR-142 in these cells resulted in a 30-40% increase in the T cell lineage. The 
importance of miR-142-3p and miR-142-5p in T cell immune function was strengthened 
when miRNA profiling revealed that 60% of all the miRNAs present in T cells are constituted 
by just 7 miRNAs; two of which were miR-142-3p and 142-5p [526]. This observation 
suggests that although the majority of miRNAs have fine tuning role in cellular gene 
expression, a small subset in each tissue may be significant mediators of cellular signalling. 
Recently, the contribution of miRNAs to B cell differentiation was investigated by Zhang et 
al [524] who demonstrated a specific pattern of miRNA expression at each stage of B cell 
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differentiation. This led to the identification of the miR-30 family and miR-9 as miRNAs 
whose expressions were elevated in GC B cells, and decreased in plasma cells. These 
miRNAs were shown to effectively target B-lymphocyte induced maturation protein 1 
(BLIMP1), a gene important for B cell differentiation, thereby aiding the regulation of the GC 
to plasma cell stage of B cell differentiation [524]. Collectively, these data demonstrate that 
miRNAs are significant mediators of B and T cell differentiation, and consequently immune 
regulation. 
In addition to the modulation of lymphocyte differentiation, miRNAs have been demonstrated 
to regulate T cell activation. For example, miR-181a was demonstrated to fine tune the 
sensitivity of T cell receptor signalling (TCR) during thymic development. This was achieved 
through miR-181a mediated regulation of multiple phosphatases which act as negative 
regulators of the TCR signalling pathway [284]. The regulation of TCR strength by miR-181a 
was shown to be capable of altering the T-cell threshold and sensitivity to antigens; thus, 
miR-181a is an example of a miRNA which is able to modulate the expression of multiple 
target genes to control a complex signalling pathway. 
miRNAs may also have a role in the regulation of the immune response, demonstrated by 
miRNA expression profiling of monocytes following toll-like receptor (TLR) activation. miR-
146a/b were shown to be induced by ligands of TLRs which recognise bacteria (TLR2, 
TLR4and TLR5), and these miRNAs were also shown to be capable of inhibiting the 
expression of two adaptor molecules in the TLR and interleukin-1β (IL1-β) pathways; TNF 
receptor-associated factor 6 (TRAF6) and IL-1 receptor-associated kinase 1 (IRAK1). 
Consequently, both miR-146a/b were proposed to play a role in dampening the TLR 
signalling response to bacterial products, preventing excess inflammation [508]. The 
importance of miR-146a/b in controlling the inflammatory response was supported by the 
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observation that the expression of these miRNAs is altered in the chronic inflammatory 
disease, psoriasis [527]. However, the effect of LPS stimulation on mouse lungs revealed 12 
miRNAs whose expression was significantly altered following LPS stimulation in vivo, and 
miR-146a/b were not altered in this model [528]. It is clear that miRNAs are modulators of 
the immune response but which miRNAs are involved and what genes are specifically 
regulated by miRNAs remain obscure.  
It has been shown that miRNAs are involved in the host-response to viral infection. 
Interestingly, miR-122 has been shown to actually enhance the translation of hepatitis C virus 
(HCV), possibly through aiding RNA folding as the seed sequence of miR-122 is not required 
for the enhancement of HCV replication [482]. Consequently, miR-122 is a therapeutic target 
for the treatment of HCV infection, and the development of chemical inhibitors of miR-122 
are currently being investigated [529]. Interferon-β (IFN-β) signalling has been shown to up-
regulate the expression of 8 miRNAs which have seed matches in the HCV genome, and 
therefore may contribute to the viral defence against this gene [530]. IFN-β signalling was 
also shown to down-regulate the expression of miR-122, suggesting that the cellular miRNA 
expression profile is altered in response to viral infection as a host-defence mechanism [530]. 
Additionally, miR-32 is able to repress the replication of the retrovirus primate foamy virus 
type 1 (PFV1) by negatively regulating the expression of five PFV1 mRNAs in vitro [531]. 
Furthermore, a suppressor protein encoded by PFV1 (Tas) can counteract the repressive effect 
of miR-32, although this effect may not be specific to miR-32, as Tas showed a broad 
negative effect on miRNA and siRNA function in a plant system [531]. These data 
demonstrate the wide ranging functions of miRNAs in the modulation of the immune 
response, including anti-viral, and in some instances pro-viral responses, providing an 
additional level of complexity to the host-innate immune response. 
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(ii) Regulation of cell proliferation: There is accumulating evidence to suggest that miRNAs 
have a central role in cell-cycle regulation. For example, miR-34 family members have been 
shown to be direct targets up-regulated by p53 [532], and the ectopic expression of miR-34 
induces cell-cycle arrest [533]. A family of miRNAs sharing seed region homology with miR-
16 were shown to negatively regulate cell-cycle progression from G0/G1 to S phase [534]. 
Interestingly, the transcription factor c-myc, which regulates cell proliferation and apoptosis, 
has been shown to up-regulate a cluster of six miRNAs called the miR-17-92 cluster. Two of 
these miRNAs (miR-17-5p and miR-20a) were found to negatively regulate E2F1, a target of 
c-myc whose down-regulation is required for cell-cycle progression [511, 535]. Furthermore, 
the miR-106b family were also shown to target the E2F1 transcription factor, as well as the 
cyclin dependent kinase inhibitor p21/CDKNIA, promoting cell-cycle progression [536, 537]. 
Multiple reports have linked the expression of miRNAs to the control of cell-cycle regulation 
and apoptosis, and not surprisingly, the majority of these reports have been in the context of 
cancer development and are therefore discussed in the following section. 
 
1.17 miRNAs and cancer 
The role of miRNAs in mammalian cells is exemplified by the apparent deregulation of 
miRNA expression observed in numerous diseases, particularly cancer. Approximately half of 
all known miRNAs are located at fragile sites and regions associated with cancer [538]. 
Furthermore, miRNA expression increases in a spatial and temporal manner during 
embryonic development [516, 539], suggesting that miRNAs are involved in regulating the 
process of cellular differentiation. This led to the hypothesis that the global down-regulation 
of miRNAs observed in most cancer reflects a loss of cellular differentiation [398, 540], 
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which is a common characteristic of cancerous cells. This hypothesis is strengthened by 
reports which demonstrate that Dicer-1, Drosha and DGCR8 knock-down tumour cell lines 
show a global decrease in miRNA expression, coupled with an enhanced tumourogenic 
phenotype [402]. Additionally, miRNA biogenesis associated genes such as Dicer-1, Drosha 
and Ago-2, show high frequency copy number abnormalities in cancer tissue relative to 
healthy tissue [398, 541].  
It has been reported that expression of the oncogene c-myc causes a global down-regulation 
of miRNA expression, perhaps representing an additional mechanism by which c-myc 
enhances tumourogenesis [542]. The global miRNA down-regulation induced by c-myc had a 
notable exception, which was the miR-17-92 cluster of miRNAs, and the 6 miRNAs in this 
cluster are generally accepted to be oncogenic miRNAs, or ‘oncomiRs’ [543, 544]. 
(i) oncogenic miRNAs: As the number of functional studies of miRNAs has increased, a 
subset of miRNAs which display unambiguous oncogenic phenotypes have been indentified, 
most notably, miR-155, the miR-17-92 cluster and miR-21. 
(a) miR-155: miR-155 is encoded by the non-coding gene, B cell integration cluster (BIC), 
which was found to be a common integration site of Avian Leukosis Virus (ALV) of 
chickens, commonly in conjunction with c-myc activation in tumours [545]. ALV causes the 
up-regulation of BIC expression through integration at the BIC locus where the provirus 
drives expression of BIC through promoter insertion. A chimeric BIC RNA can be detected 
which contains the viral LTR R-U5-leader-gag sequence of AVL spliced to exon 2 of BIC, 
driving miR-155 expression through ALV integration [545]. The identification of miR-155 as 
a miRNA elevated in conjunction with c-myc in tumours led to the hypothesis that miR-155 
enhanced c-myc induced lymphomagenesis [545]. Indeed, transgenic mice with a miR-155 
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transgene expressed in B cells (Eμ-mmu-miR-155) were studied, and 7/7 of the mice showed 
preleukemic pre-B cell proliferation in spleen and bone marrow which later progressed to 
high grade B cell neoplasms [546]. Thus, miR-155 was the first miRNA classified as 
oncogenic [547], and its over-expression has since been linked to many cancers [548-550], 
particularly lymphomas [374, 551-556].  
(b) miR-17-92: The miR-17-92 cluster is regarded as an oncogenic polycistron as its 
expression is up-regulated in both haematopoietic and solid tumours [160, 557-559]. The 
human miR-17-92 cluster is located on 13q31.3, a locus which is frequently amplified in 
lymphoma [557, 560, 561]. The miR-17-92 polycistron encodes 6 mature miRNAs: miR-17, 
miR-18a, miR-19a, miR-20a, miR-19b and miR-92a; the sequences of these miRNAs are 
highly conserved across all vertebrates [560]. The miR-17-92 locus was shown to be a 
common integration site in mouse models of retroviral induced leukaemia, which was further 
indication that this miRNA cluster had an oncogenic role [559, 562]. 
Myc was demonstrated to be a potent transcriptional activator of the miR-17-92 cluster [535]. 
Additionally, mouse models have shown that the miR-17-92 cluster of miRNAs enhances c-
myc induced tumourogenesis through inhibition of apoptosis, strongly suggesting an 
oncogenic function for these miRNAs [544, 563]. The anti-apoptotic phenotype induced by 
miR-17-92 over-expression in c-myc-induced tumours has been demonstrated to involve the 
targeted down-regulation of the tumour suppressor gene, phosphatase and tensin homologue 
(PTEN), by miR-19a/b [563, 564]. Inhibition of PTEN results in the activation of the pro-
survival Akt-mTOR pathway, thereby antagonising the apoptotic phenotype induced by c-
myc [563, 564]. An anti-apoptotic phenotype for the miR-17-92 cluster was also observed 
when expression of miR-17-92 was demonstrated to inhibit hypoxia-induced apoptosis. 
Moreover, the expression of miR-17-92 were down-regulated by wild type p53 under hypoxic 
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conditions [565]. Finally, miR-17 and miR-20 have been demonstrated to inhibit the 
expression of the E2F1 transcription factor, enhancing cell proliferation. Collectively these 
data demonstrate a clear oncogenic function for the miR-17-92 cluster. 
(c) miR-21: miR-21 expression has been reported to be increased in breast cancer [566], 
pancreatic cancer [549], head and neck cancer cell lines [567], cervical cancer tissue [568], 
NK-cell lymphoma [556] and DLBCL [551], suggesting an oncogenic role for this miRNA. 
The inhibition of miR-21 has been shown to induce apoptosis in a number of cell lines [566, 
569, 570], including multiple myeloma cells, where miR-21 was up-regulated by STAT3, and 
it was shown to have an anti-apoptotic effect on the cells [571]. miR-21 knockdown was also 
demonstrated to induce apoptosis of breast cancer tumour cells in a xenograft mouse mode, 
which was partly ascribed to indirect miR-21 mediated up-regulation of Bcl2 [566]; indicating 
an anti-apoptotic function for miR-21 in tumour development. miR-21 has also been 
demonstrated to enhance proliferation of tumour cell lines in vitro [566, 572, 573]. In addition 
to the up-regulation of the oncogene Bcl2, miR-21 has been shown to target and repress 
protein expression of the tumour suppressor genes PTEN [556, 573] and tropomyosin 1 [574]. 
Therefore, miR-21 may contribute to tumour development by enhancing cellular growth and 
protecting cells from apoptosis via the regulation of known oncogenes and tumour suppressor 
genes. 
(ii) Tumour suppressor miRNAs: The global down-regulation of miRNAs in cancer could 
be interpreted to signify that the majority of miRNAs have a tumour suppressive function. 
Nevertheless, current investigations have only identified a small number of miRNAs whose 
repression is favourable for tumour development. It may be that the combined effect from 
multiple down-regulated miRNAs is required to enhance tumourogenesis. However, it has 
been observed that B cell malignancies do not typically exhibit a global down-regulation of 
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miRNAs, although they do have miRNA expression profiles which are distinct from healthy 
tissue [524]; suggesting that a global down-regulation of miRNAs is not always required for 
tumour development.  
The miR-15a and 16 cluster is located at 13q14, a region frequently deleted in cancer [575], 
most notably in CLL [576], where loss of miR-15a and miR-16 expression was shown to 
cause an increase in the expression of the anti-apoptotic protein Bcl2 [510]. Consistent with 
this, re-expression of miR-15a and miR-16 in CLL cell lines induced apoptosis [510]. In a 
model of gastric cancer, miR-15a/16 down-regulation was shown to facilitate multi-drug 
resistance in tumours; this function could be partially ascribed to the loss of miR-15a/16 
mediated suppression of Bcl2 [577]. Consequently, it has been proposed that miR-15a/16 
mimics could be used to treat multi-drug resistance (MDR) in gastrine cancer, as re-
expression of miR-15/16 has been shown to reduce the MDR of gastiric cancer cell lines, 
partially via the up-regulation of Bcl2 [577]. Additionally, miR-15a/16 were down-regulated 
by c-myc, and the re-expression of these miRNAs in c-myc induced tumours in mice was 
detrimental for tumour growth [542], possibly due to the pro-apoptotic function of these 
miRNAs. The tumour suppressive functions of miR-15a/16 may extend to an anti-
proliferative effect, as expression of these miRNAs results in cell-cycle arrest [534] and re-
expression of miR-15a/16 in lung cancer cell lines causes cell-cycle arrest, in an Rb-
dependent manner [578]. 
Additional miRNAs which have been demonstrated to exert a tumour suppressive function 
include the let7 family of miRNAs, which have been shown to negatively regulate the 
oncogene Ras in lung tumours [579, 580]. Expression analysis has suggested that miR-143 
and miR-145 may have tumour suppressive functions as expression of these miRNAs is 
significantly decreased in a number of solid tumours including colorectal cancer, breast 
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cancer and cervical cancer [568, 581], as well as B cell malignancies [582]. A possible role 
for miR-143 in the negative regulation of the oncogene KRAS has been reported in colorectal 
cancer cell lines, suggesting that the loss of miR-143 in cancer may facilitate un-regulated 
KRAS expression [583]. 
(iii) miRNAs and therapy: The deregulated expression of miRNAs has enabled miRNA 
expression to be used as biomarkers for disease diagnosis [584] and has the potential to be 
exploited for gene therapy. miRNAs hold significant promise for gene therapy due to their 
small size and consequent ease of delivery, and their cytoplasmic localisation negates the 
need for nuclear delivery mechanisms. However, the recently described exosome-mediated 
transfer of miRNAs [419, 420, 585] will need to be investigated further before the potential 
toxicity of miRNA gene therapy can be fully evaluated. 
Gene therapy involving miRNAs would involve inhibition of oncomiRs, such as miR-21, 
using ‘antagomiRs’, and re-expression of tumour suppressive miRNAs, such as the miR-
15a/16 cluster, using miRNA mimics [456]. The mode of action of miRNAs also poses a 
significant advantage for gene therapy as miRNAs target a large number of proteins in 
multiple pathways, therefore, modulation of only one or two miRNAs could significantly 
affect the expression of many oncogenic pathways; consistent with the current view of cancer 
as a disease which involves the deregulation of multiple pathways [586]. 
miRNA gene therapy is in its infancy, however, the liver specific miR-122 is already entering 
phase II clinical trials for the treatment of HCV infection (discussed in section 1.15 [529, 
587]) and there are a number of pre-clinical and clinical trials pending for miRNA gene 
therapy in cancer treatment [588]. For example, Rosetta Genomics are currently designing a 
miRNA based therapy aimed at treating liver cancer, inspired by an in vivo mouse model 
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which demonstrated a halt in disease progression or total relapse of hepatocellular carcinoma 
in mice treated with miR-26a mimics [588]. Indeed, in vitro and in vivo models have 
demonstrated a sound scientific logic for miRNA based therapy [510, 542, 577, 579], 
although, until the results of the pending clinical trials are available, the true potential of 
miRNA therapy will remain uncertain.  
1.18 The function of miRNAs in Viruses 
It is currently believed that only DNA viruses encode miRNAs [48, 589], however, this is 
controversial for HIV [589-591]. The herpesvirus family has the most prevalent expression of 
miRNAs [48, 592-594], although primate polyomavirus and human adenoviruses have also 
been shown to encode miRNAs [48, 589, 595, 596]. It has been proposed that the presence of 
miRNAs in the genomes of herpesviruses may be due to the characteristic long-term latent 
infections of this virus family [597]; as evidence suggests that the non-antigenic miRNAs are 
able to modulate numerous host and viral pathways to facilitate latent infection, immune 
evasion and lytic replication [485, 598, 599].  
Viral miRNAs have a similar genome structure, biogenesis and mode of action to cellular 
miRNAs [48]. Viral miRNAs have been shown to target cellular, as well as viral genes [163, 
221], suggesting that the interplay between cellular and viral miRNAs is complex, with both 
host and viral miRNAs capable of regulating cellular and viral mRNAs. Despite much 
research over recent years, the number of experimentally validated viral miRNA targets is still 
only modest. Nevertheless, the few known viral miRNA targets suggest that viral miRNAs 
may play a significant role in the control of immune evasion (i) and apoptosis resistance (ii).  
(i) immune evasion: human cytomegalovirus (HCMV) miR-ULL112 has been shown to 
target the NK cell ligand, major histocompatibility complex class I related chain B (MICB), 
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inhibiting NK cell recognition of HCMV infected cells [485]. Likewise, the EBV encoded 
miR-BHRF1-3 has been shown to down-regulate the CTL chemoattractant CXCL11, 
reducing the recognition of EBV infected cells by CTLs [220]. In addition, the antigenic T 
antigens expressed by SV40 are targeted by SV40 encoded miRNAs to reduce CTL 
recognition of infected cells, indicating that viral miRNAs target host and viral genes to evade 
the immune response [600].  
(ii) apoptosis resistance: Herpes simplex virus-1 (HSV-1) encoded miRNAs, miR-LATs, can 
down-regulate components of the pro-apoptotic TGF-β pathway, including TGF-β and 
SMAD-3 [601]. KSHV encoded miRNAs have also been demonstrated to target genes which 
result in the down-regulation of the TGF-β signalling pathway via the down-regulation of the 
tumour suppressor gene, Thrombospondin-1 [602]. Additionally, EBV encoded miR-BART5 
has also been shown to target the pro-apoptotic protein, p53 up-regulated modulator of 
apoptosis (PUMA) in NPC, as a means of protecting cells from apoptosis [221].   
The discovery of viral miRNAs has added a layer of complexity to the viral-host interaction, 
and a greater understanding of how viral miRNAs modulate the cellular environment is 
required to fully understand viral infection and persistence.  
 
1.19 Cellular miRNAs and EBV 
When this project began in 2007, there was little information available regarding EBV-
mediated regulation of cellular miRNA expression. Only one study to our knowledge had 
documented the expression of cellular miRNAs following EBV infection of resting B cells 
and this study had used subtractive hybridisation and northern blotting to identify miRNA 
species in LCLs [603]. However, the sensitivity of this assay was limited and only 7 cellular 
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miRNAs were identified as up-regulated by EBV infection of resting B cells (miR-155, miR-
21, miR-29b, miR-146a, miR-23a, miR-27a and miR-34a), and no miRNAs were identified as 
down-regulated following EBV infection. Thus, a comprehensive investigation into EBV-
mediated regulation of cellular miRNA expression had not yet been performed. 
Aims and objectives 
It is evident that growth-transformation of resting B cells by EBV requires the modulation of 
cellular gene expression, including genes associated with oncogenesis, such as tumour 
suppressor genes and oncogenes. It is the EBV-mediated modulation of cellular gene 
expression which is likely to lead to immortalisation of LCLs in culture, a process which is 
analogous to the multi-pathway deregulation required for tumourogenesis. miRNAs are 
capable of regulating a large number of genes in multiple pathways, therefore, the modulation 
of the cellular miRNA environment by EBV may enable the virus to modulate the multiple 
signalling pathways required to facilitate the maintenance of viral latency, viral persistence, 
and possibly contribute the development of EBV associated-malignancies. The objective of 
this thesis was to investigate the role of cellular miRNAs in EBV-mediated B cell 
transformation.  
In results chapter I, we investigate the regulation of the oncogenic miRNA miR-155 by EBV, 
a miRNA which was known to be abundantly expressed in HL. We also sought to investigate 
the reported processing defect of miR-155 in BL and to determine whether the biogenesis of 
this miRNA was regulated by EBV.  
In results chapter II, we sought to identify the extent to which expression of particular 
miRNAs were regulated by EBV during B cell transformation. We used sensitive QPCR-
arrays to measure the cellular miRNA expression profile of EBV infected B cells and CD40L 
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+ IL4 stimulated B cell blasts. A comparison between proliferating B cell blasts and EBV 
transformed B cells was designed to enable the identification of miRNAs whose modulation 
by EBV was specific to transformation rather than transient activation and proliferation of a 
resting B cell. The expression and function of miRNAs whose expression changes were 
transformation specific were subsequently investigated. 
In results chapter III we profiled the cellular gene expression of EBV infected and CD40L + 
IL4 stimulated blasts. The aims of results chapter III were twofold: firstly, to identify 
transformation associated genes whose expression may have been modulated by 
transformation associated miRNAs from results chapter II; secondly, to identify candidate 
tumour suppressor genes whose down-regulation by EBV may aid transformation and 
contribute to the development of EBV associated malignancies. The expression and function 
of candidate tumour suppressor genes was further investigated using a lentiviral based 
expression system.  
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2. Materials and Methods 
 
2.1 Cell Culture 
2.1.1 Maintenance of cell lines 
B cells, B cell lines and virus producing 2089 cells were grown in cell culture medium which 
contained  medium (RPMI1640 medium, Sigma) supplemented with 10% v/v foetal calf 
serum (FCS), 2mM glutamine (Gibco), and 5000U penicillin/streptomycin (Gibco). Mutu-BL 
were grown in normal BL medium with 20nM Bathocuproine disulfonic acid (BCS) (Sigma), 
50µM α-thioglycerol (Sigma) and 10mM HEPES buffer (Sigma).  
293-FT cell culture media contained DMEM medium (Invitrogen) supplemented with 10% 
v/v bovine calf serum (BCS), which was previously heat inactivated at 56°C for 1 hour, 
5000U penicillin/streptomycin (Gibco) and 1.2mg of G418. The lentivirus production media 
consisted of DMEM medium (Invitrogen) supplemented with 10% v/v BCS, which was 
previously heat inactivated at 56°C for 1 hour, 5000U penicillin/streptomycin (Gibco). All 
cells were grown at 37°C, 5% CO2 in 25cm
2
 flasks (suspension cells) or 100mm plates 
(adherent cells). 
2.1.2 Cryopreservation of cells 
Approximately 1x10
7 
cells were pelleted by centrifugation at 1,400rpm for 5 minutes and re-
suspended in 1ml of medium (RPMI1640 medium, Sigma) supplemented with 20% v/v foetal 
calf serum (FCS), 10% v/v dimethylsulphoxide (DMSO), 2mM glutamine (Gibco) and 5000U 
penicillin/streptomycin (Gibco). Cells were placed in a Mr Frosty container surrounded by a 
sponge soaked in propan-2-ol and stored for at least 4 hours at -80°C before being transferred 
to the vapour stage of a liquid nitrogen freezer at -180°C for long term storage.  
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2.1.3 Recovery of cells from liquid nitrogen 
10ml of cell culture medium was pre-warmed to 37°C. Cells were then quickly defrosted at 
37°C to minimise exposure to DMSO and then added drop-wise to the pre-warmed media. 
Cells were then pelleted by centrifugation at 1,400 RPMI for 5 minutes and re-suspended in 
10ml of tissue culture medium in a 25cm
2
 flask and cultured at 37°C and 5% CO2. 
2.2 Isolation of B cells 
2.2.1 Separation of PBMCs from whole blood 
Blood from buffy coat samples (Blood Transfusion Service, Birmingham) was diluted with 
sterile PBS to a total volume of 125ml and layered underneath lymphoprep separation 
medium (Lymphoprep, Robbins Scientific) in a 250ml centrifuge tube (Corning). This was 
then centrifuged at 1800rpm for 30 minutes and slowed without a brake to maintain a 
gradient. Peripheral blood mononucleocytes (PBMCs), which form a distinct buffy coloured 
layer at the interface between the serum and the red blood cells were extracted using a 10ml 
pipette. The PBMCs were washed twice in sterile PBS by centrifugation at 1600 rpm for 10 
minutes and then 1200 rpm for 10 minutes. PBMCs were then re-suspended in 10ml of RPMI 
1% v/v FCS and counted. The number of B cells was estimated based on the assumption that 
5% of the PBMCs were B cells. PBMCs were either stored overnight at 4°C or processed 
immediately for CD19
+ 
B cell isolation. 
2.2.2 CD19 selection of B cells from PBMCs 
CD19 is a B cell specific maker and can be used to isolate resting B cells from peripheral 
blood. Magnetic polystyrene beads coated in monoclonal antibody to CD19 (Pan B CD19 
Dynabeads (Dynal)) were used to positively select B cells from PBMCs by exposure to a 
magnet. The number of CD19 Dynabeads needed was calculated (4 Dynabeads per B cell) 
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and added to the PBMCs at a concentration of 10
7
 Dynabeads per ml in a 14ml round 
bottomed tube and incubated at 4°C for 30 minutes on a roller. The B cells bound to the 
Dynabeads were then removed from the PBMCs by exposure to a magnet for 2 minutes. Non- 
B cells were removed with a Pasteur pipette and the B cells bound to the Dynabeads were 
washed 5 times with 10ml of RPMI 1% v/v FCS. The B cells bound to Dynabeads were then 
re-suspended in 1ml RPMI 1% FCS and 50ul of Detatchabead CD19 (Dynal) was added to 
the cells in a 14ml round bottomed tube and incubated at room temperature for 45 minutes on 
a roller. 9ml of RPMI 1% v/v FCS was then added to the suspension and the Dynabeads 
removed from the B cells by exposure to a magnet. The Dynabeads were washed once with 
10ml of RPMI 1% v/v FCS and the total number of CD19
+
 B cells counted. 
2.2.3 Analysis of cell purity by fluorescence activated cell sorting (FACS) 
The purity of the B cell preparation was assessed by staining cells with the alternative B cell 
marker, CD20. 2x10
6
 CD19
+
 B cells were each washed 3 times in PBS in a FACS tube. Both 
the CD21 antibody (Mouse CD21/RPE-Cy5, Dako) and the isotype control (Mouse 
IgG1/RPE-Cy5, Dako) were diluted 1/20 with 5% v/v heat inactivated goats serum (HINGS). 
Cells were mixed with the antibody and incubated on ice for 30 minutes in the dark. Cells 
were then washed 3 times with PBS and re-suspended in either 1ml of PBS if they were going 
to be analysed immediately or in 1ml of 2% paraformaldehyde in PBS and stored at 4°C in 
the dark until used.  
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2.3 EBV infection experiments 
2.3.1 Preparation of EBV stocks 
293 cell clones stably transfected with the recombinant B95.8 EBV genome were plated into 6 
well plates 24-48 hours prior to transfection. When the cells were 70% confluent they were 
transfected with 0.5µg of BZLF1 and 0.5µg of BALF4 (gp110) plasmids [604, 605] per well 
using Lipofectamine (Invitrogen) reagent in Optimem minimal medium (Gibco) according to 
manufacturer’s instructions and incubated for 3 hours at 37°C, 5% CO2. 1ml of cell culture 
medium was then added to each well and the supernatant was harvested 72hours later, 
centrifuged at 2000rpm for 5 minutes and filtered using a 0.45µm filter to remove cellular 
contaminants. This supernatant was either used directly or stored as aliquots at -80°C. 50µl of 
virus supernatant was kept for virus quantification. 
2.3.2 Recombinant EBV 
Recombinant EBV was provided as 293 producer clones deleted for either LMP1 [606] or 
gp42 [604] and these viruses were  prepared, titred and used to infect B cells via the same 
methods as the wtEBV (sections 2.3.1, 2.3.3 and 2.3.4) 
2.3.3 Quantitation of EBV titre by Q-PCR 
An equal volume of  lysis buffer (100mg/ml proteinase K (Roche), 10mM Tris-HCL pH 8.8, 
1.5ml MgCl2, 50mM KC:, 0.1% v/v Triton X-100) was added to the virus supernatant and 
incubated at 55°C for 1 hour followed by 99°C for 10 minutes to heat inactivate the proteinase 
K. quantitative PCR was then carried out for the EBV polymerase gene (BALF4) (see section 
2.8.3) 5µl of processed viral supernatant was added per well of a 96 well to a quantitative 
PCR reaction to determine the number of EBV genomes per ml of virus supernatant.  
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2.3.4 B cell infection with EBV 
CD19-positive B cells were spun down at 1200rpm for 5 minutes and re-suspended in an 
appropriate volume of virus supernatant to give the desired m.o.i and incubated at 4°C for 2 
hours. B cells were then spun out of the virus supernatant at 1200rpm and re-suspended in cell 
culture medium (2x10
6
 B cells/ml) and cultured at 37°C and 5% CO2. At each time point 
between 2x10
6
 and 7x10
6
 cells were harvested for RNA and between 8x10
6
 and 20x10
6
 cells 
were harvested for protein. 
  
2.4 Generation of B cell blasts 
5x10
6
 CD19
+
 resting B cells per well of a 6 well plate were cultured in cell culture medium 
with 50ng/ml of soluble trimeric human recombinant megaCD40L (Alexis Biochemicals) and 
50ng/ml interleukin 4 (IL4) (ProSpec-Tany). For comparison, 5x10
6
 B cell blasts were also 
generated using mouse fibroblast cells stably transfected with CD40L (L-CD40L cells), as 
previously described [607] and 50ng/ml of IL4 (ProSpec-Tany) in culture medium. Medium 
was changed twice a week.  
 
2.5 Stimulating B cells with anti-CD21 
1x10
7
 CD19
+
 resting B cells were spun down and re-suspended in 500µl of 10% heat 
inactivated goat serum (Hings) with 12µl of CD21 mouse monoclonal antibody (Abcam) and 
incubated at room temperature for 1hour. Cell culture medium was then added to the cells and 
they were cultured at 37°C, 5% CO2. 
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2.6 Stimulating ERK phosphorylation in LCLs 
LCLs were washed in culture media, counted and re-suspended in culture media at a 
concentration of 0.5 x 10
6
 cells per ml. ERK phosphorylation was stimulated in LCLs 
following the addition of 20µg/ml of 12-O-tetradeconoylphorbal-13-acetate (TPA), dissolved 
in DMSO, to the culture media. Cells were cultured for 24 hours at 37°C, 5% CO2. Cells were 
harvested for protein (section 2.17.1) and lysed in mirVana™PARIS™ cell disruption buffer, 
plus 100µl/ml of phosSTOP (Roche), a cocktail of phosphatase inhibitors designed to prevent 
the loss of phosphorylation in protein samples. Sample preparation for western blot was 
otherwise the same as described in section 2.17.1. 
 
2.7 RNA extraction 
All procedures were performed on ice with RNase free eppendorff tubes and filter tips. Total 
RNA was extracted using the mirVana
TM
 PARIS
TM
 kit (Ambion, Europe) according to the 
manufacturer’s instructions. Briefly, between 5 x 105 and 1 x 107 cells were harvested, 
washed once with PBS and re-suspended in 300-600ul of ice cold Cell Disruption Buffer and 
an equal volume of Denaturing Solution and then extracted with an equal volume of Acid-
Phenol:Chloroform. The aqueous phase was extracted and 1.25 volumes of 100% ethanol was 
added to the lysate which was then passed through a filter cartridge. The bound RNA was 
washed three times in the Wash Buffers and then eluted in 50-100ul of 95°C Nuclease Free 
Water (Ambion, Europe). The RNA concentration was determined using a Nanodrop (Thermo 
Scientific) according to manufacturer’s instructions and the RNA samples were aliquotted and 
stored at -80°C. 
 
Materials and Methods 
 
Page 69 
 
2.8 Reverse Transcription 
2.8.1 Principle of Taqman miRNA Reverse Transcription 
The reverse transcription of miRNAs requires primers specifically designed to bind to the 3’ 
portion of the mature miRNA sequence. These primers have a stem-loop structure which 
shows increased specificity and sensitivity over linear primers (figure 2.1). This is predicted 
to be a result of the spatial constraint and base stacking interactions of the stem-loop structure. 
The spatial constrain of the primers is believed to be the reason why these primers cannot 
bind genomic DNA or miRNA precursors. The base stacking interactions may improve the 
thermal stability of RNA primers/miRNA interaction over those of conventional linear 
primers which may be of particular importance when using relatively short primers for 
miRNA reverse transcription [608].  
2.8.2 Reverse transcription of miRNAs 
cDNA synthesis of miRNAs was performed using the Taqman® Reverse Transcription Kit 
(Applied Biosystems) according to the manufacturer’s instructions. 1-10ng of total RNA was 
added to a reaction mix containing 115nmoles dNTPs, 0.05U of MultiScribe
TM
 Reverse 
Transcriptase, 3.8U of RNase Inhibitor, 1.5µl of 10X Reverse Transcription Buffer, 4.16µl of 
nuclease free water and 3µl of a specific miRNA RT primer (table 1) to give a total volume of 
15µl per reaction in a thin walled, 0.5ml PCR tube. The Reaction mix was incubated at 16°C 
for 30 minutes, 42°C for 30 minutes and then 85°C for 5 minutes in a thermal cycler and the 
cDNA was then stored at -20°C. 
2.8.3 Reverse transcription of EBV genes 
200ng of RNA was heated to 90°C for 3 minutes to denature the RNA which was then 
incubated on ice. The RNA was added to a reverse transcription reaction mix containing 5U 
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Figure 2.1 Diagram representing the Taqman miRNA real time PCR system. This figure is 
adapted from Chen et al 2005 [608]. The reverse transcription primers are stem-loop primers 
specific for each miRNA to be assayed. These stem-loop primers are specific for the mature 
miRNA and allow extension of the cDNA providing enough length for Taqman real time 
primers and probe to bind in the real time amplification step. In traditional Taqman 
quantitative real time PCR design, the probe consists of a quencher (Q) dye and a Fam 
labelled flourescer dye (F).  
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 Avian Myeloblastosis Virus Reverse Transcriptasr (AMV-RT), reaction buffer (50mM Tris-
HCL pH 8.5, 30mM potassium chloride (KCL), 8mM magnesium chloride (MgCl2), 1mM 
dithiothreithol (DTT) (Roche), 200uM dNTPs, 1µM of the 3’ specific primer (Alta 
Bioscience) (table 2) in a total volume of 20µl. The reaction was incubated at 42°C for 1 hour 
and then 90° for 5 minutes in a thermal cycler and the cDNA was stored at -20°C. 
2.8.4 Reverse transcription of cellular genes 
20-400ng of total RNA was added to a reaction mix containing 15nmoles dNTPs, 0.05U of 
MultiScribe
TM
 Reverse Transcriptase, 3.8U of RNase Inhibitor, 1.5µl of 10X Reverse 
Transcription Buffer, 6.16µl of nuclease free water and 50pmoles  random hexamers in a total 
volume of 15µl. The Reaction mix was incubated at 16°C for 30 minutes, 42°C for 30 
minutes and then 85°C for 5 minutes in a thermal cycler and the cDNA was then stored at -
20°C. 
 
2.9 Taqman Quantitative PCR (QPCR) 
2.9.1 Principle of real time PCR using Taqman probes 
Real time PCR is a method which allows the accurate quantitation of a specific gene as the 
PCR amplification occurs. The data is collected during the exponential (log) phase of 
RNA/DNA amplification when the quantity of PCR product is directly proportional to the 
amount of nucleic acid template.  
2.9.2 Quantitative PCR of miRNAs 
miRNAs were reverse transcribed individually (singleplex) as described in 2.7.2 and this 
cDNA was used for real-time amplification to quantitate the miRNA. A 20µl reaction was set 
up in one well of a 96 well Optica Reaction Plate (Applied Biosystems) containing 10µl of 
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Taqman 2X universal PCR master mix, No AmpErase, no UNG (Applied Biosystems), 1µl of 
miRNA specific primer and probe mix (Table 1) (Applied Biosystems), 7.67µl nuclease free 
water (Ambion) and 1.33µl of miRNA specific cDNA. The plate was then sealed with Optical 
Adhesive Film (Applied Biosystems) and thermocycling and fluorescence detection were 
carried out in a 7500 Real-Time PCR System (Applied Biosystems).The samples were heated 
to 95°C for 10 minutes to activate the ApliTaq
®
 Gold polymerase enzyme, followed by 40 
cycles of denaturation at 95°C for 15 seconds and primer annealing and extension at 60°C for 
60 seconds. 
The data was analysed using the provided 7500 system software using the ddCt method of 
quantification[609]. Small nucleaolar RNAs are used as suitable endogenous controls for the 
miRNA reverse transcription and QPCR steps of the assay. The nucleolar RNAs RNU48 or 
Z30 (Applied Biosystems) were assayed separately from the miRNAs (singleplex) as both 
probes were FAM labelled. Relative expression of the miRNAs was then calculated relative to 
a calibrator sample. The dCt values were used to calculate the significance of certain results 
using the student T test. 
2.9.3 Quantitative PCR of EBV genes 
The titre of EBV viruses produced was determined by quantitative DNA-PCR using a probe 
specific for the EBV polymerase (pol) BALF5 gene. This probe was labelled with FAM at the 
5’ end and with TAMRA at the 3’ end (Eurogentiec) [610]. The Q-PCR reaction was set up in 
a 25µl reaction volume containing primer and probe combinations for BALF5 (see table 2) 
Viral number was quantified using serial dilutions of DNA from the reference BL cell line 
Namalwa-BL which is known to contain two integrated copies of EBV per cell. 
QRT-PCR assays for the EBV latent transcripts (with the exception of the EBER1 and 
EBER2 transcripts) and for the lytic cycle transcripts are described in [227].  Briefly, the  
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endogenous control used in these assays was GAPDH and the probe for this gene was labelled 
at the 5’ end with VIC and labelled at the 3’ end with BHQ (Applied Biosystems). All EBV 
latent gene probes were labelled at the 5’ end with FAM and at the 3’ end with TAMRA, thus 
allowing the expression of the gene of interest and the endogenous control to be measured at 
the same time, in the same well of the QPCR plate (multiplexed). The plate was then sealed 
with Optical Adhesive Film (Applied Biosystems) and thermocycling and fluorescence 
detection were carried out in a 7500 Real-Time PCR System (Applied Biosystems).The 
samples were heated to 95°C for 10 minutes to activate the ApliTaq
®
 Gold polymerase 
enzyme, followed by 40 cycles of denaturation at 95°C for 15 seconds and primer annealing 
and extension at 60°C for 60 seconds. 
 A full list of EBV transcripts investigated, along with their primer and probe combinations, 
are shown in table 3. EBV coordinates are based on the revised B95.8 sequence [611]. 
2.9.4 Quantitative PCR of cellular genes 
Quantitative PCR of cellular genes was performed on cDNA generated using random 
hexamers as described in section 2.8.4. Primers and probes for the gene BIC have been 
described previously [612] and were synthesised by Alta Biosciences and Eurogentec 
respectively (Table 4). Commercially available QPCR assays were purchased from Applied 
Biosystems for the following genes; Drosha, Dicer1, SPINT2, NR4A3, DUSP6, and Beta-2- 
Target Primer Sequence Final 
conc. 
B98.8 coords 
EBV pol 5’ primer 
3’ primer 
probe 
5’-AGTCCTTCTTGGCTAGTCTGTTGAC-3’ 
5’-CTTTGGCGCGGATCCTC-3’ 
5’(FAM)CATCAAGAAGCTGCTGGCGGCCT(TAMRA)-3’ 
200nM 
200nM 
200nM 
154828-154804 
154738-154754 
154779-154757 
Table 2: Primer and probe sequences for QPCR titre of EBV 
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micoglobulin. All commercially available QPCR assays were FAM labelled and used at a 
concentration of 1/20. 
Target Primer Sequence Final conc. 
BIC 
NR_001458.5 
5’ primer 
3’ primer 
probe 
5’-TCAAGAACAACCTACCAGAGACCTT-3’ 
5’-TCCTGGTTTGTGCCACCAT-3’ 
5’-6-(FAM)ACCTTGGCTCTCCCCACCCAATGGA(TAMRA)-3’ 
200nM 
200nM 
900nM 
Table 4: BIC QPCR primer and probe sequences, previously described by van den Berg et al 
[612] 
 
2.10 Taqman micro fluidic cards 
2.10.1 Principle of Taqman microfluidic cards 
Taqman microfluidic cards allow QPCR of many different genes on a single 364 well 
microfluidic card. A cDNA specific for the type of microfluidic card being run is made and 
then added to 8 ports of the card. Once centrifuged, the cDNA is distributed evenly to each of 
the 364 wells on the card to give a 1µl volume per well. Each well has a primer for a specific 
gene target dried into the bottom so the cDNA re-suspends this primer to give the final ready 
to run cDNA/primer mix. 
2.10.2 Multiplex reverse transcription for Taqman® Array Human miRNA panel v1 
A pre-designed Taqman human cellular miRNA array early release, version 1 (Applied 
Biosystems) was used to measure the expression of cellular miRNAs. The array contained 
primers for 365 human miRNAs. All reactions contained primers for two endogenous 
controls, RNU46 and RNU48. 
cDNA synthesis of miRNAs was performed using the Taqman® Reverse Transcription Kit 
according to the manufacturer’s instructions. Briefly, eight independent multiplex reverse 
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transcription reactions were prepared for each sample with eight different pre-defined 
multiplex primer pools. For each reverse transcription reaction, 100ng of RNA was added to a 
reaction mix containing 20nmoles dNTPs, 0.1U MultiScribe
TM
 Reverse Transcriptase, 2.5U 
RNase inhibitor, 1µl of 10X Reverse Transcription Buffer, 1µl of miRNA multiplex RT 
primers and 3.675µl of nuclease free water, to give a total volume of 10µl per reaction in a 
thin walled, 0.5ml PCR tube. The Reaction mix was incubated at 16°C for 30 minutes, 42°C 
for 30 minutes and then 85°C for 5 minutes in a thermal cycler and the cDNA was used 
immediately.  
2.10.3 Quantitative PCR for Taqman® Array Human miRNA panel v1 
The Taqman miRNA array cards were loaded and run according to the manufacturer’s 
instructions. Briefly, cDNA was diluted 62.5 fold by the addition of 40µl of nuclease free 
water. This was combined with 50µl of Taqman universal PCR master mix (Applied 
Biosystems) to give a 100µl total cDNA/master mix. 100µl of this RT reaction-specific 
cDNA/master mix was added to the corresponding port on the microfluidic card (figure 1.2).  
 
Figure 2.2: Diagram representing the Taqman microfluidic card system. Taqman microfluidic 
cards contain 394 wells fed by 8 ports with each port feeding approximately 50 wells. Each 
well has quantitative PCR primer and probe mix for a single gene or miRNA dried into the 
bottom which is re-suspended when the cDNA and mastermix are added. This allows 394 
individual, singleplex QPCR reactions to occur on one card. 
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The card was then centrifuged to evenly distribute the cDNA/master mix between the wells 
and the card was then sealed and loaded into a 7900HT PCR machine with a Low Density 
Array upgrade (Applied Biosystems) and run at 50°C for 2 minutes, 95.4°C for 10 minutes 
and then for 40 cycles of 97°C for 30 seconds followed by 59.7°C for 1 minute. Data was 
analysed using the supplied SDS2.2.2 software (Applied Biosystems) according to 
manufacturer’s instructions using the ΔΔCt method [609] and exported into Microsoft Excel 
for further analysis. 
2.10.4 Taqman® Custom Array 
To validate by QPCR the expression of genes of interest from the Affymetrix Exon array 
(section 2.11) we used a Taqman® Custom Arrays (Applied Biosystems). These custom 
arrays are 384 well micro fluidic cards with primers of your choice dried into the bottom of 
each well. We used format 48 cards which allow the quantitation of 47 unique assays (Table 
5) plus one mandatory control (GAPDH) for 8 unique samples per card.  
2.10.4.1 Reverse transcription for the Taqman® custom array 
For each sample, 50ng of total RNA in a total volume of 5µl was added to 10µl of master mix 
containing 115nmoles dNTPs (Applied Biosystems), 0.05U of MultiScribe
TM
 Reverse 
Transcriptase (Applied Biosystems), 3.8U of RNase Inhibitor (Applied Biosystems), 1.5µl of 
10X Reverse Transcription Buffer (Applied Biosystems), 6.16µl of nuclease free water 
(Ambion) and 50pmoles random hexamers (Applied Biosystems).  
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Table 5: List of genes and Taqman assay numbers used for the custom designed Taqman 
cards. These genes were identified on an Affymetrix exon array. Genes highlighted in yellow 
are potential tumour suppressor genes, highlighted in green are genes of other interest in the 
group and highlighted in grey are extra endogenous controls to GAPDH. The rest of the genes 
were up-regulated by EBV and not CD40L simulation of resting B cells and were included for 
the work of Heather Long (Cancer Sciences, The University of Birmingham) as a 
collaborative study. 
Gene Name Applied Biosystems 
Assay Number 
 
Gene Name 
Applied Biosystems 
Assay Number 
  
 7A5 Hs00766186_m1  LY6E Hs00158942_m1 
ELOVL6 Hs00225412_m1  IFI6 Hs00242571_m1 
CD300A Hs00381974_m1  PTP4A3 Hs00845785_m1 
C3orf37 Hs00220172_m1  RNASE6 Hs00377819_m1 
CARD6 Hs00261581_m1  CECR1 Hs00602615_m1 
NETO2 Hs00983152_m1  IFIT3 Hs00382744_m1 
CCL25 Hs00171144_m1  OAS2 Hs00159719_m1 
OASL Hs00388714_m1  GPR155 Hs00400624_m1 
FCGR2B Hs00414000_m1  IFITM1 Hs01652522_m1 
TXNDC5 Hs00229373_m1  STK3 Hs00169491_m1 
MAP2K6 Hs00992389_m1  LGMN Hs00559848_m1 
IFI44 Hs00197427_m1  SCL44A1 Hs00223114_m1 
MX2 Hs00159418_m1  NR4A3 Hs00235001_m1 
OAS3 Hs00196324_m1  NR4A1 Hs00172437_m1 
CABLES1 Hs00292828_m1  DUSP6 Hs00169257_m1 
IFIT1 Hs00356631_g1  SPINT2 Hs00173936_m1 
IL12RB2 Hs00155486_m1  PLSCR1 Hs00275541_m1 
RSAD2 Hs00369813_m1  PLAC8 Hs00930936_m1 
TRIM25 Hs00231947_m1  PRDM1 Hs01068508_m1 
PIK3R3 Hs01103591_m1  BCL2LII Hs00197892_m1 
CHI3L2 Hs00187790_m1  BACH2 Hs00222364_m1 
LGALS3BP Hs00174774_m1  B2M (endo) Hs00187824_m1 
MX1 Hs00895598_m1  PPIA (endo) Hs99999904_m1 
USP18 Hs00276441_m1    
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2.10.4.2 Quantitative PCR for Taqman® custom array 
The Taqman miRNA array cards were loaded and run according to the manufacturer’s 
instructions. Briefly, for each sample, total cDNA (15μl) was diluted with 35µl of nuclease 
free water to make a 50μl total cDNA volume. This was combined with 50µl of Taqman  
universal PCR master mix (Applied Biosystems) to give a 100µl total cDNA/master mix. 
100µl of this RT reaction-specific cDNA/master mix was added to one of the eight ports on 
the microfluidic card. The card was then centrifuged to evenly distribute the cDNA/master 
mix between the wells and the card was then sealed and loaded into a 7900HT PCR machine 
with a Low Density Array upgrade (Applied Biosystems) and run at 50°C for 2 minutes, 
95.4°C for 10 minutes and then for 40 cycles of 97°C for 30 seconds followed by 59.7°C for 1 
minute. Data was analysed using the supplied SDS2.2.2 software (Applied Biosystems) 
according to manufacturer’s instructions using the ddCt method [609] and exported into 
Microsoft Excel for further analysis. All miRNA QPCR data in results I was normalised to the 
snoRNA endogenous control Z30 and in results chapters II and III, unless otherwise stated, 
data was normalised to the snoRNA endogenous control RNU48. All data expressed relative 
to an LCL in all Results I was LCL-PER and in results II and III, where not otherwise stated, 
was LCL A6 
 
2.11 GeneChip Human Exon 1.0 ST Array 
Gene expression profiling, using microarray technology, allows the measurement of 
thousands of genes and can be used to identify genes which are differentially expressed 
between multiple samples. To search for genes which were differentially expressed between 
EBV and CD40L blasts, the gene expression of resting B cells, EBV day 7 and CD40L day7 
blasts was profiled using the GeneChip Human Exon 1.0 ST Arrays (Affymertix).  
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Each exon array can be analysed to give two different levels of gene expression information: 
the first is ‘gene level analysis’, which produces the conventional gene expression changes 
from microarrays. Each of the ~30,000 human genes is represented at least once and in many 
cases several times on the array; the second is an ‘exon level analysis’ which produces a list 
of gene expression changes which distinguish between different gene isoforms. The exon 
array contains an average of 4 probes per exon, which corresponds to approximately 40 
probes per gene, allowing the expression of each exon, and therefore each gene isoforms, to 
be profiled. 
RNA samples were sent to an in-house microarray service where the samples were prepared 
and the microarray was run. Briefly, 100ng of RNA was used to transcribe single stranded 
cDNA using oligo dT primers. A second strand was then synthesised and the double stranded 
cDNA purified. This double stranded cDNA was used as a template to generate fluorescently 
labelled cRNA by in vitro transcription, which was purified and fragmented before being 
hybridised to the microarray chip. 
2.11.1 Sample preparation 
RNA was extracted from resting B cells isolated from peripheral blood, B cells stimulated 
with CD40L and IL4 for 7 days or infected with EBV at an m.o.i of 100 and harvested 7 days 
post-infection, using the mirVana™PARIS™ kit (Applied Biosystems, section 2.7). 
2.11.2 Microarray analysis 
Data was analysed by bioinfomatician Wenbin Wei, using the Significance Analysis of 
Microarrays (SAM) analysis [613], to produce a gene level analysis of the microarray data. 
SAM analysis assigns a score to each gene based on the change in gene expression relative to 
the standard deviation of repeated measurements. The analysis uses gene specific T-tests to 
account for gene specific variation, as fluctuations in the signal to noise ratio are gene 
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specific. To maximise the significance of the statistical analysis, multiple permutations of the 
repeated measurements are compared; this data is used to estimate the percentage of genes 
identified by change, the false discovery rate (FDR). The parameters of SAM analysis can be 
defined by the user and SAM analysis of our data set a FDR of 0.05 and a minimum fold 
change of 1.5. 
 
2.12 Transfection of miR-148a inhibitors and mimics into suspension cells 
2.12.1 miR-148a inhibitor 
miR-148a inhibitors (Applied Biosystems) are single stranded nucleic acids which bind to and 
inhibit miRNA function. Each miRNA inhibitor is designed to be complementary in sequence 
to its target miRNA, resulting in efficient binding following transfection. The inhibitors are 
chemically modified to increase the stability of the inhibitor and to prevent disassociation of 
the miRNA:inhibitor complex in the miRISC, enabling efficient inhibition of miRNA 
function.  
To control for the transfection of the miR-148a inhibitors, a miRNA negative control was 
used, called anti-miR-negative control-1 (Applied Biosystems). This control inhibitor was a 
random sequenced molecule, tested extensively in human cell lines and tissues and validated 
not to produce any identifiable affect.  
2.12.2 miR-148a mimic 
To ectopically express miR-148a, Pre-miR™-precursor molecules (Applied Biosystems), 
referred to as ‘miRNA mimics’, were transfected into B cell lines. miRNA mimics are double 
stranded miRNA molecules which have been designed to ensure that they will only be taken 
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up by the miRISC complex in the correct orientation, resulting in production of only the 
mature miRNA of interest.  
To control for the transfection of the miR-148a mimic, a miRNA mimic negative control was 
used, called Pre-miR™-negative control-1 (Applied Biosystems). This control mimic was a 
random sequenced molecule, tested extensively in human cell lines and tissues and validated 
not to produce any identifiable affect.  
2.12.3 Transfection 
To estimate the transfection efficiency of miRNA mimics and inhibitors, a siRNA 
fluorescently labelled with DY-547 (siGLO, Dharmacon) was transfected into an appropriate 
B cell line, and the percentage of cells transfected was measured by flow cytometry 24-48 
hours post-transfection. 
B cell cultures were passaged 24 hours prior to transfection to ensure that cells were in the 
optimal growth phase. Cells were washed 2 x ice cold PBS, counted, and re-suspended in 
Optimem medium (Gibco) to a concentration of 2 x 10
7
 cells/ml. 500µl of cells were 
transferred to a sterile, 4mm electroporation cuvette (Geneflow) containing the stated 
concentration of miRNA mimic, inhibitor, or control RNA. When the co-transfection of the 
pMIR-REPORT luciferase system and miR-148a inhibitors were performed, 5µg of β-gal and 
either the luciferase or luciferase-148a plasmids were added to the electroporation curvette, 
along with the stated concentration of miR-148a inhibitor or control inhibitor. 
Electroportation was carried out using a Bio-Rad Gene Pulser II, with a capaticitance of 
975µF and a voltage of 270. Transfected cells were transferred immediately to 9ml of pre-
warmed cell culture medium and incubated at 37°C, 5% CO2 for 24-48 hours. If the cells were 
to be prepared for western blotting, dead cells and debris were removed by carefully layering 
of the cells over 3ml of lymphoprep (Axis Shield) and centrifugation at 1,600RPM for 30 
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minutes without the brake. Live cells were then collected from the interphase between the BL 
medium and lymphoprep, and washed twice in fresh culture medium.  
2.13 DNA extraction 
DNA was extracted from approximately 5x10
6
 cells. Cells were washed with PBS to remove 
serum and DNA was extracted using the Qiagen DNeasy kit according to manufacturer’s 
instructions. DNA was then eluted in 100µl of nuclease free water (Applied Biosystems) and 
the concentration determined using the Nanodrop (Thermo Scientific) according to the 
manufacturer’s instructions. DNA samples were typically diluted to a concentration of 
100ng/µl and stored in aliquots at -20°C 
 
2.14 PCR amplification of DNA 
2.14.1 PCR amplification of cDNA 
A 50µl reaction mix was set up in a 0.5ml microfuge tube containing 100ng of cDNA, 2.5U 
Taq high fidelity enzyme bland (Roche), Expand 1x PCR buffer with 1.5nM MgCl2 (Roche), 
200µM dNTP, 300nM of each primer. An Eppendorf Thermocycler was used to hot start the 
PCR at 94°C for 5 minutes and then to incubate the samples through 35 cycles of 95°C to 
denature the DNA strands, 45-60°C to allow the primers to anneal to the DNA and 72°C to 
allow extension of the product. The annealing temperature and incubation time at each stage 
varied according to the specific primers and product size of each PCR. The PCR products 
were separated on agarose gel (section 2.15). 
2.14.2 Sequencing PCR 
200-500ng of DNA was put into a 10µl reaction volume sequencing reaction, containing 
3.2pmol of sequencing primer (table 6) and nuclease free water. The samples were then 
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subjected to a full, automated DNA sequencing analysis using a 3700 DNA Analyser 
(Applied Biosystems) as part of a service provided by the functional genomics laboratory, 
School of Biosciences, The University of Birmingham. Olignucleotide primers were 
synthesised by Alta Biosystems, The University of Birmingham. 
Plasmid Position Primer Sequence 
Pmir-REPORT-
luciferase-148a 
5’ primer pmirREPOR
T Forward 
5'–AGGCGATTAAGTTGGGTA–3' 
FT(DUSP6)UTG 
5’ primer FT-UTG 
Forward 
5’-AAAGGATCCACCATGATAGATACGCTCAGACCCGTGC-3’ 
3’ primer FT-UTG 
Reverse 
5’TTTTGTACATTAATTAATCACGTAGATTGCAGAGAGTCCACC-3’ 
Table 6: Primer sequences used to sequence the final lentivirus and luciferase vectors. The 
pmir-REPORT luciferase-148a plasmid and the FT(DUSP6)UTG lentivirus plasmid were 
sequenced following cloning. 
 
2.15 Agarose gel electrophoresis 
The DNA solution was mixed with 6 x gel loading buffer (0.25%w/v xylene cyanol, 0.25% 
w/v bromophenol blue, 30% v/v glycerol) and the DNA fragments separated by gel 
electrophoresis at 120 volts through a 1 x TBE (0.09M Tris-borate, 0.002M EDTA), 1% 
agarose gel (molecular biology grade) (Eurogentec). A1kb DNA ladder (GibcoBRL) was also 
loaded into the gel so the size of the PCR products could be determined. After electrophoresis 
the gel was stained in a bath of 1 x TBE containing 0.5μg/ml ethidium bromide and the DNA 
visualised with UV light on a transilluminator. A Polaroid photograph of the gel was often 
taken for record.  
 
2.16 DNA extraction and purification form agarose gels 
PCR products were visualised using a UV light box and the desired band cut out the gel using 
a sterile scalpel and placed into a sterile 1.5ml eppendorf. The gel fragment was then weighed 
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and the DNA extracted using the DNA gel extraction kit (Quiagen) according to the 
manufacturer’s instructions. DNA was eluted in nuclease free water (Ambion). 
2.17 Western blotting 
2.17.1 Preparation of gel samples 
Protein preparations were made from between 4x10
6
 and 1.5x10
7
 cells. Cells were washed 
twice in PBS to remove FCS and then pelleted by centrifugation at 1,200rpm for 5 minutes 
and lysed in 100-200µl of lysis buffer (Ambion). The viscosity of samples was reduced by 
disruption of genomic DNA by sonication using an ultrasonic cell disruptor (Misonix). The 
protein concentration was determined using a Bio-Rad DC protein assay kit according to the 
manufacturer’s instructions. The desired concentration of protein (usually 2mg/ml) along with 
an equal volume of gel sample buffer (0.4M sodium 2-mercaptoethanesulfonate (MESNA), 
125mM Tris-HCL pH 6.8, 20% v/v glycerol, 4% v/v SDS and 0.004% v/v bromophenol blue) 
were added together and heated to 100°C for 5 minutes. Gel samples were either used 
immediately or stored at -20°C. 
2.17.2 SDS-PAGE 
Pre-cast NuPAGE
®
 Novex
®
 Bis-Tris 10 well gels (Invitrogen) were loaded with 
approximately 20-40µg of protein alongside 10µl of Seeblue plus 2 pre-stained protein 
standards (Invitrogen). Electrophoresis was carried out in MOPS SDS running buffer 
(Invitrogen) at 78V for 3 hours in the XCell SureLock™ Mini-Cell (Invitrogen). 
2.17.3 Blotting 
Invitrolon™  polyvinylidine difluoride (PVDF) membranes (Invitrogen) were prepared by 
soaking in 100% methanol for 5 seconds and then soaking in blotting buffer (25mM TRIS-
BASE, 192mM glycine and 20% v/v methanol) for 5 minutes. Once the dye front reached the 
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end of the gel, samples were blotted onto the pre-soaked PVDF membrane in an XCell II™ 
Blot Module (Invitrogen) blotting cassette. Onto the cathode side of the blotting cassette was 
placed 2 sponges and a sheet of filter paper (Invitrogen) soaked in blotting buffer. The gel was 
then placed onto the filter paper followed by the PVDF membrane and another pre-soaked 
filter paper. Finally 3 more pre-soaked sponges were added to the blotting cassette to ensure 
air bubbles were between the gel and the PVDF membrane. The blotting cassette was then 
filled with blotting buffer and the tank outside of the cassette filled with distilled water to 
allow cooling of the gel during transfer. The gel was blotted at 30V, 250mA for 100 minutes 
in a XCell SureLock™ Mini-Cell (Invitrogen).. 
After blotting, the blotting cassette was disassembled and the PVDF membrane incubated in 
I-Block/Tween buffer (IBT) (0.4% w/v casein powder (I-Block™, Applied Biosystems), 
0.05% v/v Tween, 0.02% sodium azide (NaN3)) on a shaker at room temperature for 1 hour to 
prevent non-specific antibody binding. PVDF membranes were then incubated with primary 
antibody (table 7) diluted with blocking buffer either over night at 4°C or at room temperature 
for 2 hours depending on the antibody used. PVDF membranes were then washed 3 times for 
2 minutes in PBS Tween. The appropriate secondary antibody conjugated to either peroxidise 
or alkaline phosphatase (table 7) and diluted in either blocking buffer or 5% w/v milk 
respectively, and then incubated with the PVDF membrane at room temperature with shaking 
for 1 hour. The membrane was then washed 5 times for 5 minutes in PBS Tween. 
2.17.4 Chemiluminescence detection of antibody staining 
Enhanced chemiluminescence (ECL) was used to visualise antibody bound proteins probed 
with a peroxidise-conjugated secondary antibody. 0.5ml of each of the two ECL reagents A 
and B (Amersham) were mixed together and the 1ml of combined reagents added to the 
PVDF membrane and incubated for 1 minute in Saranwrap. The excess reagents were then 
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removed from the membrane which was then sealed in the Saranwrap and placed in an 
autoradiograph cassette. Kodak X-Omat AR film (Kodak) was exposed to the membrane for 
between 30 seconds to 1 hour depending the strength of the luminescence signal.  
Alkaline Phosphatase (AP) chemiluminescence was also used to visualise antibody bound 
proteins probed with an AP-conjugated secondary antibody (see table 7). PVDF membranes 
were incubated with 2 x 7ml AP buffer (0.1M diethanolamine pH 9.5, 1mM MgCl2,) with 
shaking for 2 minutes and then transferred to Saranwrap where 0.8ml of CDP-star™ 
developer (Invitrogen) was added to the membrane and incubated for 15 minutes. Excess 
reagent was then removed from the membrane and the Saranwrap sealed and then placed in an 
autoradiograph cassette for detection. 
Target 
Primary 
Antibody 
Species 
Working 
Dilution 
Incubation 
Secondary 
Antibody 
Working 
dilution 
LMP1 CS1-4 [614] mouse  1/50 
4°C over 
night 
Anti-mouse IgG-
peroxidase (Sigma) 
1/1000 
EBNA2 PE2 [615] mouse 1/25 
4°C, over 
night 
Anti-mouse IgG-
peroxidase (Sigma) 
1/1000 
EBNA3A EBNA3A sheep  1µg/ml 
22°C, 
2hours 
AP-anti-sheep IgG 
(Biorad) 
1/10,000 
EBNA3C EBNA3C mouse  1/20 
22°C, 
2hours 
AP-anti-mouse IgG 
(Biorad) 
1/10,000 
EBNA1 EBNA1 human 1/200 
22°C, 
2hours 
AP-anti-human 
IgG (Biorad) 
  1/10,000 
LMP2A LMP2A rat  1/10,000 4°C, 3hours 
AP-anti-rat IgG 
(Biorad) 
1/10,000 
DUSP6 MK3 (Sigma) mouse 1µg/ml 
4°C over 
night 
Anti-mouse IgG-
peroxidase (Sigma) 
1/1000 
Phospho-
ERK 
p-ERK 
 (Cell 
Signalling) 
Mouse 1/2000 
4°C over 
night 
Anti-mouse IgG-
peroxidase (Sigma) 
1/1000 
ERK1/2 
ERK1/2  
(Cell 
Signalling) 
Rabbit 1/1000 
4°C over 
night 
Anti-rabbit IgG-
peroxidase (Sigma) 
1/1000 
Calregulin 
Calregulin 
(Santa-Cruz) 
Goat 1ug/ml 
22°C, 
2hours 
Anti-mouse IgG-
peroxidase (Sigma) 
1/100,000 
Table 7: Antibodies used for western blotting  
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2.17.5 Stripping PVDF membranes 
The secondary antibody used during western blotting can be removed (stripped) to allow re-
probing of a blot with another primary and secondary antibody from a different species. The 
blots were stripped by incubation with Ponceau S stain (1% Ponseau S w/v (Sigma) in 3% v/v 
trichloroacetc acid (TCA)) at room temperature for 2 minutes with shaking. The Ponseau S 
stain was then washed off the membrane with tap water and the membrane was subsequently 
washed 3 times for 5 minutes in PBS Tween and re-blocked in blocking buffer for 1 hour. 
Blots were either re-probed immediately or stored at 4°C in Saranwrap to prevent drying out. 
 
2.18 Fluorescence activated cell sorting  
Flourescence activated cell sorting (FACS) was used to isolate either green fluorescent 
protein (GFP) positive cells transduced with a GFP expressing lentivirus or to sort primary 
tonsillar B cells into sub-populations based on CD10 and CD77 expression. FACS was 
performed using the cell sorting service at the Institute of Biomedical Research (IBR) using  a 
MoFlo cell sorter (Beckman Coulter). 
To isolate LCLs successfully transduced with either a GFP positive DUSP6 or control (empty 
vector) expressing lentivirus, cells were sorted a minimum of 48 hours post transduction to 
allow maximal expression of GFP and FACS was then used to sort individually GFP-positive 
LCLs.  
To sort centrocytes and centroblasts isolated from a tonsil, 200 x 10
6
 tonsillar cells were 
stained with CD10 (CD10-PC5, (BD Pharmingen)) and CD77 (CD-77-FITC (BD 
Pharmingen)). The CD10
+
/CD77
+ 
(centroblasts), CD10
+
/CD77
- 
(centrocytes) and CD10
-
/CD77
-
 (non-GCBCs) were isolated by FACS. 
 
Materials and Methods 
 
Page 91 
 
2.19 Bacteriology 
Plasmid vectors were grown in DH5α bacterial cells. Small scale DNA preparation was used 
to screen colonies containing recombinant plasmids while large scale preparations were used 
to make large amounts of high purity DNA suitable for transfection. 
2.19.1 Bacterial growth medium 
Liquid bacterial cultures were grown in Lennox Broth (L-Broth) medium. 2.5% w/v L-broth 
(Fisher Scientific) was dissolved in 400ml distilled water and sterilised before use by 
autoclaving at 121°C, 15psi for 15 minutes.  
Bacterial colonies were cultivated on L-Broth Agar (L-agar) plates. 1.5% w/v of agar (Fisher 
Scientific) was dissolved in 400ml of deionised water and sterilised by autoclaving at 121°C, 
15psi for 15 minutes. The L-agar was re-melted by microwaving, cooled to approximately 
50°C and ampicillin was added to make a final concentration of 100µg/ml. 20ml of L-agar 
was poured into Petri dishes and left to solidify at room temperature and was then ether used 
immediately or stored at 4°C for up to one week. Before use plates were dried at 37°C. 
2.19.2 Generation of competent DH5α E.coli 
DH5α E coli were spread onto an L-agar plate and grown at 37°C overnight. 10-12 colonies 
were then picked from the plate and used to inoculate 250ml of SOB medium. Cultures were 
grown for 24-36 hours at 18-20°C until their absorbance at 600nm reached 0.6 when they 
were then placed on ice. Bacteria were then pelleted by centrifugation at 3000rpm for 10 
minutes at 4°C. The supernatant was discarded and the pellet re-suspended in 80ml of 
sterilised, ice cold TB (10mM Pipes, 15mM calcium chloride, 250mM KCL, adjusted to pH 
6.7 with potassium hydroxide (KOH) and then supplemented with 55mM manganese 
chloride) and incubated on ice for 10 minutes. The culture was then centrifuged again at 
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3000rpm for 10 minutes at 4°C and the pellet re-suspended in 20ml of ice cold TB. 1.5ml of 
DMSO was added and the mixture incubated in ice for a further 10 minutes. 200µl aliquots of 
competent bacteria were snap frozen in liquid nitrogen and stored at -80°C ready for 
transformation.  
2.19.3 Transformation of DH5α E.coli 
Aliquots of competent DH5α E.coli were thawed on ice and 100µl transferred to an 
autoclaved 1.5ml microcentrifuge tube containing 10ng of plasmid DNA or the product of a 
DNA ligation reaction. The mixture was incubated on ice for 30 minutes and then heat 
shocked for 90 seconds at 42°C. 900µl of L-Broth was added to the culture and incubated at 
37°C in a shaker to allow the bacterial to grow. 30µl of the culture was then spread onto L-
agar/ampicillin plates and incubated overnight at 37°C. 
2.19.4 Preparation of plasmid DNA 
A single bacterial colony was picked using a sterile loop and used to inoculate 3ml of L-Broth 
containing the appropriate antibiotic (usually ampicillin). Cultures were then incubated with 
shaking at 37°C for 6 hours. 0.5ml of the culture was then added to 50-200ml of L-Broth 
containing the appropriate antibiotic in a 250ml conical flask and incubated at 37°C in a 
shaker overnight. The next day the bacteria were pelleted by centrifugation at 15,000rpm for 
10 minutes and plasmid DNA extracted using the midi or maxi prep system (Jetstar) 
according to the manufacturer’s instructions. The DNA pellet was then air dried before re-
suspension in 200µl of TE buffer. The concentration of the plasmid DNA was determined 
using a Nanodrop (Thermo Scientific) according to manufacturer’s instruction. Plasmid DNA 
was typically diluted to 1µg/µl and stored at -20°C until required.  
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2.20 pMIR-REPORT™ 
The pMIR-REPORT expression reporter vector system (Ambion) consists of two mammalian 
expression vectors: pMIR-REPORT-luciferase and pMIR-REPORT-βgal. The pMIR-
REPORT luciferase miRNA expression vector contains firefly luciferase under the control of 
a CMV promoter with a miRNA target cloning region down-stream of the luciferase 
sequence. This vector is designed for cloning putative miRNA target sites to evaluate miRNA 
regulation though the detection luciferase expression. pMIR-REPORT β-galactosidase 
reporter control vector is used for normalisation of transfection efficiency.  
The pMIR-REPORT vectors were supplied as glycerol stocks and were cultured according to 
manufacturer’s instructions. 
2.20.1 Generation of pMIR-REPORT luciferase-hsa-miR-148a target 
To evaluate the efficacy of the anti-hsa-miR-148a inhibitors following transfection into an 
LCL, we used the pMIR-REPORT system (Ambion) which included a luciferase vector for 
cloning miRNA target sites into the 3’UTR of the luciferease gene and a betagalactosidase (β-
gal) plasmid used for co-transfection to normalise for transfection efficiency. To create a 
miR-148a responsive luciferase reporter we cloned a synthetic hsa-miR-148a binding site into 
the pMIR-REPORT luciferase vector (figure 1.3). This vector was designed to contain a 
binding site with 100% complimentarity to the hsa-miR-148a sequence in the 3’UTR of the 
luciferase gene for maximal binding efficiency and luciferase mRNA 
degradation/translational repression. Luciferase expression will then be inhibited by the high 
hsa-miR-148a expression in an LCL and the addition of anti-hsa-miR-148a inhibitors should 
therefore restore luciferse expression back to control vector (pMIR-REPORT luciferse with 
no insert) levels, allowing a read-out for the efficacy of the hsa-miR-148a inhibitors.  
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C 
5’-CTAGTACAAAGTTCTGTAGTGCACTGAGAATTCA-3’       Coding Strand 
          3’-ATGTTTCAAGACTACACGTGACTCTTAAGTTCGA-5’  Reverse Strand 
  
Figure 2.3:  Schematic map of A; pmiR-
REPORT-luciferase, and B; pmiR-
REPORT-luciferase-148a. The miR-148a 
target site was cloned into the luciferase 
reporter in the multiple cloning site using 
SpeI and HindIII enzyme sites, enabling 
miR-148a to target the luciferase mRNA 
for degradation/translational repression. 
C; miR-148a binding site insert for 
pmiR-Report-luciferase. The EcoR1 
restriction enzyme site is highlighted in 
green, Spe1 in red and HindIII in grey 
 
A 
B 
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The hsa-miR-148a target insert (figure 2.3) was designed to contain the reverse compliment 
of the hsa-miR-148a sequence (mature sequence accession number MIMAT0000243) taken 
from miRBase version 14 (http://www.mirbase.org/), and included an EcoR1 site to allow 
identification of clones containing the insert and Spe1 and Hind III sticky end sites for 
insertion into the vector.  
 
2.21 FT(DUSP6)UTG lentivirus 
2.21.1 Generation of FT(DUSP6)UTG lentivirus 
To generate a lentivirus expressing DUSP6 under the control of a tetracycline repressor 
(TREX) which also constitutively expressed GFP for identification of DUSP6 lentivirus 
positive cells, DUSP6 was cloned into two lentivirral vectors designed by Marco Herold 
[616]. A DUSP6-HIS Topo vector was kindly donated to us by Toru Fuukawa [617] and was 
used as a PCR template for the lentivural cloning strategy and also served as a positive control 
for western blotting. The cloning strategy involved firstly inserting DUSP6 into an 
intermediate vector to pick up the tetracycline promoter and then the tetracycline promoter 
and DUSP6 were ligated into the final lentiviral vector which contained the tetracycline 
repressor protein and eGFP under the control of a ubiquitin promoter.  
DUSP6 PCR primers were designed to contain a BamHI site at the 5’ end of the forward 
primer and at the 5’ end of the reverse primer they contained a BsrG1 site followed by a PACI 
site. The DUSP6 PCR product was first TA cloned into a Topo vector (Invitrogen) and then 
released by digestion with BsrG1 and BamHI restriction enzymes. DUSP6 was then ligated 
into an intermediate vector (FTGW, figure 2.4) where it replaced eGFP and was inserted 
downstream of a tetracyclin promoter (TREX-P) contained within the FTGW vector. DUSP6 
was then cut of this intermediate vector along with the TREX-P and cloned into the final  
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Figure 2.4: Schematic map of the 
intermediate cloning vector 
FTGW-DUSP6 and the final 
lentiviral vector FT(DUSP6)UTG. 
The DUSP6 PCR product was 
ligated into the intermediate 
vector FTGW using BsrG1 and 
BamHI sites to produce FTGW-
DUSP6 (A) DUSP6 was cut out 
of FTGW-DUSP6 along with the 
TREX promoter (TREX-P) using 
two Pac1 sites (red boxes), and 
ligated into FIHt(INSR)UTG to 
produce the final lentivirus vector 
FIHt(DUSP6)UTG (B), where 
DUSP6 expression is under the 
control of the TREX-P and the 
tetracycline repressor protein 
(hTetR) and eGFP are 
constitutively expressed from the 
ubiquitin promoter (Ubiquitin-P) 
 
B 
A 
FT(DUSP6)UTG 
10793bp 
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vector (FHIT-IR5-UTG) to produce FT(DUSP6)UTG (figure 2.4). This final vector was 
packaged into a lentivirus and used to transduce selected LCLs. The majority of this cloning 
was kindly performed by Dr Jianmin Zuo. 
2.21.2 Production of FT(DUSP6)UTG lentivirus 
Lentivirus was produced using a second generation system and the lentivirus was 
pseudotyped with the VSV-G envelope glycoprotein (plasmid MD2G). 293-FT cells  
(Invitrogen) were plated out 24 hours prior to transfection to be 70-90% confluent on the day 
of transfection, in lentivirus production media. On the day of transfection, lentivirus 
production media was replaced 2 hours prior to transfection with 10ml of fresh, pre-warmed 
lentivirus production media. The following were mixed at room temperature for 5 minutes: (i) 
1.5ml of Optimem (Gibco) was mixed with 36µl of Lipofectamine 2000 (Invitrogen) and (ii) 
1.5ml of Optimem was mixed with 4µg of FT(DUSP6)UTG, 2µg of the envelope plasmid, 
MD2G and 6µg of the packaging plamid psPAX2. The contents of (i) and (ii) were then 
mixed and incubated at room temperature for 20 minutes. This transfection mix was then 
added to the 10ml of lentivirus production media on the 293-FT cells. 16 hours post-
transfection the medium containing the transfection reagents was removed and replaced with 
10ml fresh lentivirus production media plus 100µl of sodium pyruvate. 48 hours later, the 
media containing FT(DUSP6)UTG lentivirus was harvested by centrifugation at 1200RPM 
for 5 minutes to pellet any cells. Lentivirus supernatant was then filtered using a 0.45µM 
syringe filter. Lentivirus supernatant was either used immediately or stored at -80°C. 
2.21.3 Transduction of LCLs with FT-DUSP6-UTG lentivirus 
10ml of lentivirus supernatant was concentrated by ultracentrifugation prior to use. 10ml of 
lentivirus supernatant was added to a 14 ml thinwall polyallomer tube (Beckman). Tubes were 
weighed to ensure the centrifuge was balanced and then secured in the buckets of a SW40 
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swing rotor (Beckman) and centrifuged at 19000 RPM for 2 hours at 16°C in a Beckman 
ultracentrifuge. The supernatant was carefully removed and discarded until approximately 
100-200µl of supernatant remained, which was used to re-suspend the lentivirus pellet. 5x10
5
 
LCLs were pelleted by centrifugation at 1200 RPM for 5 minutes and the LCLs were re-
suspended in the 100-200µl of concentrated lentivirus supernatant and incubated overnight at 
37°C, 5% CO2. LCLs were then cultured in culture media and transduction efficiency 
determined by flow cytometry for GFP expression. 
  
2.22 LCL-DUSP6 growth assay  
2.22.1 Trypan blue assay 
To determine the number of viable stably transduced LCLs/ml either induced or un-induced to 
express DUSP6, a trypan blue assay was performed. 50µl of the culture was mixed with 50µl 
of trypan blue (Sigma) and the number of negatively stained cells/ml was determined using a 
haemocytometer. To ensure equal confluency in each sample at the beginning of the 
experiment, cells were pelleted by centrifugation at 1,200 RPM for 5 minutes and re-
suspended at 0.2 x 10
6
 viable cells/ml in culture media either containing 0.5µg/ml of 
tetracycline (DUSP6 induced), or with no tetracycline (DUSP6 un-induced) in one well of a 6 
well plate. The number of viable cells were determined each subsequent day for 7 days. 
2.22.2 Determination of cell growth by GFP 
In this experiment, LCLs transduced with FT(DUSP6)UTG (LCL-DUSP6) were >99% 
positive by flow cytometry for GFP, following FACS. To monitor cell growth in the presence 
and absence of DSUP6 expression the LCL-DUSP6 GFP positive cell line was mixed at a 1:1 
ratio with the parental, GFP negative, LCL to give a final cell concentration of 0.2 x 10
6
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cells/ml. Cells were cultured in one well of a 6 well plate in the presence or absence of 
0.5µg/ml of tetracycline, and GFP expression was measured after 7 days to determine whether 
the growth of the GFP positive DUSP6-LCL was altered following induced DUSP6 
expression. If cell growth was inhibited then an outgrowth of the GFP negative, DUSP6 
negative LCL would be expected, and vice versa.  
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3. Results Part I 
Micro-RNA-155 regulation by EBV 
 
3.1  Introduction 
The observation which formed the basis of this aspect of the work came from a microarray 
experiment which showed the up-regulation of a gene called B cell integration cluster (BIC) 
following LMP1 expression in GC B cells [618]; BIC was the precursor (pri-miRNA) for the 
miRNA, miR-155. Although miRNA research was still in its infancy at this time, miR-155 
was already regarded as a potentially oncogenic miRNA, or an ‘oncomiR’ [547], with many 
reports linking it to malignancies, particularly lymphomas [374, 545, 546, 554]. BIC and 
miR-155 were shown to be over expressed in HL [553, 612] and BIC was reported to have 
extremely low expression in BL [619]. A possible defect in the processing of BIC to miR-155 
had also been demonstrated in BL cell lines [375].  There was some literature emerging 
regarding miR-155 and EBV, with miR-155 expression being reported to be high in EBV 
transformed LCLs [374, 603, 620]. Despite the observation that BIC was highly expressed in 
EBV transformed LCLs and one EBV associated lymphoma, no link between EBV and miR-
155 in these malignancies had been investigated, providing a unique opportunity for further 
study. The broad aims of this part of the study were to (i) validate the regulation of BIC/miR-
155 by LMP1, (ii) investigate the regulation of miR-155 by EBV in the context of the whole 
virus infection and (iii) further examine the BIC to miR-155 processing defect in BL reported 
by Kluiver et al [375].  
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3.2 Characterising miR-155 expression  
Previously in the literature, miR-155 expression had been measured by northern blotting and 
in-situ-hybridisation in a variety of cell lines, tumour cell lines and primary tissue. These 
techniques lack the sensitivity and specificity for the miRNA. We chose to take advantage of 
a newly available Taqman RT-QPCR technique which claimed to show much greater 
sensitivity and specificity for the mature miRNA. 
3.2.1 miR-155 expression in BL and HL cell lines 
First, we sought to confirm the reported high expression of miR-155 in HL and low 
expression in BL, using a series of EBV positive and negative HL cell lines and a panel of 
latency I BL cell lines for QPCR measurement of miR-155 (Figure 3.1). With the exception 
of L540, the HL cell lines showed very high levels of miR-155 expression regardless of EBV 
status. The panel of BL cell lines show detectable but very low expression of miR-155 when 
compared with the LCL or HL cell lines but the expression level is variable in the BL cell 
lines, with the Ezema-BL cell line showing higher miR-155 expression than the resting B 
cells. These data are broadly consistent with published reports. 
3.2.2 miR-155 expression in B cells 
Previous studies into miR-155 expression in primary cells have not been able to detect miR-
155 due to the lack of sensitivity of their techniques. The QPCR method of miRNA detection 
allowed us to detect and quantitate miR-155 in primary cells, which was previously not 
possible.  
RNA in-situ-hybridisation for BIC (pri-miR-155), demonstrated that the few BIC positive 
cells detected in the tonsil and lymph node were located predominantly within germinal 
centres [612]. Since HL and BL both have GC phenotypes but very different expression levels  
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Figure 3.1: miR-155 expression by QPCR in HL and BL cell lines. A; Panel of HL cell lines, 
L591 is the only EBV positive HL cell line and DG75 is an EBV negative BL cell line. B; 
Panel of latency I BL cell lines and peripheral blood CD19
+ 
resting B cells. Error bars 
represent the range in fold change within one experiment calculated from the standard 
deviation of the ∆∆Ct values. 
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of miR-155, we wanted to establish if either lymphoma represented the original cell type. To 
address this, we examined miR-155 expression in different populations of B cells isolated 
from healthy tonsils by co-staining for CD10 and CD77 (Figure 3.2). CD10 is a marker for 
GC B cells and CD77 staining subdivides the CD10
+
 GC B cells into: CD77
+
 centrocytes and 
CD77
-
 centroblasts. miR-155 expression showed little variation between different B cell 
subsets, with no greater expression seen in the germinal centre B cells compared with the 
CD19
+
 B cells. This suggests that the high expression of miR-155 in HL is a feature of the 
malignant cell rather than reflecting the normal cell origin. 
 
3.3 Regulation of miR-155 by EBV 
When we began this work in 2007 it was not known whether miR-155 expression was 
regulated by EBV, despite its high expression in LCLs and HL, a tumour which is often 
associated with EBV infection. The following work aimed to validate the observed regulation 
of BIC and miR-155 by LMP1 and further investigate their regulation by the virus. 
3.3.1 miR-155 association with EBV latency in BL 
Following on from the observation that miR-155 expression was low in latency I BL cell 
lines, we asked whether a latency III pattern of EBV gene expression in a BL cell line would 
result in up-regulation of miR-155, especially considering latency III cells express LMP1. We 
decided to examine a panel of Mutu-BL lines in addition to the Mutu-I cell line. These Mutu-
BL clones included an EBV loss clone (EBV negative) and two clones which had drifted in 
culture from a latency I, to a latency III pattern of EBV gene expression. These Mutu-BL 
clones would allow the correlation of miR-155 expression and EBV latent gene expression in 
the same cell background. The EBV latent gene expression of the Mutu-BL clones was 
confirmed by western blot (Figure 3.3). 
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Figure 3.2. miR-155 expression by QPCR in different tonsillar B cell subsets. Populations of 
B cells were sorted by FACS staining from a non-IM tonsil. Germinal centre B cells were 
stained for CD10 and CD77. CD77
+
 cells are centrocytes and CD77
-
 cells are the centroblasts. 
CD19
+
 cells are the total B cells and these were positively selected using CD19
+
 beads. Data 
is expressed relative to an LCL. Error bars represent the range in fold change within one 
experiment calculated from the standard deviation of the ∆∆Ct values. 
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Figure 3.3. A; Western blot analysis of EBV latent gene expression and QPCR for miR-155 
expression in a panel of Mutu-BL clones. Mutu I represents the biopsy phenotype of this 
tumour, while Mutu negative has lost the EBV genome and the two latency III clones (j8 and 
95)  have drifted in culture to express a latency III type of EBV gene expression similar to 
that seen in an LCL. B; The status of EBV was confirmed in the clones (neg; EBV negative, 
lat I; latency I; lat III; latency III and an LCL) using western blot to various EBV latent genes. 
Error bars represent the range in fold change within one experiment calculated from the 
standard deviation of the ∆∆Ct values and data was normalised to the snoRNA, Z30. 
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We examined the expression of miR-155 by QPCR and miR-155 was clearly up-regulated by 
a latency III pattern of gene expression but it was still less than half the miR-155 expression 
seen in an LCL (figure 3.3). 
3.3.2 miR-155 expression following induced EBV latent gene expression in DG75-BL 
To determine which latency III associated EBV genes were capable of up-regulating miR-155 
in BL cell lines, we used previously established stable clones of the EBV negative BL cell 
line DG75 with inducible EBV latent gene expression under the control of a tetracycline 
activator [162]. These DG75 clones expressed either: an empty vector control (DG75-tTA), 
LMP1 (DG75-tTA/LMP1), LMP2A (DG75-tTA/LMP2A) or EBNA2 (DG75-tTA/EBNA2); 
and the gene expression was induced upon removal of tetracycline. We also examined 
inducible clones of the BL-like cell lines, BJAB-tTA and BJAB-tTA/LMP1. These inducible 
transfectants were assayed for miR-155 expression to determine the effects of LMP1 
expression in different B cell backgrounds.  
LMP1 expression in BJAB resulted in a modest increase in miR-155 expression to only 
approximately 10% of the expression seen in an LCL (figure 3.4). Whereas, LMP1 expression 
in DG75 caused a more significant increase in miR-155 expression, to approximately 20% of 
the expression seen in an LCL (figure 3.5). This result is more convincing when it is 
expressed relative to the un-induced DG75tTA/LMP1 control (figure 3.5, C), with an increase 
in miR-155 expression of 15 fold; thus verifying the up-regulation of miR-155 by LMP1.  
Comparing the miR-155 expression in DG75 with induced LMP1 expression (figure 3.5) and 
latency III Mutu-BL (figure 3.3), it is clear that the latency III Mutu-BL express a higher level 
of miR-155. This is despite the fact that both Mutu III clones express less LMP1 than the 
induced DG75 by western blot. There could be many possible explanations for this but it does 
suggest that there may be other latency III associated genes which are involved in the up- 
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Figure 3.4: Western blots analysis of LMP1 expression and QPCR for miR-155 expression in 
BJABtTA/LMP1 clones. A; LMP1 induction in stable BJAB tTA and tTA/LMP1 
transfectants either un-induced (-) or induced (+) by the addition or removal of tetracycline 
respectively. B; Representative QPCR data showing miR-155 expression relative to an LCL 
in BJAB tTA clones stably expressing either a control (CTR) or LMP1 expression vector 
under the control of a tetracycline responsive promoter. Samples are shown at 48 hours as 
either induced (+) or un-induced (-). Error bars represent the range in fold change within one 
experiment calculated from the standard deviation of the ∆∆Ct values.  
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Figure 3.5: Western blot analysis of EBV latent gene expression and QPCR for miR-155 
expression in DG75tTA clones. A; Western blots confirming the expression of LMP1, LMP2 
and EBNA2 in the induced DG75 samples. B; Representative data showing miR-155 
expression in DG75 clones stably expressing either a control (CTR), LMP1, LMP2A or 
EBNA2 expression vector under the control of tetracycline. Samples are shown at 48 hours as 
either induced (+) or un-induced (-). Data is expressed relative to an LCL. C;. The same data 
as for (B) but expressed relative to the un-induced controls. Error bars represent the range in 
fold change within one experiment calculated from the standard deviation of the ∆∆Ct values.  
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regulation of miR-155 in BL cell lines, or that the effects of LMP1 are dependent on the cell 
context. LMP1 expression in BJAB resulted in a similar level of miR-155 expression to the 
induced DG75 (approximately 0.1 of an LCL), despite the fact that the induced BJAB showed 
greater LMP1 expression than DG75 relative to the same LCL (figures 3.4 B and 3.5 C). 
Collectively these data suggest that miR-155 expression does not directly correlate with the 
amount of LMP1 expression. However, induction of LMP2A or EBNA2 expression in DG75 
did not result in the up-regulation of miR-155 in DG75, in fact, EBNA2 may have resulted in 
a 5 fold down-regulation (figure 3.5).  
3.3.3 miR-155 expression during infection of primary B cells 
We wanted to determine the time course of miR-155 up-regulation by EBV as LMP1 is not 
expressed until approximately 5 days post-infection (p.i) [341]. Therefore, the kinetics of 
miR-155 up-regulation p.i may support or oppose the hypothesis that miR-155 up-regulation 
by EBV is mediated exclusively by LMP1.  
We began by measuring miR-155 expression in resting B cells infected with EBV or 
stimulated with CD40L and IL4 to produce activated, proliferating B cell blasts [621] which 
are phenotypically very similar to EBV-transformed LCLs. As LMP1 is in many respects a 
functional homolog of CD40 [622-624], we speculated that it may also be capable of up-
regulating miR-155. 
CD19
+
 resting peripheral blood B cells from several donors were pooled and a sample of the 
B cells was kept as a day 0 control. The remaining cells were either infected with EBV at an 
m.o.i of 100 or stimulated with CD40L and IL4 to produce B cell blasts.  The results 
confirmed the high expression of miR-155 in LCLs and also showed that miR-155 was up-
regulated by EBV infection and CD40L stimulation within 24 hours (figure 3.6). This is 
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before LMP1 is expressed in resting B cells, suggesting other EBV genes, or simply resting B 
cell activation through virus binding, is sufficient to up-regulate this miRNA. 
3.3.4 miR-155 regulation by LMP1-knockout EBV 
The kinetics of miR-155 up-regulation suggested that miR-155 was up-regulated prior to 
LMP1 expression in B cells. Nevertheless, LMP1 expression in BL-cell lines was sufficient to 
cause a significant up-regulation of miR-155. This suggests that miR-155 may be up-
regulated early in B cell transformation by virus binding or other EBV latent genes, but that 
LMP1 may be responsible for further up-regulation and maintenance of miR-155 expression. 
This hypothesis is further supported by the observation that CD40L stimulation of miR-155 
decreased at later time points, whereas LMP1 stimulation increased over the time course 
(figure 3.6). To address this, we used an LMP1-knockout (LMP1KO) virus [606] and 
monitored miR-155 expression by QPCR. The LMP1KO virus is non-transforming and 
infected B cells are activated initially and after approximately 10 days the cells begin to die, 
therefore all time points were harvested within 10 days post-infection. B cells infected with an 
LMP1KO virus up-regulated miR-155 to a similar level as the wild type virus (wtEBV) at all 
time points harvested (figure 3.7, A). This suggests that LMP1 plays no role in the up-
regulation of miR-155 in the early stages of transformation. 
3.3.5 miR-155 up-regulation following virus binding 
Previous data which examined miR-155 expression following individual latent gene 
expression in a variety of BL cell lines indicated that miR-155 up-regulation by another EBV 
latent gene was unlikely (section 3.3.2). Virus binding to B cells is mediated through the viral 
glycoprotein gp350 (BLLF) binding to the complement receptor CD21 on the B cell surface  
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Figure 3.6: miR-155 expression by QPCR in primary B cells either infected with EBV or 
stimulated with CD40L and IL4. CD19
+
 purified B cells were infected with EBV (m.o.i 100) 
or stimulated with CD40L + IL4 for 24 hours, 48 hours, 7 days (d7) or 4 weeks (wk 4). Data 
is expressed relative to the resting B cells and error bars represent the range in fold change 
within one experiment calculated from the standard deviation of the ∆∆Ct values. 
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[331]. Penetration of the cell membrane requires a complex of three additional glycoproteins, 
including gp42 which binds to HLA II molecules to initiate virus-cell fusion [625]. A mutated 
EBV which has the gp42 protein deleted from the genome (∆gp42 virus) can bind to the B 
cell surface through gp350-CD21, but it cannot enter and subsequently infect the B cell [39]. 
B cells incubated with ∆gp42 virus will therefore still bind virus as normal and the B cells 
may still be activated though the gp350-CD21 interaction, but no virus particles will enter the 
B cells. This allows the effect of just virus binding to the surface of the B cell to be examined, 
in the absence of any viral gene expression, and the effect on miR-155 expression to be 
measured. 
Infection of B cells with wtEBV, LMP1KO and Δgp42 virus was performed to determine 
whether the up-regulation of miR-155 seen during early infection with wtEBV and LMP1KO 
virus was due to virus binding and activation of the resting B cells.  Δgp42 virus infection of 
B cells consistently resulted in an up-regulated miR-155 expression. The up-regulation 
observed following Δgp42 infection was always lower than that seen following wtEBV or 
LMP1KO infections; however it was consistently a 5-10 fold up-regulation (figure 3.7, B). 
The up-regulation of miR-155 following B cell receptor (BCR) activation has been reported 
[612, 626, 627]. It appears, therefore, that B cell activation through virus binding may explain 
the early up-regulation of miR-155 by wtEBV, before LMP1 is expressed. The up-regulation 
of miR-155 by the Δgp42 virus complicates interpretation of the LMPKO virus data, as any 
up-regulation of miR-155 in the LMP1KO or wtEBV infections seen at 5-7 days pi will be 
masked by the effect of virus binding, and later time points are not possible due to the non-
transforming nature of the LMP1KO virus. Therefore, influence of LMP1, or any other EBV 
gene, on the regulation of miR-155, cannot be determined using these recombinant viruses.  
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Figure 3.7 miR-155 expression by QPCR in primary B cells infected with LMP1KO, Δgp42 
or wt EBV. A; resting B cells (d0) infected with either wt EBV (EBV), an LMP1 knock-out 
virus (LMP1KO) or stimulated with sCD40L and IL4 and harvested after 24 hours, 48 hours 
and 5 days. Data is expressed relative to the resting B cells. B; Resting B cells were infected 
with either wt EBV, LMP1KO virus or a GP42 knock-out virus (Gp42) and cells were 
harvested after 24hours, 4 days and 8 days. Data is expressed relative to the resting B cells. 
Error bars represent the range in fold change within one experiment calculated from the 
standard deviation of the ∆∆Ct values. 
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3.4 Processing of BIC to miR-155 in BL 
Kluiver et al reported in 2007 that stimulation of BIC expression (using anti-IgM) or even 
ectopic BIC expression in the EBV negative BL cell lines, Ramos and DG75, did not result in 
miR-155 expression and that this suggested a specific block in the processing of BIC to miR-
155 in this tumour [375]. Two observations from our own data could be interpreted as 
evidence which supports a possible processing defect in BL: Firstly, latency III Mutu-BL 
expressed approximately 50% less miR-155 than an LCL which may represent inefficient 
processing of BIC to miR-155 in these cells. Secondly, LMP1 expression in BL cell lines 
caused an increase in miR-155 expression to approximately 0.1-0.2 of the miR-155 
expression seen in an LCL, which could also represent inefficient processing of BIC in these 
cells. Additionally, the BJAB and DG75 cell lines showed variable increases in miR-155 
expression which could represent variability in the processing defect in different cell 
backgrounds.   
Collectively, the reported BIC processing defect and our own observations raised the 
following questions: is the miR-155 expression seen in latency III BL cell lines the result of 
increased BIC, and therefore miR-155 expression? Or, is BIC already expressed in BL and an 
EBV latent is gene required to stimulate the processing of BIC to miR-155? To address these 
questions we examined the expression of major components of the miRNA processing 
machinery and used a QPCR assay specific for spliced BIC mRNA, as previously described 
[612], to re-examine the BIC processing defect proposed by Kluiver et al [375].  
3.4.1 Dicer-1 and Drosha expression in BL cell lines 
The processing of BIC to miR-155 will involve a number of proteins which comprise the 
miRNA processing machinery. Two major components of the miRNA processing pathway are 
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the enzymes Drosha and Dicer-1. Drosha is a nuclear protein which cleaves the primary 
miRNA transcript and Dicer-1 cleaves the pre-miRNA transcript to produce the mature 
miRNA. Any defects in either of these proteins would result in defective miRNA processing. 
Increased expression of Drosha has been reported in cervical carcinoma [404], and loss of 
either gene was associated with increased tumourogenesis in a mouse model [402]. Thus, 
there is evidence to suggest that the expression of these enzymes may be altered in certain 
cancers, and the processing of miRNAs will consequently be altered.  
To determine whether the reported BIC processing defect in BL was due to dysregualtion of 
the expression of either Drosha or Dicer-1, we used commercially available Dicer-1 and 
Drosha QPCR assays to measure the expression of these two genes in a variety of cell lines. 
Initially we measured Drosha and Dicer-1 expression in cells which could effectively process 
miR-155 to establish an estimate of functional Drosha and Dicer-1 expression; primary B 
cells, EBV and CD40L day 7 blasts plus an LCL were examined (figure 3.8) and these cells 
all expressed at least 50% of the Dicer-1 and Drosha expression of an LCL, therefore this 
level of expression is likely to be sufficient for BIC processing.  
Next, we examined the DG75 tTA and DG75 tTA/LMP1 BL clones used in section 3.4.2. All 
DG75-BL clones showed similar levels of Dicer-1 and Drosha expression to the LCL, 
therefore these two miRNA processing enzymes are highly expressed at the transcript level in 
this BL cell line and are unlikely be the cause of a miRNA processing defect. 
Kluiver et al also compared the processing of BIC in the epithelial cell line, 293 cells and 
DG75-BL, following ectopic BIC expression [375]. To assist in the interpretation of these 
data, we compared the expression of Drosha and Dicer-1 in 293 cells and DG75-BL. Neither 
cell expressed less Drosha or Dicer-1 than the LCL, indicating that the expression of these  
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Figure 3.8 Dicer1 and Drosha expression by QPCR in primary B cells, DG75-BL tetracycline 
inducible clones and 293 cells. A; primary B cell infection, B; stable DG75 tTA cell lines 
expressing either an empty control or LMP1 expression vector with (+) or without (-) 
induction by removal of tetracycline, and C; 293 and DG75-BL expressed relative to an LCL. 
Error bars represent the range in fold change within one experiment calculated from the 
standard deviation of the ∆∆Ct values.  
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two enzymes is unlikely to a contributing factor to the reported processing defect of BIC in 
DG75-BL. 
3.4.2 BIC expression and EBV latent gene expression in Mutu-BL 
BIC expression in the same panel of Mutu-BL cell lines used in section 3.3.1 mirrored the 
expression of miR-155 in these lines (figure 3.9). BIC expression is high in latency III BL cell 
lines and very low in the EBV negative and latency I, suggesting increased BIC transcription 
and subsequent processing are responsible for the elevated miR-155 expression seen in 
latency III BL. This result supports the observation by Kluiver et al [375] who also reported 
high BIC expression in the latency III BL cell line Raji.  
3.4.3 BIC is processed in Ramos-BL after BCR stimulation 
Van den Berg et al were the first to report that BIC was up-regulated in B cells after BcR 
stimulation with anti-IgM [612]. This observation was later repeated and expanded upon by 
Kluiver et al [375], who showed that BIC was up-regulated in Ramos-BL cells following 
treatment with anti-IgM but this did not result in miR-155 expression, further supporting the 
observation that BIC cannot be processed in BL. We re-examined this result using Ramos cell 
lines, including a transfectant expressing LMP1 under the control of a tetracycline activator, 
similar to the DG75 tTA cell lines used in section 3.3.2. This allowed us to compare BIC 
processing after anti-IgM treatment in the absence or presence of LMP1. The LMP1 
expressing clone would serve as a positive control for BIC to miR-155 processing as we had 
previously shown that LMP1 was able to induce BIC to miR-155 processing in DG75-BL and 
BJAB cell lines. An empty vector Ramos tTA control cell line was used to control for the 
effect of tetracycline on BIC/miR-155 expression.  
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Figure 3.9: BIC and miR-155 expression by QPCR in a panel of Mutu-BL clones. A; BIC 
and B; miR-155 in four sub-clones of Mutu-BL by quantitative RT-PCR. Mutu I represents 
the biopsy phenotype of this tumour, while Mutu negative has lost the EBV genome and the 
two latency III  clones (j8 and 95)  have drifted in culture to express a latency III type of EBV 
gene expression similar to that seen in an LCL. EBV latent gene expression was confirmed 
(figure 3.3). Error bars represent the range in fold change within one experiment calculated 
from the standard deviation of the ∆∆Ct values. 
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Both BIC and miR-155 were induced by anti-IgM treatment and by LMP1 expression in the 
Ramos tTA/LMP1 cell line (figure 3.10) which was in disagreement with the data reported by 
Kluiver et al [375], who used QPCR to measure BIC expression in their experiments; 
however, they used northern blotting to detect miR-155 expression, which may explain our 
differing results. QPCR is a very sensitive technique which is recognised to be more specific 
and sensitive then northern blotting [608]. miR-155 expression is very low in BL and our 
previous data on DG75 showed that a 10-20 fold up-regulation of miR-155 in a BL cell is still 
only 10-20% of the expression seen in an LCL.  It is therefore possible that the northern blot 
assay in Kluiver’s study was unable to detect the increase in miR-155 expression following 
anti-IgM treatment, whereas their QPCR assay was sensitive enough to detect the increase in 
BIC expression. 
3.4.4 Ectopic expression of BIC in DG75-BL 
In the Kluiver et al study [375], ectopic BIC expression in Ramos-BL did not result in miR-
155 expression, despite very high levels of BIC mRNA after transfection.  We were kindly 
donated some of the BIC PCDNA.3 expression vector used by Kluiver, which contained the 
full length BIC cDNA. We sought to confirm the results seen by Kluiver et al by re-
examining the processing of BIC to miR-155 in DG75-BL and 293 cells, using the sensitive 
miRNA QPCR assay.  
293 cells were transfected using lipofectamine with 1μg of PCDNA.3-BIC or PCDNA.3 and 
the cells were selected in 0.5mg/ml G418 for 3 weeks. DG75-BL cells were transfected via 
electropration with 5μg of PCDNA.3-BIC or PCDNA.3 and positive cells selected in 2mg/ml 
of G418 for 3 weeks. BIC and miR-155 expression in the stably transfected 293 and DG75-
BL cell lines was measured by QPCR.  
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Figure 3.10: BIC and miR-155 expression in Ramos-BL cells following either LMP1 
expression or BCR stimulation. A; BIC and B; miR-155 expression in induced (+) or 
uninduced (-) Ramos tTA and Ramos tTA/LMP1, and after BCR stimulation with anti-IgM. 
Data is expressed relative to un-induced controls (grey bars). Error bars represent the range in 
fold change within one experiment calculated from the standard deviation of the ∆∆Ct values. 
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The data clearly show that BIC was successfully transfected and expressed in both the DG75-
BL and the 293 cells. However, only the 293 transfectant appears to expressed miR-155, 
suggesting that the BIC expression vector was not being processed to miR-155 in the BL cell 
line (figure 3.11). This result is consistent with those of Kluiver et al who used northern 
blotting to detect miR-155 in their study. However, when the same data are expressed relative 
to an LCL (figure 3.12), it can be seen that the expression of BIC, in both the 293 and the 
DG75-BL cells, was substantially higher than  an LCL (10-40 fold); whereas the miR-155 
expression, in both 293 cells and DG75, was much lower than those seen in an LCL. This 
suggests that the BIC expression vector was not being processed efficiently in either cell line, 
indicating that there may be a problem with the vector itself which is causing artificially low 
processing efficiencies.  
Another point to note about these experiments is that the comparative amounts of endogenous 
BIC and miR-155 in the cell lines is not a 1:1 ratio to begin with. For example, the expression 
of miR-155 by QPCR is approximately 9 Ct values higher in the DG75 cells compared with 
the LCL, which corresponds to an expression level 500 fold lower than the LCL. However, 
the BIC expression in the 293 cells is only approximately 4 Ct values higher than the LCL, 
which corresponds to an expression level only 16 fold less than an LCL. This discrepancy 
may be due to the different specificities and sensitivities of the two assays or may represent a 
real difference in the endogenous levels of BIC and miR-155 in the 293 cells. There is no 
reason to assume that the miR-155 expression levels should correlate exactly with BIC 
expression levels in a 1:1 ratio; the processing of pri-miRNAs is poorly understood and is 
further complicated in this instance by the fact that miR-155 is an exonic miRNA rather than 
an intronic miRNA.  
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Figure 3.11: BIC and miR-155 expression by QPCR in DG75-BL and 293 cells following 
transfection of either PCDNA.3 or BIC-PCDNA.3. A; BIC and B; miR-155 expression in 
stably transfected DG75-BL and 293 cells expressing either PCDNA.3-BIC or PCDNA.3 
expression vectors. Data is expressed relative to the PCDNA.3 control transfections. Error 
bars represent the range in fold change within one experiment calculated from the standard 
deviation of the ∆∆Ct values. 
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Figure 3.12: Data from figure 3.11, expressed relative to an LCL. A; BIC expression, B; 
miR-155 expression in stably transfected DG75-BL and 293 cells expressing either 
PCDNA.3-BIC or PCDNA.3 expression vectors. Error bars represent the range in fold change 
within one experiment calculated from the standard deviation of the ∆∆Ct values. 
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3.4.5 Processing of BIC to miR-155* 
During miRNA processing the pre-miRNA is cleaved by Dicer-1 to produce the mature 
miRNA duplex. The miRNA duplex is asymmetric and is believed to be preferentially 
‘loaded’ into the RISC complex in a specific orientation which designates one strand (usually 
the 5’ end) of the pre-miRNA as the mature miRNA strand due to its enhanced flexibility 
[394, 628]. It is also possible for the alternative arm (passenger strand) to be processed (the 3’ 
arm) preferentially over the dominant arm. There is evidence to suggest that this alternative 
processing can be controlled in a tissue specific manner, with the 3’ arm mature miRNA 
being expressed in one tissue and the 5’ mature miRNA being expressed in a different tissue 
[396]. When there is evidence for tissue specific expression of both arms of the pre-miRNA, 
the two mature miRNAs are then called 3p and 5p to distinguish between them. There are 
miRNAs in which the alternative arm is processed all the time but at very low levels in 
comparison to the dominant arm, and in this case the alternative arm is designated the minor 
miRNA and is symbolised by a * (figure 3.13).  
miR-155 has a minor miRNA (miR-155*) which has not been shown to have any significant 
level of expression in any tissue to date, hence its designation as a minor miRNA. We sought 
to measure the miR-155* expression in the BIC transfected 293 and DG75-BL cell lines to 
determine whether BIC was being processed to the alternative arm of miR-155, explaining the 
apparent processing defect of BIC in these experiments. There was a small increase in miR-
155* expression in the DG75 BIC transfected cells but not enough to explain the lack of BIC 
processing in these cells as it was still very small in comparison to the expression of BIC 
(figure 3.13). miR-155* expression increases with miR-155 expression in the 293-BIC 
transfected cells as you would expect; the expression of the minor form of a miRNA is 
observed to increase and decrease with the expression of the major form as the ratio of  
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A 
B  
 
Sample Ct miR-155 Ct miR-155* Ct Z30 
DG75 PCDNA.3 30.4 36.7 30.4 
DG75 BIC 30.8 34.1 30.7 
293 PCDNA.3 31.8 36.3 29.0 
293 BIC 27.2 32 29.5 
Table 8: miR-155 and miR-155* Ct values following BIC transfection. The mean Ct values 
from one experiment showing that miR-155* is expressed at a lower level than miR-155 in all 
samples. The snoRNA Z30 was used as the endogenous control. 
 
Figure 3.13: Schematic of pre-miRNA. Graphs representing miR-155 and miR-155* 
expression in DG75-BL and 293 cells following BIC transfection. A; Diagram representing 
pre-miR-155 showing the 3’ arm which can also be processed into the minor miR-155* B; 
QPCR data showing BIC expression, miR-155 and miR-155* expression in stably transfected 
DG75-BL and 293 cells expressing either PCDNA.3-BIC or PCDNA.3 expression vectors. 
Data is expressed relative to the PCDNA.3 controls. Error bars represent the range in fold 
change within one experiment calculated from the standard deviation of the ∆∆Ct values.  
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major:minor miRNA remains the same. The mean Ct values from one experiment are shown 
in figure 3.15 to demonstrate that miR-155* is consistently expressed at a lower level than 
miR-155 and at no point does the expression of miR-155* become the dominant miRNA. 
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Discussion I 
 
(a) Characterising miR-155 Expression 
Using a panel of HL cell lines we were able to demonstrate high expression of miR-155 in HL 
relative to resting B cells, which was consistent with the results shown by van den Berg who 
used in-situ-hybridisation of paraffin embedded HL tissue to show very high expression of 
BIC [612]. We were also able to confirm the low expression of miR-155 observed by other 
groups [375, 626, 629] in BL cell lines after assaying a panel of BL cell lines expressing the 
original tumour biopsy pattern of EBV latent gene expression, latency I. The in-situ 
hybridisation data on HL tissue by van den Berg suggested that GC B cells may have a higher 
level of BIC expression than the other B and T cell tumour infiltrate. However, when we 
sorted CD10 positive GC B cells from a tonsil, neither the centrocytes nor the centroblasts 
showed higher miR-155 expression when compared with the CD19 positive tonsillar B cells. 
Our data indicate that GC B cells, which are argued to be the precursor cell for HL and BL 
[314, 630], express less miR-155 than HL cell lines and more miR-155 than the BL lines, 
suggesting that a change in miR-155 expression has occurred in both of these tumours.  
It is worth noting, that during the course of my study there was a significant advancement of 
knowledge regarding the expression and function of miR-155, which led to a change in the 
interpretation of much of the pre-2007 data. The expression of miR-155 was considered to be 
very low/non-existent in resting B cells [631] with GC B cells expressing a low but detectable 
level of expression [553]. However, miR-155 is now regarded as having an important role in 
normal B cell function, germinal centre formation and immune responses [509, 632, 633], 
causing us to re-evaluate what a ‘low level’ of miR-155 expression is. Likewise, the apparent 
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lack of BIC/miR-155 expression reported in BL, with hindsight, appears to represent 
expression levels which may still be functionally significant as they are approximately 10% of 
those seen in B cells, where miR-155 plays an important functional role. 
(b) miR-155 regulation by EBV 
We were able to demonstrate a correlation between BIC and miR-155 expression and a 
latency III pattern of EBV gene expression in the BL cell line Mutu, consistent with the 
hypothesis that miR-155 expression is regulated by EBV gene expression. The initial 
observation that BIC expression could be up-regulated by LMP1, which came from a 
microarray experiment conducted at our institute [618], was then validated using a model of 
induced LMP1 expression in DG75-BL, which clearly resulted in increased BIC and miR-155 
expression.  
During the course of this work and after, several papers were published regarding the 
regulation of miR-155 by EBV and the function of this observed regulation. One paper 
published by Yin et al 2008 [634] examined the regulation of BIC and miR-155 expression by 
EBV. They demonstrated that an AP-1 promoter element upstream of the BIC transcription 
initiation site is involved in the transcription initiation of BIC in latency III BL cell lines. 
Since LMP1 and LMP2A have both been shown to signal through AP-1 [635], they examined 
the effect of LMP1 and LMP2A expression on miR-155 expression, using retroviruses 
expressing LMP1 or LMP2A. After transducing EBV negative BL cell lines, including Mutu-
BL and Ramos-BL, they could not show any increase in miR-155 expression in the LMP2A 
expressing BL cell lines, in agreement with our results. They could only show a 2 fold 
increase in miR-155 expression with the LMP1 expressing retrovirus in EBV negative Mutu-
BL and Akata-BL, but they saw no increase in Ramos-BL. This only partially agrees with the 
data presented in this chapter as we demonstrated a 10-15 fold increase in miR-155 
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expression relative to the un-induced controls following LMP1 expression. We also saw a 
significant up-regulation of miR-155 with LMP1 expression in Ramos-BL, and these 
differences may be the consequence of differing experimental design. Yin et al used 
retoviruses and drug selected the cells for 14 days prior to harvesting, whereas our DG75 and 
Ramos tTA/LMP1 transfectants were harvested 48 hours after induction. The time difference 
post-LMP1 expression may be important here as cells with a high BIC to miR-155 processing 
efficiency may have time to be negatively selected against, as suggested in another report 
published later that year [376].  
Lu et al 2008 [636] also examined the regulation of miR-155 by LMP1 and LMP2, and they 
found that miR-155 was up-regulated approximately 7 fold after LMP1 transfection into 
DG75, and by less than 3 fold after transfection of LMP2A. Collectively, these results and my 
own strongly suggest that LMP1 can up-regulate miR-155 in BL cell lines but this alone is not 
sufficient to reproduce the miR-155 expression levels seen in latency III BL cell lines or 
LCLs. A more complicated mechanism of BIC/miR-155 expression regulation must be taking 
place in these cells which has yet to be elucidated. 
We observed a strong up-regulation of miR-155 following B cell stimulation with CD40L and 
IL4 to produce proliferating B cell blasts. This result partially supports the previous data, 
which show an up-regulation of miR-155 by LMP1, as LMP1 is a functional homologue of an 
activated CD40 receptor. The strong up-regulation of miR-155 in CD40L blasts also suggests 
a possible role for miR-155 in B cell proliferation and activation as miR-155 is abundantly 
expressed in these proliferating blasts. EBV and CD40L blasts are phenotypically very 
similar; therefore, it is likely that miR-155 is regulating overlapping gene sets in these two 
blasts.  
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We have shown that miR-155 expression is up-regulated during EBV infection and 
transformation of primary B cells, a result also shown by numerous groups [603, 620, 636]. 
We also demonstrated a large increase in miR-155 expression 24 hours post EBV infection, 
which was not consistent with an up-regulation by LMP1.  However, in BL cell lines, the only 
EBV gene that we, or anybody else, were able to identify as capable of up-regulating miR-
155, was LMP1. Despite this, we could not demonstrate that LMP1 was essential for up-
regulation of BIC/miR-155 during infection of primary B cells because an LMP1KO virus 
was as efficient at up-regulating miR-155 as the wtEBV. This result was further complicated 
by the observation that a ∆gp42 virus, which was only capable of binding to the cell surface 
and not of entering the cell, was also able to up-regulate miR-155 expression in resting B 
cells. These results would suggest that miR-155 is up-regulated by EBV binding and 
subsequent activation of the B cell. Virus binding to the B cell may activate TLR signalling as 
EBV infection and CD40L stimulation of resting B cells has been shown to activate TLR 
signalling pathways [637], and miR-155 expression is induced by TLR signalling in 
macrophages [638]. 
(c) Processing of BIC to miR-155 in BL 
The BIC to miR-155 processing defect in BL outlined by Kluiver et al [375] was the 
reasoning for the subsequent work in this chapter which aimed to re-examine this processing 
defect and potentially identify the mechanism behind it and how it may relate to EBV. Our 
data showed that miR-155 and BIC were up-regulated in the latency III BL cell line Mutu, a 
result later confirmed by other groups [639, 640]. This indicated that the reported processing 
defect of BIC in BL was apparently overcome through a latency III pattern of EBV gene 
expression; providing an interesting and novel opportunity to study the role of EBV in 
regulating the expression and processing of this oncogenic miRNA.  
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Initially, we measured the expression of Dicer-1 and Drosha, two essential components of the 
miRNA processing machinery, to rule out an obvious miRNA processing defect in the DG75 
cell line. We measured the expression of Dicer-1 and Drosha during primary B cell infection 
and in the DG75 tTA cell lines, with and without LMP1 induction. There was no loss of 
expression of these genes in any sample. The expression of Dicer-1 and Drosha varied 
between samples with no apparent pattern. None of the cells showed very low levels of Dicer-
1 or Drosha expression, with most showing higher level of expression than an LCL, which 
was capable of processing BIC to miR-155.  
Next, we sought to characterise the proposed BIC processing defect in BL cell lines.  We 
measured BIC expression in the panel of Mutu-BL cell lines and demonstrated increased BIC 
expression in the latency III Mutu-BL clones; consistent with an increased BIC transcription 
being the cause of the increased miR-155 expression. 
In order to reproduce the BIC processing defect outlined by Kluiver et al we sought to repeat 
an experiment which they had published, where the Ramos-BL cell line was stimulated with 
anti-IgM to produce an increase in BIC transcription, with no subsequent miR-155 expression 
[375]. We were not able to reproduce this result as we observed increased BIC expression 
coupled with increased miR-155 expression in the Ramos-BL cells following anti-IgM 
treatment. Kluiver et al used northern blot to detect miR-155 expression, whereas we used 
QPCR, a much more sensitive technique, which may explain our differing results. miR-155 is 
expressed at low levels in BL, therefore an increase in miR-155 expression in these cell lines 
may still not be enough miR-155 expression for the northern blot to detect. Another group has 
since shown that BcR stimulation using anti-IgM results in both BIC and miR-155 expression 
in Ramos-BL, in agreement with our data [639].  
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Kluiver et al were aware of the limited sensitivity of their miR-155 northern blotting system 
so they decided to transfect the full length BIC cDNA in a PCDNA.3 vector, into Ramos-BL 
and 293 cells as a positive control. Their reasoning being that the supra-physiological levels 
of BIC expression caused by BIC transfection, should result in miR-155 expression high 
enough for a northern blot to detect if there was no BIC processing defect. They could not 
detect any miR-155 expression in the BIC transfected Ramos-BL whereas they could in the 
293 cells, supporting their previous data which indicated a processing defect in the Ramos-BL 
cell line.  
Kluiver et al kindly donated their PCDNA.3-BIC plasmid for us to use in an attempt to 
reproduce their data. After transfection of PCDNA.3-BIC into DG75-BL and 293 cells we 
observed the same apparent processing defect, with a large up-regulation of BIC expression in 
both cell lines but only the 293 cells showed an up-regulation of the mature miR-155. Thus 
far, none of the results in this chapter had shown any processing defect in BL cell lines, 
contradicting the data published by Kluiver et al and there was no loss of Dicer-1 or Drosha 
expression in DG75 which would explain a processing defect. A possible explanation for the 
lack of miR-155 expression in DG75-BL after BIC transfection was that BIC transcript was 
being processed into the alternative arm of the pre-miR-155, to produce the minor miR-155*. 
We used QPCR to measure the miR-155 expression along with miR-155* and the data 
showed no evidence of preferential processing of BIC to miR-155*, with the expression of 
miR-155 being at least 8 fold higher than miR-155* in all samples.  
The fact that PCDNA.3-BIC could be processed to miR-155 in the 293 cells suggested that 
the PCDNA.3-BIC vector was producing a BIC transcript with the correct sequence and 
conformation to allow recognition by the processing machinery. We had shown that BIC was 
able to be processed in DG75 after LMP1 expression and we had also shown that Ramos-BL 
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was able to process BIC after anti-IgM treatment, indicating that the BL cell lines were able to 
process BIC to miR-155. We could rule out an alternative processing mechanism as we had 
demonstrated that BIC is not being preferentially processed into miR-155*. Additionally we 
demonstrated that Dicer-1 and Drosha were present in BL lines at similar levels to the 293 
cells and an LCL, which collectively, would strongly suggest there was no BIC to miR-155 
processing defect in BL cell lines. In support of this, when the PCDNA.3-BIC transfection 
data was expressed relative to an LCL, it can be seen that the BIC expression in the 293 cells 
is approximately 40 fold higher than the BIC expression in an LCL, however, the miR-155 
expression is approximately 50 fold less than the expression seen in an LCL. This suggests 
that there is a possible flaw in the experiment because even this positive control cell line 
cannot process BIC to miR-155 efficiently. As there may be a problem with the experimental 
design or the BIC expression vector being used, it would be unwise to attempt to draw firm 
conclusions from these data.  
There are several possible explanations for the lack of BIC processing after transfection with 
the PCDNA.3-BIC expression vector, but there are three which appear most likely: Firstly, 
miR-155 is unusual because it is an exonic miRNA and it is, therefore, not simply spiced out 
in the nucleus where it is accessible to Drosha for processing as intronic pri-miRNAs are. The 
mechanisms which govern miRNA processing and regulation are still not fully understood 
and whether or not they are coupled to the splicing of the pri-miRNA transcript is also 
unknown. This makes interpretation of pri-miRNA versus mature miRNA expression data 
very difficult to interpret, as in the absence of a proper understanding of the details of the 
miRNA processing pathway, there is actually no reason to assume that the expression of the 
two should correlate. If miRNA processing, particularly exonic miRNA processing, is in any 
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way coupled to splicing then it might be expected that the processing efficiency of a BIC 
cDNA expression plasmid would be low.  
Secondly, the cellular localisation of BIC after transfection may affect processing efficiency 
as BIC would need to be present in the nucleus to have access to Drosha for the first 
processing step to take place. Lipid mediated transfection of epithelial cells and electropration 
of B cells may result in slightly different cellular localisation which could affect the ability of 
the BIC to be processed. An interesting report published by Eis et al highlighted the flaw in 
measuring BIC expression by QPCR [374]. BIC QPCR assays are usually designed across the 
spice junction of exons 2 and 3 (our QPCR assay included), therefore, the assay will only 
detecting the spliced BIC RNA. Eis et al [374] showed that un-spliced BIC RNA was 
predominantly nuclear whereas the spliced RNA was predominantly cytoplasmic, where it has 
no access to Drosha for the first processing step. It is likely that exonic miRNAs can be 
regulated transcriptionally and/or post-transcriptionally, with miR-155 potentially being 
processed from un-spliced BIC, spliced BIC pre-nuclear export, or spliced BIC RNA exported 
back into the cytoplasm. This again calls into question the methods and assumptions which 
are commonly used when measuring mature miRNAs and their precursors. It is very difficult 
to interpret pri-miRNA versus mature miRNA data until these questions have been answered.  
The third possibility is the impact of drug selection on the processing of BIC in both cell 
lines. We and Kluiver et al used hygomycin drug selection to produce a stable cell line after 
BIC transfection, and it had since been reported by Zhang et al that transient transfection of 
BIC into Ramos-BL and 293 cells resulted in efficient BIC to miR-155 processing [376]. 
Zhang et al propose that drug selection in culture may allow for the clonal selection of cells 
which do not express miR-155 as it may be unfavourable for cell proliferation and/or survival. 
They imply that this clonal selection may be more pronounced in the BL cell lines than the 
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293 cells, hence the apparent processing defect observed by Kluiver et al selectively in the BL 
cell line. My own results would suggest that clonal selection may also be occurring in the 293 
cells as the processing efficiency of BIC to miR-155 appeared to be very low in both 293 and 
DG75-BL cells when compared with an LCL, therefore, transient transfection of BIC may 
produce different results form those which we obtained following drug selection.  
(d) miR-155 function 
The function of miR-155 in normal B cells and EBV associated tumours is a rapidly 
expanding area of research with many significant breakthroughs occurring throughout the 
course of my work. The observation that miR-155 plays an essential role in germinal centre 
formation and immune responses [509, 632, 633] was an extremely important discovery 
which caused the miR-155 literature to date to be re-evaluated, as discussed earlier. Many 
targets of miR-155 identified through microarrays and reporter assays revealed that miR-155 
targets many genes already known to be involved in B cell development and EBV signalling, 
such as PU.1 [633], IKKε [636] and multiple members of the bone morphogenic protein 
signalling pathway [641]. Another significant discovery was the identification of miR-155 
orthologs in other oncogenic herpesviruses. KSHV encodes a miRNA (miR-K12-11) which 
possesses an identical seed sequence to hsa-miR-155 and has been shown to target some of 
same genes as miR-155, including BACH1 [642, 643]; miR-K12-11 is therefore classified as 
a functional ortholog of miR-155. It was later shown that an oncogenic alpha herpes virus, 
Marek’s disease virus of chickens, also encodes a functional ortholog of gga-miR-155 which 
was able to target some of the same target genes as gga-miR-155, including PU.1 [644, 645]. 
The possession of miR-155 orthologs in distantly related oncogenic herpes viruses 
strengthens the evidence that this miRNA is very important in lymphomagenesis. It also 
suggests that miR-155 may play an important role in herpes virus infection and 
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transformation. Additionally, the down-regualtion of PU.I, a transcription factor required for 
LMP1 transactivation, may provide a possible negative feedback mechanism whereby LMP1 
up-regulation of miR-155 results in a reduction of LMP1 expression. However, miR-155 
inhibiton in an LCL did not result in decreased EBNA2 or LMP1 protein expression [646]. 
The role miR-155 plays in HL is still an unsolved question, although clues are starting to 
emerge from miR-155 target identification studies. It might seem counter-intuitive that low 
expression of an oncogenic miRNA might be important in BL development but there is 
literature emerging which suggests that this may be the case. For example, activation induced 
deaminase (AID) is one of miR-155 targets which has been verified [647] and a mouse model 
where the miR-155 target site in AID was removed showed an increased half life of the AID 
mRNA, resulting in a high degree of Myc-Igh translocations [648]. Loss of miR-155 
expression may therefore be relevant in the development of BL, which is characterised by a c-
myc translocation to the IgH locus.  
In summary, we have shown that miR-155 is an EBV regulated cellular miRNA which is 
expressed at a very high level in LCLs and HL cell lines. LMP1 is able to up-regulate miR-
155 expression in BL cell lines but not to the levels seen in latency III BL lines, suggesting 
that LMP1 may be working in synergy with other EBV latent genes to up-regulate miR-155. 
The expression of miR-155 in BL is relatively low and this is the result of low transcription of 
BIC and not a block in the processing of BIC to miR-155 in BL cell lines. 
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4. Results Part II 
Identifying cellular miRNAs involved in EBV-mediated B cell transformation 
 
4.1 Introduction 
In the previous chapter, it was shown that EBV infection of B cells causes the up-regulation 
of miR-155, a cellular miRNA known to be involved in lymphomagenesis.  The next logical 
step to determine to what extent EBV modulates cellular miRNA expression during B cell 
transformation, was to perform an array of cellular miRNA expression. Many of the changes 
in miRNA expression will not be specific to EBV growth transformation, but will simply 
reflect changes in gene and miRNA expression associated with activation and proliferation of 
resting cells. B cells stimulated with CD40L and IL4 to generate proliferating B cell blasts are 
phenotypically very similar to EBV transformed blasts; they both show homotypic adhesions 
in culture, and express a similar repertoire of activation associated antigens. However, CD40L 
generated B cell blasts will only proliferate transiently in culture whereas EBV transformed B 
cell blasts may eventually produce an immortalised cell line [348, 649].  
We aimed to compare the expression profiles of EBV generated B cell blasts and CD40L and 
IL4 stimulated B cell blasts, as a means of identifying miRNA expression changes which 
were not just associated with transient proliferation of resting cells, but were specific to the 
transformation of resting B cells by EBV. We hypothesised that these cellular miRNA and 
subsequent gene expression changes may predispose the LCL to the additional changes 
necessary for immortalisation, in contrast to the CD40L blasts. miRNA and cellular gene 
expression changes which facilitate the production of an immortalised cell line in vitro may 
also be relevant to the formation of EBV associated B cell tumours in vivo. 
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The aims of this chapter were to (i) identify the subset of miRNAs differentially expressed 
between EBV and CD40L blasts, (ii) characterise the expression of these miRNAs in a panel 
of EBV associated tumour cell lines and (iii) select one miRNA for target prediction and 
functional analysis. 
4.2 Cellular miRNA expression profiling 
To identify miRNAs potentially involved in the cellular transformation of resting B cells by 
EBV, we performed a Taqman QPCR miRNA array of 365 cellular miRNAs on the following 
samples: resting B cells, CD40L generated B cell blasts, EBV blasts and matched LCLs 
(figure 4.1). The Taqman array was only performed in biological duplicate for expense 
purposes but it was reasoned that the expression of miRNAs of interest could subsequently be 
validated on a larger sample set. 
4.2.1 Cells used for miRNA profiling 
The following experiment was performed in duplicate to obtain biological duplicate sample 
sets for the Taqman miRNA array: CD19 positive resting B cells were isolated from 
peripheral blood using CD19 dynabeads. B cells from 4 to 6 donors were pooled and a 
fraction was taken immediately for RNA extraction as a resting B cell sample (d0) and the B 
cell purity was confirmed by FACS staining for CD21 expression (figure 4.2). B cells from 
multiple donors were pooled to reduce the possibility of identifying miRNA expression 
differences which were donor specific and not typical of B cells, thus making the data more 
reproducible. The remaining B cells were either stimulated with 50ng/ml of soluble CD40L 
and 50ng/ml of IL4 to generate proliferating B cell blasts, or, infected with EBV at an m.o.i of 
100, and both sets of blasts were harvested after 7 days. EBV infected B cell blasts were also 
grown for a further 5 weeks to produce an established LCL.   
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Figure 4.1: Diagram representing the experimental design of the Taqman miRNA array. 
Resting B cells were isolated from peripheral blood and either stimulated with CD40L and 
IL4 for 7 days or, infected with EBV at an m.o.i of 100 and harvested after 7 days or 6 
weeks (LCL) 
 
CD40L + IL4 
EBV 
CD40L blasts EBV blasts 
7 days 
5 weeks 
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Figure 4.2: Activation and miRNA expression of miRNA array samples A: Flow cytometry data 
showing the purity of B cells isolated from peripheral blood after selection with CD19+ 
dynabeads, determined by CD21 staining. Grey, filled histograms represent cells stained with a 
matched isotype control: B and C: Flow cytometry data showing activation of resting B cells 7 
days after either stimulation with sCD40L and IL4 (B) or infection with EBV (C), determined by 
CD23 staining. D and E: QPCR for miR-155 in the two biologically distinct samples used for the 
Taqman miRNA array. Array sample set 2 does not contain CD40L blasts 4 weeks post-
stimulation as cells did not survive (not determined(ND)). Error bars represent the range in fold 
change from the standard deviation of the ∆∆Ct values.  
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CD40L blasts were generated using soluble trimeric CD40L to avoid contamination of the 
blast sample with CD40L secreting mouse L-cells, which are the standard method used to 
produce CD40L blasts. Mouse miRNAs are very similar, and in some instances identical in 
sequence to human miRNAs, therefore, contamination from mouse L-cells could produce 
false positives in the miRNA QPCR array.  
Prior to the array analysis, activation of the B cells stimulated with sCD40L and IL4 or 
infected with EBV was verified by FACS for the B cell activation marker, CD23. 
Additionally, the expression of miR-155 was measured by QPCR in the biological duplicate 
array samples to ensure RNA quality, miRNA expression, and to further confirm activation of 
the B cells (figure 4.2).  
4.2.2 Taqman miRNA array 
The cellular miRNA expression profile of the following samples was determined on 
biological duplicates, prepared from pooled peripheral blood B cells at different time points: 
resting B cells (d0), EBV blasts, CD40L blasts and the LCL (6 weeks p.i). The miRNA 
expression of each sample was measured using a QPCR array; Taqman Array Human miRNA 
Panel version 1. The QPCR array measured the mature miRNA expression profile of 365 
cellular miRNAs and the data was analysed using the comparative ∆∆Ct method [609], the 
details of which are described fully in materials and methods section 2.9.2. Briefly, RNA was 
extracted from each sample using Ambion’s mirVana kit to ensure the quantitative isolation 
of miRNAs and cellular mRNA. The RNA was reverse-transcribed in pools of stem loop 
primers specific for each of the 365 mature miRNAs and loaded into a microfluidics card 
where 365 cellular miRNAs and RNU48 and RNU 44 endogenous controls were assayed in 
singleplex QPCR reactions. 
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4.2.3 Taqman miRNA array fold change analysis  
The miRNA expression data from the Taqman miRNA array was exported into Microsoft 
Excel for ∆∆Ct analysis, and the fold changes of each miRNA in the EBV blasts, CD40L 
blasts and the LCL were calculated relative to the resting B cells. The aim of this analysis was 
to identify miRNAs which were differentially regulated between EBV blasts and CD40L 
blasts, relative to resting B cells. In addition, miRNAs differentially expressed between EBV 
blasts and the LCL were of interest as these miRNA expression changes may represent 
transformation specific changes only seen in established LCLs.  
The array data was analysed using the following criteria: Firstly, for a miRNA to be classified 
as ‘expressed’ it required a ΔCt value of ≤12 (using RNU48 as an endogenous control). This 
was in line with the manufacture’s recommendations because in this system, a ΔCt of 12 
approximately corresponded to a Ct value of 38, the threshold for miRNA detection. 
Secondly, miRNAs which gave a ≥2 fold change, in the same direction, in biological 
duplicate samples, were classified as up or down-regulated. Thirdly, up-regulated miRNAs 
had to classify as ‘expressed’ after up-regulation and miRNAs which were down-regulated 
had to classify as ‘expressed’ before down-regulation in the resting B cells. Statistical analysis 
could not be performed on this data due to the limited number of replicates. 
The miRNAs were classified accordingly and the results presented in figure 4.3. The majority 
of miRNAs (70%) were not expressed (dCt≤12) in any sample, which may reflect the tissue 
specific expression associated with many miRNAs [650]. A further 19% of the miRNAs 
assayed did not change in expression between any of the samples, thus, nearly 90% of the 365 
miRNAs on the array were not involved in the transformation of resting B cells by EBV. The 
remaining miRNAs assayed did change expression in response to EBV infection and/or CD40 
stimulation: 19 miRNAs (5%) were up-regulated in all samples, 7 (2%) were down-regulated 
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in all samples and 10 miRNAs (3%) were differentially regulated between the three samples 
(EBV blasts, CD40L blasts and LCLs. Tables 9-11). A further 6 miRNAs (miR-34a, -30e-5p, 
-335, -486, -650 and -151) gave inconsistent expression in biological duplicates (i.e. greater 
than 2 fold change in expression in only one of the biological duplicate samples), hence these 
miRNAs were classified as undetermined. 
Of the 10 differentially regulated miRNAs, 7 showed differential expression between CD40L 
blasts and EBV blasts (miR-148a, -200b, -199a-3p, -28-5p, - 95, -31 and miR-15a). miR-15a 
was the only miRNA which showed differential expression between CD40L blasts and EBV 
day 7 blasts as well as between EBV blast and the LCLs. The remaining three miRNAs 
showed differential expression between EBV blasts and the LCL: miR-193a-3p, -132, and -
125b (table 9). 
4.2.4 Taqman miRNA array ∆Ct analysis 
The fold change in miRNA expression relative to resting B cells is informative for 
determining how a miRNA has changed in response to a specific stimulus, such as EBV 
infection or CD40 stimulation. However, it cannot give any indication of absolute expression, 
which may need to be taken into account when considering miRNA expression changes which 
are most likely to be functionally significant. For example: a miRNA which is up-regulated 
20 fold by EBV infection may still be expressed at a lower level than another miRNA which 
has been down-regulated by 20 fold. To estimate the significance of results produced by the 
miRNA fold change analysis, an indication of absolute expression, such as the ∆Ct analysis, 
was required.  
The ΔCt values produced by the QPCR analysis are essentially the normalised raw miRNA 
expression data (ΔCt = Ct miRNA – Ct RNU48). The Taqman miRNA individual QPCR 
assays and arrays have been designed to produce comparable ΔCt values, allowing the ΔCt  
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Figure 4.3: Pie chart representing the results from a Taqman miRNA array for 365 cellular 
miRNAs. Data represents duplicate biological samples from pooled peripheral blood B cells either 
harvested immediately after isolation (resting B cell sample),  7 days post-stimulation with 
CD40L and IL4, or 7 days and 6 weeks (LCL) post-infection with EBV. Data labels represent the 
percentage of miRNAs in each category, with the total number of miRNAs in each category 
indicated in brackets in the legend. miRNAs which were not expressed had a ΔCt value of ≥12 in 
all samples. miRNAs up or down-regulated by CD40L and EBV showed a ≥2 fold change in 
duplicate biological samples in CD40L blasts and both the EBV blasts and LCLs. Differentially 
regulated miRNAs showed consistent expression in biological duplicates and differential 
expression between the three samples: CD40L d7 blasts, EBV blasts and the LCLs. miRNAs 
classified as undetermined did not show consistent biological duplicates and therefore could not 
be classified.  
 
 
Table 9: Fold change in expression of 10 miRNAs classified as differentially regulated 
between either CD40L d7 blasts and EBV d7 blasts or EBV blasts and LCLs. Fold change 
was calculated using the ΔΔCt method of analysis and was expressed relative to resting B 
cells. The fold change is the mean fold change in expression of duplicate biological replicates 
from a Taqman miRNA array. Red shading represents a ≥ 2 fold increase in expression 
relative to resting B cells and blue shading represents a ≥ 2fold decrease in expression. 
 Fold Change 
miRNA CD40L d7 EBV d7 LCL 
hsa-miR-148a -1.4 11.0 63.3 
hsa-miR-200b 1.1 -66.6 -18.2 
hsa-miR-199a-3p -1.9 -12.9 -25.9 
hsa-miR-28-5p 3.1 -2.1 -10.6 
hsa-miR-95 9.1 -2.4 -186 
hsa-miR-31 2.0 -72.7 -51.3 
hsa-miR-15a 2.0 -1.9 -6.9 
hsa-miR-193a-3p 1.0 1.6 -5.4 
hsa-miR-132 14.0 12.0 -2.8 
hsa-miR-125b -29.4 -42.5 -1.9 
CD40L d7 vs EBV d7 
EBV d7 vs LCL 
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 Fold Change 
miRNA CD40L d7 EBV d7 LCL 
hsa-miR-21 2071 2007 2897 
hsa-miR-301 746 391 803 
hsa-miR-18a 223 259 320 
hsa-miR-9 166 59.4 362 
hsa-let-7b 139 46.3 15.8 
hsa-miR-20a 38.1 25.2 37.6 
hsa-miR-210 14.6 24.3 15.2 
hsa-miR-93 52.6 23.9 46.0 
hsa-miR-365 4.9 23.0 61.7 
hsa-miR-155 40.7 18.6 55.7 
hsa-miR-130b 6.8 15.2 22.3 
hsa-miR-20b 8.9 12.5 25.4 
hsa-miR-17-5p 13.3 9.3 8.9 
hsa-miR-92 9.6 7.0 13.2 
hsa-miR-146a 3.1 6.0 15.6 
hsa-miR-22 10.5 4.8 7.1 
hsa-miR-146b 4.6 3.5 4.4 
hsa-miR-19b 3.7 3.2 5.6 
hsa-miR-330 2.2 2.4 3.4 
Table 10: Fold change in expression of 19 miRNAs classified as up-regulated in both CD40L 
d7 blasts and EBV d7 blasts. Fold change was calculated using the ΔΔCt method of analysis 
and was expressed relative to resting B cells. The fold change is the mean fold change in 
expression of duplicate biological replicates from a Taqman miRNA array. Red shading 
represents a ≥ 2 fold increase in expression relative to resting B cells 
 Fold Change 
miRNA CD40L d7 EBV d7 LCL 
hsa-miR-126* -18.1 -150 -191 
hsa-miR-451 -26.7 -131 -29.1 
hsa-miR-126 -12.6 -17.6 -45.1 
hsa-miR-223 -3.6 -9.0 -35.1 
hsa-miR-26a -2.9 -4.5 -10.1 
hsa-miR-26b -2.0 -3.3 -4.3 
hsa-miR-195 -2.2 -2.7 -3.7 
 
Table 11: Fold change in expression of 7 miRNAs classified as down-regulated in both 
CD40L d7 blasts and EBV d7 blasts. Fold change was calculated using the ΔΔCt method of 
analysis and was expressed relative to resting B cells. The Fold change is the mean fold 
change in expression of duplicate biological replicates from a Taqman miRNA array. Blue 
shading represents a ≤ 2fold decrease in expression. 
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values of different miRNAs to be compared directly. Expressing the miRNA array data as the 
ΔCt values alone allows the expression of one miRNA to be directly compared with another. 
To aid the visual interpretation of the data, the mean ΔCt values have been expressed as 12-
mean ∆Ct values. The endogenous control (RNU48) had a Ct value in of approximately 26 in 
every sample. The threshold of detection is set by the manufacturer as Ct38, therefore, the 
lowest detectable miRNA in this system will have a ∆Ct value of 12 (Ct38-Ct26). Expressing 
the miRNA QPCR data as 12-∆Ct allows the lowest detectable miRNA expression to be set at 
0, with an increase in 12-∆Ct corresponding to an increase in miRNA expression; this is 
visually easier to interpret in a graph than the raw ∆Ct values. 
Combining information from relative fold change and ΔCt analyses allows the potential 
functional significance of each miRNA expression change to be estimated. This may be 
important when only limited numbers of miRNAs can be selected for further analysis. Graphs 
which represent the 20 most abundantly expressed miRNAs in each of the four samples are 
shown in figure 4.4. A summary of the ∆Ct analysis is presented in table 12, with the total 
number of miRNAs classified as ‘expressed’ being indicated for each sample. Further to this, 
a relative rank position was assigned to each of the differentially expressed miRNA with 
regard to the total miRNA expression in that sample. For example: the most abundantly 
expressed miRNA in a sample was ranked 1
st
. The mean ΔCt value for each miRNA is also 
included in brackets for comparison. It can be seen from this analysis that the CD40L and 
EBV blasts show very similar miRNA expression profiles in the top 20 abundantly expressed 
miRNAs and these include several oncomiRs such as miR-155, miR-21, miR-92 and miR-
20a. Additionally, several miRNAs show very high expression in all samples, such as miR-
142-3p, which although not significantly altered following EBV infection, may play an 
important role in B cell signalling processes. 
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miRNA 
Expression 
Resting B cells 
114 total miRs 
(12-ΔCt) 
Expression 
CD40L d7 blasts 
131 total miRs 
(12-ΔCt) 
Expression EBV 
d7 blasts. 
122 total miRs 
(12-ΔCt) 
Expression in  
LCL 
121 total miRs 
(12-ΔCt) 
miR-148a 63
rd     
(3.4) 89
th      
(2.9)
 
 39
th    
(6.6) 10
th
   (9.3) 
miR-200b 98
th
    (1.2) 117
th
  (1.4) NE NE 
miR-199a-3p 107
th   
(0.3) NE NE NE 
miR-28-5p 38
th     
(6.2) 33
rd     
(7.8) 58
th    
(5.2) 84
th
   (2.8) 
miR-95 61
st      
(3.9) 41
st      
(7.0) 88
th    
(2.6) NE 
miR-31 82
nd     
(2.1) 86
th      
(3.0) NE NE 
miR-15a 29
th
    (6.9) 34
th
    (7.8) 46
th
   (6.0) 61
st
   (4.7) 
miR-193a-3p 83
rd     
(1.9) 105
th   
(1.9) 87
th    
(2.7) NE 
miR-132 97
th
    (1.1) 61
st
    (4.8) 67
th
   (4.4) NE 
miR-125b 101
rd
  (0.8) NE  NE 121
st
 (0.8) 
 
Table 12: Summary of the ΔCt analysis (figure 4.4) for the 10 differentially regulated 
miRNAs from the Taqman miRNA array fold change analysis. Results are presented as the 
rank expression of each miRNA in either; resting B cells, CD40L blasts, EBV blasts 7 days pi 
and 6 weeks pi (LCL). The 12-ΔCt values for each miRNA are indicated in brackets. The 
total number of miRNAs classified as ‘expressed’ in each sample is listed in the heading 
columns. Any miRNAs with a 12- ΔCt value of ≤ 0 were classified as not expressed (NE). 
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4.2.5 Validation of fold change analysis 
The Taqman miRNA array was only performed in duplicate biological samples. The purpose 
of the array was to identify transformation associated changes in miRNA expression, which 
would be confirmed on a larger set of replicate samples. The expression of all 10  
differentially regulated miRNAs (table 9) was measured by QPCR in 5 biological replicate 
samples using individual miRNA QPCR assays for validation.  
Although it would have been ideal to validate the Taqman miRNA array result using a 
different method from the array, neither solution hybridisation nor northern blot had the 
sensitivity of the QPCR assays, therefore, these alternative methods may not have been able 
to detect the miRNAs which needed to be validated.  
There was an additional complication to the validation of the Taqman miRNA array. The 
array primers were designed based on the current version of the miRBase registry [513, 651].  
After our Taqman miRNA was performed, a new version (v.10) of the miRBase registry was 
released. Unfortunately, this new release re-classified the sequences for many miRNAs on the 
array, including 4 of the 10 differentially regulated miRNAs we intended to validate (miR-31, 
miR-200b, miR-193a-3p and miR-199a-3p). Consequently, the individual Taqman assays 
used to validate 4/10 of the miRNAs from the array were not the same primers used in the 
original array. The significance of these primer changes is unclear and thus, the 
reproducibility of the array data is difficult to infer from these validations.  
The miRNA validation experiments are expressed as 15-∆Ct as the Ct of RNU48 in this 
system was 23 (38-23=15). It is worth noting that the Taqman miRNA array produced slightly 
different Ct values than the individual Taqman miRNA assays used for the validations, 
(presumably due to the multiplex reverse-transcription step and the 1µl QPCR reaction 
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volume) and a ΔCt of 12 corresponded to a Ct value of 38 in the array system. Nevertheless, 
plotting the data as the 15-ΔCt values rather than fold change allowed all 5 biological 
replicate points to be displayed and the reproducibility of the data to be easily evaluated for 
each miRNA.  
The 10 miRNAs which were assayed can be split into two groups according to their 
expressions in the original array: i) the 7 miRNAs which showed differential expressions 
between CD40L and EBV day 7 blasts (miR-148a, -200b, -199a-3p, -28-5p, -95, -31, -15a); 
ii) the 3 miRNAs which showed differential expression between EBV day 7 blasts and the 
LCLs (miR-193a-3p, -132, -125b).  Whether or not a miRNA was validated was therefore 
determined by the significant difference in expression of each miRNA between the relevant 
samples, as determined by the student T test. A P value of ≤0.05 was considered significant.  
Of the 7 miRNAs in group i), 4 miRNAs showed a significant difference in expression 
between CD40L day 7 and EBV day 7 blasts (P value ≤ 0.05), and these were: miR-148a, 
miR-28-5p, miR-31 and miR-95 (figure 4.5, A). Of the remaining 3 miRNAs from this group 
(miR-200b, miR-199a-3p and miR-15a), miR-200b and miR-199a-3p showed a significant 
difference in expression between CD40L blasts and the LCL (P= ≤ 0.05, figure 4.5 B); these 
two miRNAs were classified as differentially expressed between CD40L blasts and the LCL. 
The reasoning for continuing to investigate miR-200b and miR-199a-3p was that the 
expression difference in the EBV blasts 7 days pi may not have been large enough to be 
statistically significant, but it may still be functional significant; especially considering the 
continued down-regulation of these miRNAs in the LCL. Finally, miR-15a did not show a 
significant difference in expression between the CD40L blasts and either EBV time point so 
therefore was not further investigated (figure 4.5 C).  
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Figure 4.5: Taqman miRNA array validations. miRNA expression measured by QPCR in 5 
biological replicate samples: resting B cells from peripheral blood (B cells d0); B cells 
stimulated with CD40L and IL4 for 7 days (CD40L d7); B cells infected with EBV at an m.o.i 
of 100 7 days pi (EBV d7) and 6 weeks pi (LCL). Data is expressed as 15 -∆Ct values (∆Ct 
represented by dCt in Y axis label). A; 4 miRNAs which showed a significant difference in 
expression between CD40L d7 blasts and EBV d7 blasts P=  ≤ 0.05 on the Taqman array. P 
values are calculated using the student T test paired sample analysis between CD40L d7 and 
EBV d7 B cell blasts. Red P values indicate significant differences (P= ≤ 0.05) in expression. 
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Figure 4.5 Taqman miRNA array validations continued. B; the 3 miRNAs which showed a 
significant difference in expression (P= ≤ 0.05) between CD40L blasts and the LCLs. P 
values were calculated using the student T test paired sample analysis. Grey P values indicate 
non-significant differences (P= ≥ 0.05) in expression whereas red P values indicate significant 
differences (P= ≤ 0.05) in expression. 
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Figure 4.5 Taqman miRNA array validations continued. miRNAs differentially expressed 
between EBV d7 blasts and the LCL on the array. C; the 3 miRNAs which did not show a 
significant difference in expression between EBV day 7 blasts and the LCLs, nor CD40L 
blasts and either EBV infected time points. P values were calculated using the student T test 
paired sample analysis between. Grey P values indicate non-significant differences (P= ≥ 
0.05) in expression. 
 
  
Results II 
 
Page 154 
 
miR-125b and miR-132 from group ii), plus miR-15a, did not show any significant difference 
in expression between the EBV day 7 blasts and the LCL (figure 4.5, C). However, miR-
193a-3p did show a significant difference in expression between both EBV blast and CD40L 
blasts and the LCL and was therefore re-classified as a miRNA differentially expressed 
between CD40L day 7 blasts and the LCL (figure 4.4, B) for further study. 
Collectively this data resulted in the successful validation of 7/10 miRNAs. Additionally, 
whilst miR-193a-3p did not validate the expression difference between EBV day 7 blasts and 
LCLs seen on the array, it did however, produce a significant difference in expression 
between CD40L blasts and LCLs. The change in miR-193a-3p classification may be due to 
the miRBase sequence modification and subsequent QPCR primer change, or it may simply 
reflect the reproducibility of the array. No statistical differences were observed for miR-125b, 
miR-132 and miR-15a, and these 3 miRNAs were consequently excluded from further 
analysis, as we could not demonstrate differential expression of these miRNAs upon 
validation. 
4.3 Characterising the expression of differentially regulated miRNAs 
4.3.1 miRNA expression in Mutu-BL 
The 7 miRNAs which were differentially regulated between B cells stimulated with CD40L 
and IL4 and B cells infected with EBV (P value ≤ 0.01, figure 4.5 A and B) may be regulated 
by EBV latent gene expression during primary infection. To examine the possible regulation 
of these miRNAs by EBV latent gene expression we used QPCR to measure the miRNA 
expression in a panel of Mutu-BL clones. The EBV latent gene expression of the Mutu-BL 
clones was confirmed by western blot in section 3.3.1, figure 3.3.A. The miRNA expression 
data is expressed relative to the EBV loss clone. The most striking correlation between 
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miRNA expression and latency was seen with miR-95, miR-199a-3p and miR-28-5p (figure 
4.6). 
miR-95 and miR-199a-3p expression was lower in latency I Mutu-BL compared with EBV 
loss Mutu-BL and was down-regulated even further to un-detectable levels in the latency III 
clones, indicating that these two miRNAs are down-regulated by latency I gene expression, 
which appears to be further enhanced by a latency III pattern of EBV gene expression. miR-
28-5p was specifically down-regulated in latency III Mutu-BL clones, a trend which has since 
been observed in a range of latency I and latency II BL cell lines [652].  
The remaining 4 miRNAs did not show a convincing correlation with EBV latent gene 
expression in the Mutu-BL cell lines, however, it worth noting that this was a small selection 
of Mutu-BL clones and had a larger panel of Mutu-BL clones or additional latency I and 
latency III BL cell lines been analysed, trends may have been observed. miR-148a showed a 
slight increase in latency III Mutu-BL, but this was more pronounced in clone 95 (c95), and 
therefore may not be a characteristic of all latency III clones. miR-193a-3p showed variable 
expression over the clones and miR-200b and miR-31 showed consistent expression in all 
four Mutu-BL clones, however, this expression was lower than the expression of either 
miRNA in an LCL and was approaching the threshold for detectable expression (ΔCt ≥ 12 in 
all samples); thus, is unlikely to be significant. 
 
4.4 miRNA expression in HL analysis 
We have identified a subset of miRNAs which may be involved in the transformation of 
resting B cells by EBV. The transforming capacities of EBV are intrinsically linked to its role  
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Figure 4.6: Relative QPCR expression data for 7 miRNAs in a panel of Mutu-BL clones 
expressing a range of EBV latent gene expression: EBV loss clone, a latency I clone (I), and 
two latency III clones (III cj8 and III c95). An LCL was included for comparison and data is 
expressed relative to the EBV loss Mutu clone. Error bars represent the range in fold change 
from the standard deviation of the ∆∆Ct values 
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in lymphomagenesis so it is reasonable to hypothesise that miRNAs involved in B cell 
transformation may also be involved in EBV-mediated tumourogenesis.  
Navarro et al [653] used QPCR to profile the expression of 157 miRNAs in the lymph nodes 
from 49 classic Hodgkin lymphoma patients (cHL) and 10 reactive lymph nodes (RLNs). 
16/49 of the cHL tumours were EBV positive as determined by in situ hybridisation for 
EBER1 and EBER2 and QPCR for EBV BamH1 W. The paper [653] aimed to identify 
miRNA expression signatures associated with cHL, and any miRNAs whose expression also 
correlated with EBV status. The miRNA expression data could be used for comparison with 
our Taqman miRNA array expression data as a means of identifying miRNAs associated with 
EBV-mediated B cell transformation and cHL tumourogenesis.  
4.4.1 Identification of EBV regulated miRNAs involved in the development of HL 
Our miRNA expression data from the 365 miRNAs profiled in resting B cells, CD40L blasts 
and EBV blasts (section 4.2.2) was compared with the expression data of 157 miRNAs in 
cHL and RLNs [653]. These comparisons revealed that 2/7 of our validated differentially 
regulated miRNAs were decreased in cHL relative to RLNs: miR-28-5p and miR-95. 
4.4.2 miR-34a  
The HL comparison identified miR-34a as significantly increased in cHL compared with 
RLNs. This miRNA was inconsistently expressed on our original Taqman miRNA array 
(section 4.2.2), hence its expression in EBV blasts and CD40L blasts was still unknown. We 
therefore decided to determine whether or not miR34a was differentially expressed between 
EBV and CD40L blasts, due to its differential regulation in cHL compared with RLNs. A 
miR-34a Taqman QPCR assay was used to confirm miR-34a expression in 5 biological 
replicates of resting B cells infected with EBV (day 7 and LCL) or stimulated with CD40L  
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Figure 4.7 miR-34a array validation by QPCR and miR-34a expression in BL and HL cell 
lines. A; 5 biological replicates of resting B cells (B cells d0), B cells stimulated with CD40L 
7 days post-stimulation, B cells infected with EBV 7 days pi (EBV d7) and 6 weeks pi (LCL). 
P values represent the results of a paired student T test comparing CD40L blasts and EBV d7 
blasts. Data is expressed as 15-ΔCt. B; a panel of Mutu-BL clones expressing different forms 
of viral latency (EBV loss, latency I and two latency III clones cj8, c95) and a EBV negative 
HL cell line, KMH2. Data is expressed relative to an LCL. Error bars represent the range in 
fold change from the standard deviation of the ∆∆Ct values. 
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and IL4 (figure 4.7) The data clearly show that miR-34a was up-regulated by CD40L 
stimulation as well as EBV infection, thus it was not an additional differentially regulated 
miRNA. Furthermore, we confirmed the high expression of miR-34a in HL by performing 
QPCR on the HL cell line KMH2, a small selection of Mutu-BL cell lines and an LCL for 
comparison.  
Interestingly, miR-34a was expressed at very low levels in the Mutu-BL lines regardless of 
EBV status or latent gene expression but was very highly expressed in the HL line KMH2, 
further supporting the evidence that this miRNA is highly expressed in HL (figure 4.7);  
miR-34a was therefore used as a positive control in the following HL cell line miRNA 
expression analysis.  
4.4.3 miRNA expression in HL cell lines 
To investigate the low expression of miR-28-5p and miR-95 in HL we used QPCR to measure 
the expression of both of these miRNAs in a panel of HL cell lines relative to resting B cells. 
The majority of the HL cell lines were EBV negative with the following two exceptions: 
L591 is an EBV positive HL cell line and expresses a latency III pattern of EBV gene 
expression and KMH2-EBV expresses a restricted pattern of latency II gene expression, with 
just EBNA1 and LMP2A expression [654]. Due to the difficulty in isolating the relatively few 
HRS tumour cells from a HL biopsy, there are only very few HL cell lines available and there 
are no HL cell lines which represent the latency II biopsy phenotype of EBV positive HL 
tumours. The HL cell lines may therefore not be representative of the EBV positive HL subset 
and the small number of cell lines available means that it is not wise to draw firm conclusions 
from miRNA expression data from such a limited panel of HL cell lines. Of the 7 miRNAs 
validated as differentially expressed between EBV and CD40L blasts, two (miR-199a-3p and  
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Figure 4.8 QPCR data showing the relative expression of 5 miRNAs in a panel of HL cell 
lines. Peripheral blood B cells and an LCL are included for comparison and the data is 
expressed relative to resting B cells. Error bars represent the range in fold change from the 
standard deviation of the ∆∆Ct values 
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miR-193-3p) were not included in the published miRNA expression profiling of lymph nodes 
from cHL patients [653], therefore, we included miR-199a-3p and miR-193a-3p in our HL 
cell line miRNA expression profiling. 
The miRNA expression in the panel of HL cell lines is expressed relative to resting B cells 
(figure 4.8). miR-34a was used as a positive control and showed high expression in all of the 
HL lines, with the exception of L1236; which may therefore have unusual miRNA expression 
for a HL cell line. miR-95 showed consistently lower expression in the HL cell lines than in 
resting B cells with only HDLM2 having a relative expression of greater than 0.1. The 
expression of miR-28-5p was variable across the cell lines with no obvious trend of down-
regulation in the HL cell lines relative to resting B cells. All of the HL lines with the  
exception of L1236 showed relative miR-28-5p expression of ≥ 0.5. miR-199a-3p and miR-
193a-3p both showed the same pattern of expression across the HL lines, with only the two 
KMH2 clones showing increased expression of these miRNAs relative to resting B cells and 
the remaining HL cell lines all showed decreased relative expression. miR-199a-3p showed  
very low relative expression in the HL lines, ranging from 0.008-0.08, which suggests that 
this miRNA may be down-regulated in HL relative to B cells. Conversely, miR-193a-3p 
showed variable expression in the HL cell lines, with relative expression ranging from 0.3-
0.75, suggesting that it may not be down-regulate in HL relative to B cells. 
In conclusion, miR-95 is a miRNA specifically down-regulated by EBV infection and not 
CD40L stimulation of B cells. We can confirm the reported low expression of miR-95 in 
cHL, suggesting that loss of expression of this miRNA may contribute to EBV-mediated 
transformation of B cells and the pathogenesis of cHL. However, we could not confirm the 
low expression of miR-28-5p in cHL using HL cell lines. The expression of miR-199a-3p and 
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miR-193a-3p was variable, nevertheless, the expression of miR-199a-3p showed that this 
miRNA is almost undetectable in HL cell lines and may therefore also be down-regulated in 
HL cell lines relative to B cells.  
 
4.5 Identifying a miRNA for functional analysis 
The aims of this chapter were to firstly identify miRNAs potentially involved in EBV-
mediated transformation and then to determine what role, if any, these miRNAs play in EBV-
mediated transformation of B cells and tumourogenesis. So far, we had identified a subset of 
7 miRNAs differentially expressed during B cell transformation compared with mitogen 
activated B cells. Of these miRNAs, 4/7 (miR-148a, miR-95, miR-28-5p and miR-31, (figure 
4.5 A)) showed a significant difference in expression at the early day 7 time points and 
represented the best candidates for functional analysis.  
We selected miR-148a for functional analysis because this miRNA was the only miRNA to be 
up-regulated by EBV infection and not CD40L stimulation of resting B cells. miR-148a was 
also up-regulated to the 10
th
 most abundantly expressed miRNA in an LCL, strongly 
suggesting a function role for this miRNA in LCLs. miRNAs often have fine tuning roles in 
gene expression, making target gene validation at the protein level difficult to confirm. By 
selecting a miRNA with very high expression in an LCL we hoped to increase the probability 
of identifying target genes which would show detectable changes in protein expression 
following inhibition of the very high, endogenous expression of miR-148a in LCLs.  
4.5.1 Further characterising miR-148a expression  
It was important to characterise the expression of miR-148a prior to functional investigation 
as information regarding the expression of this miRNA could aid in the identification of 
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functionally relevant target genes for validation. There was little information regarding the 
expression or function of miR-148a in the literature and what information was available was 
mainly in epithelial cells and not obviously relevant to B cells or EBV-mediated B cell 
transformation. High miR-148a expression had been demonstrated in human livers where 
miR-148a was found to repress the transcription factor PXR [655], and the down-regulation 
of miR-148a by DNA methylation had also been linked to cancer metastasis [656]. 
Interestingly, miR-148a had been shown to down-regulate DNMT3b in HeLa cells through a 
binding site in the coding region of the gene rather than the 3’UTR. This form of repression is 
not specific to miR-148a and evidence is accumulating which suggests that miRNAs can also 
mediate translation repression through binding to the 5’UTR and the coding regions of target 
genes [477, 657, 658]; contributing to the complexity of miRNA target identification. 
Additionally, it has been shown that miR-148a and miR-21 are up-regulated in the CD4
+
 T 
cells of lupus patients, where the two miRNAs cooperate to cause the down-regulation of 
DNMT1 protein expression, and consequently increase hypomethylation of the T cells [659].   
From our previous data, we observed an up-regulation of miR-148a by EBV infection of 
resting B cells resulted in an approximately 10 fold increase in miR-148a expression by 7 
days p.i which was further increased by week 6 (LCL) to an approximately 60 fold increase. 
To determine when miR-148a was up-regulated following EBV infection, a more extensive 
time course assay was performed with B cells harvested 2,3,4,5,6 and 14 days p.i. miR-148a 
was not up-regulated until approximately 4 days p.i (figure 4.9). The delay in miR-148a up-
regulation suggested a possible role for the EBV latent genes whose expression is also 
delayed p,i, such as LMP1 or LMP2, in the up-regulation of this miRNA. 
The expression of miR-148a in the EBV negative Mutu-BL cell line was only 8 fold less than 
the miR-148a expression in an LCL. Therefore, Mutu-BL expressed considerably more miR-  
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Figure 4.9 miR-148a expression by QPCR in a range of cell lines and tonsillar cells. A; Fold 
change in miR-148a expression relative to resting B cells (d0) post EBV infection or CD40L 
and IL4 stimulation at corresponding days (d) p.i. B; miR-148a expression in tonsillar B cells 
sorted with CD19
+
 dynabeads or by FACS for the two GC B cell subsets centrocytes and 
centroblasts and the remaining GC B cells depleted cells. An LCL and peripheral blood B 
cells (B cells) were included for comparison. Data is expressed relative to the LCL. Error bars 
represent the range in fold change from the standard deviation of the ∆∆Ct values. C; 
Comparison of miR-148a expression in different B cell subsets and cell lines including: three 
EBV negative BL cell lines Mutu, Awia and DG75; One HL cell line HDLM2; Two GCBC 
subsets, centrocytes and centroblasts. Data is expressed as15-ΔCt (15-dCt). 
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148a than resting B cells where miR-148a expression was approximately 40-60 fold less than 
an LCL (summarised in figure 4.9 C). Since BL tumour lines have a germinal centre 
phenotype we wanted to know what the expression of miR-148a was in germinal centre B 
cells compared with resting B cells. QPCR for miR-148a in the centrocytes, centroblasts and 
CD19
+
 B cells from a tonsil revealed that miR-148a expression was high in both the GCBC-
subsets, with the expression in the centroblasts being greater than that in an LCL (figure 4.9). 
The high expression of miR-148a observed in GC B cell subsets led us to analyse a panel of 
BL latency I cell lines and a panel of HL lines to determine whether this high expression was 
characteristic of all cells with a GC B cell phenotype. The results in figure 4.10 show that 
miR-148a expression varies across the cell lines with the majority of the cell lines showing  
less than 10% of the miR-148a expression seen in an LCL. This suggests that the high miR-
148a expression seen in Mutu-BL clones may not be characteristic of all BL and HL cell lines 
with a GC B cell phenotype, although analysis of miR-148a expression in a wider panel of BL 
cell lines would be required to confirm this. 
NK/T cell lymphoma is another EBV associated lymphoid malignancy, so to fully 
characterise the association of miR-148a with EBV transformation and tumourogenesis we 
analysed a panel of EBV positive (SNK6, SNK10 and SNK16) NK cell lines and an EBV  
negative NK cell line (NKL) in comparison with an LCL. Primary NK cells isolated by 
negative selection from peripheral blood were also included for comparison. The results 
presented in figure 4.10 show that the expression of miR-148a in primary NK cells was very 
low and similar to the expression of miR-148a in resting B cells. miR-148a was almost 
undetectable in all of the NK cell lines indicating that the up-regulation of this miRNA is not 
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involved in the NK lymphoma and EBV latent gene expression does not up-regulate miR-
148a in an NK cell background.  
miRNA expression is very stable in paraffin embedded tissue [551] hence the RNA extracted 
from paraffin embedded tumour samples can be used to assess miRNA expression. An LCL is 
phenotypically very similar to PTLD tumour cells which also usually express a latency III 
pattern of EBV gene expression. RNA from two PTLD, two HL and one non-Hodgkin 
lymphoma (NHL) paraffin embedded tumour biopsies was extracted and used for QPCR 
measurement of miR-148a expression. All of the tumour biopsies showed detectable miR-
148a expression with a range of 10-30% of the expression seen in an LCL.  
4.6 miR-148a primary target gene prediction 
The function of miR-148a, like most miRNAs, is still unknown. There are a few validated 
gene targets for miR-148a in the literature, including: DNMT3b [478], DNMT1[659], HLA-
G[660], TGIF2 [656] and Pregnane X receptor (PXR) [655]. However, the role of miR-148a 
during the transformation of resting B cells by EBV or its role in GC B cells remains 
unknown. To address this question we sought to identify primary miR-148a targets predicted 
by miRNA target prediction programs. These targets could then be validated using miR-148a 
inhibitors in an LCL to determine whether or not the predicted genes are repressed by the high 
expression of miR-148a in an LCL.  
4.6.1 Primary target identification using miRNA target prediction programs 
The binding of a miRNA to a target mRNA is a complicated process which is still not fully 
understood. Computer programs designed to predict miRNA targets can only produce a list of   
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Figure 4.10 QPCR expression data for miR-148a in panels of cell lines and formalin fixed 
tissue samples. Data is expressed relative to resting B cells. A; miR-148a expression in a 
panel of latency I BL cell lines. B; miR-148a expression in a panel of EBV negative HL cell 
lines with the exception of L591 which expresses a latency III pattern of EBV gene 
expression and KMH2-EBV which expresses EBNA1 and LMP2A C; miR-148a expression 
in a panel of NK tumour lines. Primary NK cells isolated from peripheral blood are included 
for comparison. NKL is an EBV negative NK cell line and SNK6, SNK10 and SNT16 are all 
EBV positive and express a latency II pattern of EBV gene expression. Error bars represent 
the range in fold change from the standard deviation of the ∆∆Ct values. 
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best estimate targets based on the most current and limited knowledge. Each miRNA target 
prediction program uses differing parameters and places more or less emphasis on certain 
parameters than others. Consequently, each miRNA target prediction program produces a 
different list of predicted miRNA targets with a presumably high rate of false positives and 
negatives. Theoretically, combining the data from multiple miRNA target prediction 
programs will enable the identification of miRNA target genes with the highest probability of 
being valid. 
Three miRNA target prediction programs with a database of miRNAs and their corresponding 
predicted gene targets available for download were: miRanda [661], Target Scan [492, 502] 
and microT [662]. The predicted gene targets for miR-148a were downloaded from these 
programs and entered into a Microsoft Access database for comparison. 
The degree of overlap between the three miRNA target prediction programs is represented in 
figure 4.11. There were 183 genes predicted by all three programs and these are listed in table 
13. 
4.6.2 Identifying the most probable primary targets 
To identify predicted miR-148a targets for validation we further reduced the number of 
predicted miR-148a targets to focus on just those with the highest miR-148a binding scores in 
each program. The three miR-148a target gene databases were sorted based on the individual 
scoring system of that database. A comparison was then performed between the genes with 
the top 10% highest score values from each database (i.e. the best predicted matches) and 2  
genes were identified as common to all three databases. A comparison was also performed 
between the top 20% of genes with the highest scores to generate a list of 12 common genes. 
(figure 4.12 and table 14).  
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Figure 4.11: Venn diagram representing the predicted miR-148a target genes from three 
independent miRNA target prediction programs and the overlap between them. 
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Gene Name Score 
ESRRG 13.51 
GPATCH8 13.51 
DEDD 13.51 
TOMM70A 13.51 
TANC1 13.51 
CCDC6 13.51 
MNT 13.51 
PNPLA6 13.51 
JARID2 13.51 
SRPK2 13.51 
MRAS 13.5 
DYRK1A 13.42 
CXorf23 13.27 
ROCK1 13.21 
SMAD2 13.17 
MTMR9 12.73 
DDAH1 12.72 
DLG2 12.72 
PIGA 12.32 
WNT1 12.32 
ZADH2 12.32 
SNF1LK 12.11 
ERBB3 12.11 
ALS2CR2 12.11 
FBXL19 12.11 
RAB34 12.11 
GTF2H1 12.11 
SLC2A1 12.11 
PIK3R3 12.11 
STARD13 12.11 
DNAJB12 12.11 
DMXL1 12.11 
TMEM9B 12.11 
SESTD1 12.11 
ASPH 12.11 
NRAS 12.11 
WDR20 12.11 
ROBO1 11.44 
PDE4D 11.43 
 
Table 13: List of 183 genes predicted to be miR-148a targets by three target prediction 
programs: miRanda, Target Scan and microT. Score values form the miRanda program are 
included for comparison.  
  
Gene Name Score 
 DCP2 26.96 
USP6 26.11 
MEOX2 25.63 
BCL2L11 24.63 
C18orf25 23.93 
B4GALT5 23.04 
OSBPL11 22.84 
RBM24 22.09 
INOC1 22.02 
CPEB4 21.58 
CDC2L6 21.41 
MTF1 21.27 
TNRC6A 21.07 
MAFB 20.91 
ATP11A 20.65 
MLL 20.63 
LEPROTL1 20.04 
EIF2C1 19.97 
C1orf144 19.33 
USP32 19.1 
NRP1 19.1 
NPTX1 19.08 
OTX2 18.79 
CAND1 18.7 
LASS6 18.51 
SH3PXD2A 18.18 
BCL11A 17.84 
MAF 17.7 
ARFIP1 17.7 
INHBB 17.7 
SMS 17.7 
FMR1 17.7 
MITF 17.6 
MXD1 17.29 
EIF2C4 16.95 
ELF5 16.95 
MIER1 16.88 
FXR1 16.3 
BTBD3 16.3 
Gene Name Score 
MAP3K9 16.3 
HOXC8 16.3 
BACH2 16.3 
NHS 16.3 
CNTN4 16.3 
MMD 16.3 
OTUD4 16.3 
YWHAB 16.3 
COL2A1 16.3 
ADAMTS5 16.09 
CDK5R1 15.69 
CCKBR 15.65 
ZDHHC17 15.51 
ITGA5 15.11 
WDR47 15.11 
C5orf30 15.11 
ATP6AP2 15.07 
LRP2 14.91 
MLLT10 14.91 
USP48 14.91 
ELAVL2 14.91 
QKI 14.91 
ERRFI1 14.91 
ATXN1 14.91 
CANX 14.91 
BAI3 14.91 
MED12L 14.91 
ATXN7L1 14.91 
NCAM1 14.91 
BRPF1 14.91 
CUL5 14.91 
PPP1CB 14.91 
DNMT1 14.91 
TGIF2 14.22 
SNN 14.16 
NFAT5 13.63 
SYNJ1 13.52 
SFRS11 13.51 
ARHGEF12 13.51 
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Gene Name Score 
USP33 8.78 
BAZ2A 8.78 
WASL 8.78 
PLAA 8.78 
LYSMD3 8.74 
SGCB 8.74 
PHF20 8.72 
CSF1 8.57 
KIAA1045 8.53 
MAP3K4 8.44 
MGAT4A 8.34 
PRNP 8.13 
ITGB8 7.94 
ANKRD13A 7.93 
NFIX 7.93 
C1GALT1 7.93 
KLHL18 7.93 
TEK 7.93 
TMEM54 7.93 
LRRC41 7.93 
SPIRE1 7.93 
LIN28B 7.93 
ST18 7.86 
TEAD1 7.72 
EPS15 7.45 
PRICKLE2 7.45 
SNX27 7.45 
 
 
 
 
 
 
Table 13: Continued. 
  
Gene Name Score 
MYST2 11.36 
ACVR2B 11.34 
PITPNM2 11.32 
ARRDC3 10.99 
EPAS1 10.78 
MTA2 10.72 
HMGB3 10.72 
YTHDC2 10.72 
CDC14A 10.72 
DYRK1B 10.72 
PRKAG2 10.72 
HECW2 10.72 
EIF4E3 10.72 
ARL6IP1 10.72 
COL4A1 10.72 
GADD45A 10.72 
FBXO28 10.55 
ZCCHC2 10.2 
MARCH3 9.97 
XPO4 9.86 
RAB14 9.66 
SIX4 9.66 
DENND4C 9.66 
POU3F2 9.66 
LYSMD2 9.32 
ABCD3 9.32 
DMPK 9.32 
SAPS1 9.32 
CDK6 9.32 
PPP1R9B 9.32 
RIPK5 9.32 
RCC2 9.32 
MTMR14 9.32 
GAPVD1 9.32 
ARF4 9.32 
NDP 9.32 
AP4E1 9.27 
SLC24A3 9.22 
CAMK2A 8.83 
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A: Top 10% analysis:        B: Top 20% analysis: 
 
 
 
 
Figure 4.12: Venn diagrams representing the results of a comparison between A; the top 10% 
and B; the top 20% of genes with the highest score values predicted to be targeted by miR-
148a by three independent target prediction programs 
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Gene Name Aka Function 
LEPROT1 
leptin receptor overlapping 
 Putative protein. Little is known 
BCL2L11 
 
Bim Pro-apoptotic member of the BCL2 family of proteins. 
USP6 
Ubiquitin specific peptidase 
6 
HRP1, 
TRE2 
TRE17 
Oncogene. Isopeptidase whose expression in normal 
tissue is testis specific but is expressed in a number of 
cancer cell lines. Initiates tumourogenesis by inducing 
the production of matrix metalloproteinases [663, 664] 
OSBPL11 
Oxyterol binding protein 
 Little is known. Widely expressed. 
MAFB 
Transcription factor MAFB 
KRML Acts as a transcriptional activator or repressor and is 
involved in erythroid differentiation [665]. Can act as a 
tumour suppressor gene [666]. 
MLL 
Myeloid lineage leukemia 
ALL1, 
HRX 
Histone methyltransferase that plays an essential role in 
early development and hematopoiesis. Chromosomal 
aberrations involving MLL are a cause of acute 
leukemias [667, 668]. 
EIF2C1 
Eukaryotic translation 
initiation factor 2C1 
AGO1 Required for RNAi and gene transcription silencing 
[669, 670]. 
USP32 
Ubiquitin specific protein 32 
 Little is known. Related to USP6 
FMR1 
Fragile X mental retardation 
1 
 RNA binding protein involved in intracellular RNA 
transport and the regulation of translation. Highly 
expressed in several cell types including lymphocytes 
[671, 672]. 
EIF2C4 
Eukaryotic translation 
inititation factor 4 
AGO4 Required for RNAi. Also required for the replication of 
the human hepatocyte delta virus.  
NHS 
Nance Horan Syndrome 
` Unknown. May be involved in eye, tooth and brain 
development 
CNTN4 
Contactin 4 
BIG-2 Mediates cell surface interactions during nervous 
system development 
 
Table 14: Genes with the top 20% (top 10%) score values from three miRNA target 
prediction programs (miRanda, Target Scan and MicroT) were compared and those predicted 
by all three programs are listed with a brief description of known function. 
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4.7 Validation of predicted miR-148a primary targets  
As discussed in section 4.6.1, one of the caveats of using miRNA target prediction programs 
is their lack of specificity. Furthermore, these programs cannot identify target genes relevant 
to the cell background or condition of interest. 3’UTR reporter assays could verify the 
existence of a miR-148a binding site in the 3’UTR of the predicted target genes. However, the 
regulation of these genes in an LCL would still need to be validated. For this reason, we 
decided to validate the repression of predicted miR-148a target genes at the protein level 
following inhibition of miR-148a in an LCL. This would quickly identify whether the protein 
expression of the gene of interest was repressed in an LCL by the endogenous level of miR-
148a expression.   
4.7.1 Creating a miR-148a responsive luciferase reporter 
To validate the efficacy of commercially available miR-148a inhibitors in an LCL, we created 
a luciferase reporter containing a miR-148a binding site with 100% complimentarity to miR 
148a inserted into the 3’UTR of the luciferase gene. miR-148a repression of luciferase could 
then be measured in an LCL in the presence or absence of miR-148a inhibitors 36 hours after 
co-transfection. Luciferase expression was normalised to β-galactosidase (β-gal) expression 
after an equal amount of both luciferase and β gal plasmids were co-transfected into each 
sample.  
An oligonucleotide with 100% complimentary to miR-148a was designed using miRBase 
(version 14) for the miR-148a sequence and synthesised with Spe1 and HindIII sticky ends for 
ligation into the pmiR-Report vector. Full details and sequences are described in section 2.20 
and simplified diagrams of the luciferase and luciferase-148a vectors are shown in figure 
4.13.  
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4.7.2 Validation of miR-148a inhibitors using a miR-148a- luciferase reporter 
miRNA inhibitors are small RNAs with a complimentary sequence to the target miRNA. 
They inhibit the function of the target miRNA by binding to it and preventing the miRNA 
from binding to mRNA target genes, thereby inhibiting the function of the miRNA. These 
inhibitors are O-methylated to prevent degradation by the cell and are stable for 48 hours 
[456].  
Commercially available miR-148a inhibitors were transiently transfected into an LCL and the 
cells were harvested for RNA extraction 36 hours post-transfection. The transfection 
efficiency of the miR-148a inhibitor could not be measured directly although it could be 
estimated by the efficiency of transfection of a fluorescently labelled oligonucleotide (siGLo). 
The transfection efficiency of siGLo as determined by flow cytometry (figure 4.14) was 
consistently between 95-98%, indicating that the transfection efficiency of the LCL with a 
small RNA was very good.  
The luciferase expression of the luciferase-148a reporter was approximately 60% of that seen 
in the control luciferase reporter (figure 4.14). The luciferase expression in luciferase-148a 
could be restored to the same levels as the control reporter after 2μM of a miR-148a inhibitor 
was transfected. The transfection of a control (scrambled) miRNA inhibitor had no effect on 
the luciferase expression from the luciferase-148a reporter in an LCL, indicating that the miR-
148a inhibitor was efficiently inhibiting the function of miR-148a.  
4.7.3 DNMT1 protein expression following miR-148a inhibition  
DNMT1 is a published gene target of miR-148a and its expression was shown to be down-
regulated by ectopic miR-148a expression in Jurkat cells [659], primary CD4
+
 T cells [659]  
and cholangiocytes [673]. To determine whether DNMT1 was regulated by miR-148a in an 
LCL, a western blot for DNMT1 protein expression was performed 36 hours post-transfection  
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Figure 4.13: Simplified maps of the pmiR-REPORT vectors created to validate the efficacy 
of miR-148a inhibitors. A; the non-modified luciferase reporter which was used as a negative 
control in transfection experiments. B; The luciferase vector with a miR-148a binding site 
with 100% complimentarity to miR-148a inserted into the 3’UTR of the luciferase gene 
(luciferase-148a). This binding site made the luciferase susceptible to miR-148a mediated 
mRNA degradation/translational inhibition, reducing the luciferase expression from the 
plasmid in the presence of functional miR-148a. 
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Figure 4.14 A; Luciferase reporter assays demonstrating the efficacy of miR-148a inhibitors. 
Flow cytometry data showing transfection efficiency of a small fluorescence labelled oligo 
(siGLo) measured 24 hours post transfection into an LCL via electroporation. Grey, filled 
histogram represents a no-RNA transfected LCL control. B; relative luciferase expression in 
an LCL transfected with either a luciferase reporter (luciferase CTR) or a luciferase reporter 
containing a miR-148a binding site in the 3’UTR of the luciferase gene (luciferase-148a). The 
luciferase CTR or Lucifease-148a plasmids were co-transfected with a β-gal plasmid, which 
was used for normalisation and 0nM or 2nM of a commercially available miR-148a inhibitors 
(anti-miR-148a) or scrambled inhibitors (scrambled). Cells were harvested 24 hours post-
transfection and luciferase and β-gal expression measured using a lunomitor. Data is 
expressed relative to the Luciferase CTR sample transfected with 0nM of miR-148a or control 
inhibitors. Error bars represent the standard deviation of triplicate assays.  
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with 2µM of a miR-148a inhibitor. The protein expression of DNMT1 and calregulin were 
measured by western blot in triplicate biological replicate samples of an LCL 36 hours post 
transfection of a control scrambled RNA or miR-148a inhibitor. However, the results in figure 
4.15 show that there was no change in DNMT1 protein expression in any of the samples, 
indicating that miR-148a inhibition in an LCL does not affect DNMT1 protein expression.  
4.7.4 Bim protein expression following miR-148a inhibition 
Bim (BCL2LII) is a pro-apoptotic member of the BCL2 family of proteins and is known to be 
down-regulated by EBV during B cell transformation [136]. Every form of analysis 
performed on the miR-148a target prediction data produced Bim as a candidate miR-148a 
target. For this reason, we decided to transfect commercially available miR-148a inhibitors 
into LCLs (Bim negative) to measure the Bim protein expression by western blot.  
2µM of miR-148a inhibitors were transfected via electroporation into an LCL and the Bim 
protein detected by western blotting. DG75 was included in the blot as a positive control  for 
Bim expression as it has high expression of Bim due to a mutation in the Bax gene [674], 
which allows the tolerance of high Bim expression. The results show that miR-148a inhibition 
in an LCL does not result in any detectable increase in Bim expression (figure 4.15) which 
was not unexpected because Bim is transcriptionally and epigenetically silenced in an LCL 
[136, 675]. Therefore, translational repression by a miRNA was unlikely to be a significant 
factor in Bim expression in an LCL. However, the repression of Bim protein by miR-148a 
may still be important in the early stages of B cell transformation, before Bim expression has 
been repressed transcriptionally and epigenetically.  
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4.7.5 miR-148a over-expression in DG75-BL 
DG75-BL has high expression of Bim, therefore the effect of miR-148a over-expression on 
Bim protein expression can easily be measured by western blot in this cell line. To over-
express miR-148a in DG75 we used commercially available miR-148a mimics. These mimics 
are the pre-miR-148a precursors, which are processed by Dicer-1 in the cytoplasm of the cell 
and incorporated into the RISC complex as a functional miR-148a.  
2µM of commercially available miR-148a mimics were transfected into DG75 via 
electroporation and the protein was harvested 36 hours post transfection for western blot. Bim 
and DNMT1 protein expression was measured by western blot. DNMT1 was included out of 
interest as a published miR-148a target gene. Bim and DNMT1 protein was consistently 
expressed across the control mimic and miR-148a mimic transfected samples. This again 
shows no effect of miR-148a on DNMT1 protein expression in a B cell background and also 
suggests that increased miR-148a expression did not affect the high Bim expression in DG75-
BL. The lack of Bim protein repression seen after miR-148a transfection could be due to the 
relatively high endogenous expression of miR-148a in DG75 (figure 4.15). Alternatively, 
miR-148a may not be a significant regulatory factor for Bim expression in an established 
LCL. 
4.8 Multiple miRNA gene target analysis 
miRNA mediated gene repression is known to be more effective when there are multiple 
miRNA binding sites, preferably in close proximity [441]. These miRNA binding sites can be 
for the same miRNA or for different miRNAs. It is thought that the enhanced repression 
caused by multiple miRNA binding sites allows a gene to have high sensitivity to a particular 
miRNA only in certain environments or tissues where other specific miRNAs are also 
expressed. It is this cooperative repression which raised two questions: (i) are any of the   
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Figure 4.15: Western blot for Bim and DNMT1 following miR-148a inhibition or ectopic miR-
148a expression. Samples were collected in biological triplicate. A; DNMT1 and calregulin 
protein expression by western blot in triplicate replicates of an LCL transfected by electroporation 
with; no RNA, 2µM control inhibitor (CTR inhibitor) or 2µM of a miR-148a inhibitor (anti-miR-
148a).  B; 2µM of miR-148a inhibitor (anti-148a) or control inhibitors (anti-CTR) were 
transfected into an LCL via electroporation and protein harvested 36 hours post transfection. 
DG75 was included as a Bim positive control. C; 2μM of pre-miR-148a (pre-148a) or control pre-
miRNAs (pre-CTR) were transfected into DG75 via electroporation and protein was harvested 36 
hours post-transfection. D; B cells, B cells stimulated with CD40L (CD40) or infected with EBV 
at 7 days p.i (EBV) or 6 weeks p.i (LCL) were probed from Bim and calregulin.  
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miRNAs identified as up-regulated by EBV and CD40L in the Taqman miRNA array also 
predicted to target any of the 183 miR-148a target genes listed in table 13? And (ii) could the 
lack of Bim protein repression observed following miR-148a over-expression in DG75-BL be 
due to the need for multiple miRNA repression? 
From the Taqman miRNA array data, there were 19 miRNAs up-regulated by EBV and 
CD40L (table 10) which was a very large data set to compare. Not all of these miRNAs had 
predicted target genes in all three target prediction programs, so to simplify the data analysis, 
all of the data comparisons were performed using the data from just one miRNA target 
prediction program, Target Scan. Target scan had predictions for all 19 up-regulated miRNAs 
and was arguably the most accurate miRNA target prediction program available [491]. 
The predicted target genes for the 19 up-regulated miRNAs were compared with each other to 
identify genes targeted by all/some of them. In order to achieve this, a computer program was 
specially written to cross analyse the data sets. The primary function of the program was to 
iterate through each of the predicted target genes from each of the 19 miRNAs to identify 
commanality of the genes regarding the predicted miRNA regulation. The results from the 7 
differentially regulated miRNAs and the 6 down-regulated miRNAs are included for 
comparison (tables 15-17)To generate a list of the predicted miR-148a target genes which 
were also predicted to be targeted by the other cellular miRNAs up-regulated during B cell 
transformation, a comparison between the data in table 15 and the 183 genes predicted to be 
miR-148a targets listed in table 13 was made. We focused the analysis on genes which were 
predicted to be targeted by ≥ 50% (9 or more miRNAs) of the miRNAs up-regulated during 
EBV infection of B cells. From the list of 183 miR-148a predicted target genes (table 13), 10 
genes were found to also be predicted targets of 9 or more miRNAs up-regulated by EBV 
infection (table 18). This list of genes is varied, however, there are two RNA binding proteins,  
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Tables 15-17: Results from a multiple miRNA target prediction analysis. miRNAs whose 
expression changed in response to EBV infection of resting B cells were analysed. Predicted 
target genes for miRNAs up-regulated or down-regulated following EBV infection, or, 
differentially regulated between EBV and CD40L blasts in a Taqman miRNA were obtained 
using Target Scan. The predicted gene targets for all miRNAs in each category were 
compared using a custom designed computer program. The numbers of genes predicted to be 
targeted by miRNAs in each category are indicated.  
 
  
Number of 
up-regulated 
miRNAs 
compared 
Number 
of genes 
predicted 
19/19 0 
18/19 0 
17/19 0 
16/19 0 
15/19 0 
14/19 0 
13/19 1 
12/19 2 
11/19 12 
10/19 28 
9/19 66 
8/19 139 
7/19 257 
6/19 415 
5/19 675 
4/19 1208 
3/19 1523 
2/19 2169 
Number of 
differentially 
regulated 
miRNAs 
compared 
Number 
of genes 
predicted 
7/7 0 
6/7 0 
5/7 1 
4/7 14 
3/7 80 
2/7 484 
Number of 
down-
regulated 
miRNAs 
compared 
Number 
of genes 
predicted 
7/7 0 
6/7 0 
5/7 0 
4/7 12 
3/7 140 
2/7 672 
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Gene Name Aka Function 
BCL2L11 Bim Pro-apoptotic gene 
ATP11A  ATPase, little known. 
ATXN1 
Ataxin 1 
 Binds RNA. May be involved in RNA metabolism, has 
been shown to bind ubiquitin binding proteins [676] 
ATXN7L1 
Ataxin like protein 
 Little known. 
FXR1 
Fragile X related 
syndrome related  protein 
 RNA binding protein. Binds FRM1 (table 3) and FXR2. 
May regulate the transport and translation of certain 
mRNAs.[677, 678] 
ITGB8 
Integrin beta 8 
 Receptor for fibronectin [679] 
MTF1 
Metal regulatory 
transcription factor 1 
 Activates the metallothionein I promoter [680]. 
MXD1 
MAX dimerisation protein 
 Little known 
NFAT5 
Nuclear factor of activated 
T cells 5 
TonEBP Transcription factor involved in the induction of gene 
expression. Induced by osmotic stress [681, 682]. 
SH3PXD2A  Required for podosome formation, degradation of the 
extracellular matrix, and for the invasiveness of some 
cancer cells. Found in several cancer cell lines, 
particularly invasive breast cancer cell lines and 
melanomas [683, 684]. 
Table 18: Genes predicted by target scan to be targeted by 9 or more of the 19 miRNAs up-
regulated by EBV infection of resting B cells and miR-148a. The list of genes predicted to be 
targeted by 9 or more of the up-regulated miRNAs were compared with the 183 genes 
predicted to be miR-148a targets by three target prediction programs (table 13). The common 
genes are listed in this table with brief known function. 
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consistent with previous miR-148a target prediction analyses which have suggested a possible 
role for miR-148a in the regulation of RNAi and mRNA transport. 
Interestingly, Bim was one of the 10 genes predicted to be targeted by ≥ 50% of the miRNAs 
up-regulated during B cell transformation, and by miR-148a. This suggests that a large 
number of miRNAs expressed in B cells blasts are able to cooperate to regulate the expression 
of Bim. Therefore, the over-expression or inhibition of only one of the many miRNAs 
predicted to down-regulate Bim, may not be sufficient to cause a detectable change in Bim 
protein expression; offering a potential explanation for the lack of Bim protein repression we 
observed following miR-148a transfection in DG75-BL. This would be consistent with miR-
148a having a fine tuning role in Bim protein expression. Alternatively, miR-148a may only 
significantly affect the expression of Bim protein in primary B cells and early in the 
transformation process, when the expressions of the other Bim regulatory miRNAs are lower. 
This could be tested using combinations of miRNA mimics for transfection into DG75. 
Alternatively, combinations of miRNA sponges, or simply over-expressing the 3’UTR of Bim 
could be used to sequester the multiple miRNAs up-regulated in early EBV blasts to examine 
the role of these miRNA in the regulation of Bim protein expression following EBV infection 
of resting B cells. Over-expression of multiple miRNAs using miRNA mimics cannot be used 
to repress Bim expression in LCLs as Bim protein expression is very low in EBV blasts 7 
days and 6 weeks p.i (figure 4.15) 
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Discussion II 
 
(a) Cellular miRNA expression profiling 
The comparison between EBV infected and CD40L and IL4 stimulated B cell blasts has 
proved to be an interesting model which has allowed the identification of a novel set of 7 
miRNAs whose expression changes are specific to EBV-mediated B cell transformation. The 
miRNA expression profiling by QPCR was, and remains, the most sensitive and specific 
technique available for quantitating miRNA expression. The miRNA array agreed with the 
limited miRNA expression data which was available at the time, demonstrating that miR-155 
[603, 640], miR-146a [629, 685] and miR-21 [603] were all up-regulated following EBV 
infection, suggesting that this technique was reliable. In addition to the oncogenic miRNAs -
155 and -21, five of the six oncogenic miR-17-92 cluster were also up-regulated by both EBV 
infection and CD40L stimulation, suggesting that activation and proliferation of resting B 
cells involves the up-regulation of at least 7 oncogenic miRNAs; a corresponding down-
regulation of tumour suppressor genes would be predicted to result from the up-regulation of 
multiple oncogenic miRNAs, which may contribute to the continuously proliferating, 
apoptotic resistant phenotype of LCLs. It would be interesting to determine whether the any 
of the oncogenic miRNAs were also up-regulated by alternate patterns of EBV latency, such 
as latency I, so the contribution of these miRNAs to EBV associated malignancies (which 
rarely express a latency III pattern of EBV gene expression) could be evaluated.   
The miRNA QPCR array was only performed in duplicate; therefore, the reproducibility of 
the array was not as thorough as it would have been had we performed the array in the 
standard triplicate samples. With hind-sight it would have been more constructive to perform 
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the array in triplicate on just the resting B cells, EBV and CD40L day 7 blasts, leaving out the 
LCL for further analysis as very few differences between EBV blasts at day 7 and the LCL 
were identified.  
To further confirm the miRNA array data we performed QPCR for individual miRNA 
expression in 5 biological replicates of peripheral blood B cells either infected with EBV or 
stimulated with CD40L and IL4. It was not ideal to use the same method of measurement for 
the validation experiments as was used for the array but miRNA QPCR was the only 
technique at the time which was sensitive enough to measure a variety of miRNAs with such 
differing expression levels (as indicated by the ΔCt analysis). Furthermore, since the original 
arrays were performed in duplicate, the analysis of 3 additional biological replicates served to 
confirm the biological reproducibility of the original data set. Of the 10 differentially 
regulated miRNAs identified, 4 (miR148a, miR-95, miR-28-5p and miR-31) showed a 
significant difference in expression between EBV and CD40L blasts in 5 biological replicates. 
These miRNAs were the most interesting candidates for further study. There were a further 3 
miRNAs which showed a significant difference in expression between the LCL and the 
CD40L blasts (miR-199a-3p, miR-193a-3p and miR-200b), which were also included for 
further investigation as these miRNAs may also be involved in transformation, even though 
the differences seen by 7 days p.i were not large enough to be significant. Ideally we would 
have included a CD40L blast at 6 weeks post-stimulation for comparison with the LCL but 
CD40L blasts generated with soluble CD40L stop proliferating after approximately 4-6 weeks 
and would therefore no longer serve as a good control for a proliferating and activated LCL.  
The ΔCt analysis was very informative and showed why miR-155, miR-21 and miR-146a 
were some of the first miRNAs identified in an LCL as these miRNAs are very abundantly 
expressed in LCLs. This analysis also revealed that miR-148a was up-regulated from the 64
th
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most abundantly expressed miRNA in B cells to the 10
th
 most abundantly expressed miRNA 
in an LCL, strongly suggesting a functional role for this miRNA in an LCL. The other 6 
differentially regulated miRNAs were all down-regulated following EBV infection and the 
ΔCt analysis showed that none of these miRNAs were in the top 20 abundantly expressed 
miRNAs in a resting B cell. Current knowledge of miRNAs doesn’t allow us to say what ΔCt 
value corresponds to a biologically relevant level of miRNA expression, and it could be that 
all the miRNAs detected in the array were at biologically functional levels. However, for our 
functional studies it was logical to pick the most abundantly expressed miRNA for analysis as 
the changes in gene expression caused by this miRNA were most likely to be detectable.  
(b) miRNA expression in BL and HL 
Three of the 7 differentially miRNAs showed a clear correlation with a latency III pattern of 
EBV latent gene expression in Mutu-BL cell lines (miR-28-5p, miR-95 and miR-199a-3p). 
Consistent with our findings, miR-28-5p was identified in an array by Cameron et al as down-
regulated in latency III Mutu-BL cell lines [652]. However, Cameron et al also showed that 
miR-34a was up-regulated in latency III Mutu-BL, which is in contrast to our data (figure 
4.7). miRNAs -95 and -199a-3p also showed a down-regulation in latency I Mutu-BL clones, 
suggesting that these miRNAs may be down-regulated as a result of EBNA1, the EBERS or 
possibly BART miRNAs.  
The remaining miRNAs, including miR-148a, did not show a correlation with EBV latent 
gene expression and this may be due to the relatively high expression of these miRNAs in the 
Mutu-BL negative clone. For example, miR-148a expression in Mutu-BL negative was only 8 
fold less than that of an LCL, already much higher than the expression seen in resting B cells 
(summarised figure 4.9). EBV latent gene expression may not have a substantial effect on 
miR-148a expression in a cell background where its expression is already elevated. Therefore, 
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a lack of correlation with EBV latent gene expression in Mutu-BL cannot exclude the 
possibility that these miRNAs are regulated by EBV latent gene expression during the 
transformation of resting B cells. Furthermore, the expression of c-Myc has been shown to 
have a significant effect on miRNA expression [542], thus the miRNA expression of BL cell 
lines would be expected to differ significantly from resting B cells. Therefore, EBV latent 
gene expression in a cell background where c-Myc expression is high would be unlikely to 
always cause the same changes in miRNA expression as those observed following EBV 
infection of resting B cells.  
The miRNA expression profiling of RLNs and the lymph nodes from patients with cHL by 
Navarro et al [653] provided a unique opportunity to identify miRNAs involved in the 
transformation of resting B cells by EBV which are also associated with cHL. A comparison 
between RLNs and cHL is complimentary to the comparison we had used between CD40L 
blasts and EBV blasts and proved a useful data set for comparison. The comparison revealed 
that miR-95 and miR-28-5p, which we had already shown to be down-regulated in latency III 
Mutu-BL, were also down-regulated in cHL compared with RLNs. This is an interesting 
result and is supporting the hypothesis that these miRNAs are involved in B cell 
transformation, although no targets for these miRNAs have been reported therefore it is not 
possible to speculate what the role of these miRNAs may be.  
miR-34a was one of two miRNAs up-regulated in cHL compared with RLNs and this miRNA 
was not consistently expressed in our biological duplicate Taqman array samples. To clarify 
the expression of miR-34a in EBV infected and CD40L blasts, the expression of miR-34a was 
measured in 5 biological replicate samples. The QPCR data clearly showed that miR-34a was 
in fact up-regulated by both EBV and CD40L and was therefore eliminated from further 
investigation. We measured the expression of miR-34a in a panel of HL cell lines to 
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determine whether these cell lines were a good model for miRNA expression in HL. miR-34a 
expression was very high, with the exception of L1236. In general, therefore, the HL cell lines 
appeared to be in agreement with Navarro et al’s data on biopsy tissues, so we continued with 
our miRNA expression analysis. The low expression of miR-34a expression in the BL cell 
line may be due to high cMyc expression, as miR-34a was reported in a microarray to be 
down-regulated by cMyc [542].  
miR-95 showed consistently lower expression in the HL cell lines relative to resting B cells 
which agreed with the data produced by Navarro et al, however, miR-28-5p expression was 
variable, with two of the six HL cell lines showing higher miR-28-5p expression than resting 
B cells. The HL cell line data cannot be expected to exactly correlate with data collected from 
the lymph nodes from patients, consequently, the miR-28-5p result could be a discrepancy 
between tissue samples and cell lines, or it could be that miR-28-5p is not consistently down-
regulated in cHL.  
miR-199a-3p and miR-193a-3p were not included in the published QPCR array of RLNs and 
the lymph nodes from patients with cHL, therefore, we included them in our HL cell line 
analysis. These two miRNAs both showed decreased expression in 4/6 of the HL cell lines 
and increased expression in the two HL cell lines, KMH2 and KMH2-EBV. This result is 
unusual and implies that the KMH2 cell line has a different miRNA expression profile from 
the other HL cell lines. This data suggests that miR-199a-3p and miR-193a-3p may also be 
down-regulated in HL, however, this would need to be confirmed using in-situ-hybridisation 
for these miRNAs in HL biopsy material. Interestingly, miR-199a-3p has recently been 
identified an anti-viral associated miRNA in a mouse model system examining the effects of 
herpesvirus infection on host cellular miRNAs. The down-regulation of miR-199a-3p was 
also confirmed in human cells post-infection with CMV and miR-199a-3p was shown to 
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affect ERK/MAPK and PI3K/AKT signalling pathways [686]. This indicates that the 
modulation of this miRNA by EBV is likely to also be a method employed by EBV to evade 
the host anti-viral response. The down-regulation of miR-199a-3p in EBV positive tumour 
cell lines may therefore reflect a down-modulation by EBV, however, the low expression of 
this miRNA in EBV negative tumour cell lines, such as the HL cell lines, is difficult to 
explain. It may be that these tumour cells are currently, or have previously, been infected with 
a virus or this miRNA has a tumour-suppressor function in addition to an anti-viral function.  
(c) Characterising miR-148a expression 
The only miRNA to be up-regulated by EBV and not CD40L was miR-148a and its 
expression was up-regulated to the 10
th
 most abundantly expressed miRNA in an LCL. There 
was very little information regarding the expression or function of miR-148a in the literature, 
particularly in relation to B cells or EBV. For these reasons we wanted to further characterise 
the expression of this miRNA as a prelude to functional analysis. miR-148a was not up-
regulated in B cells until approximately 4 days p.i, suggesting that it may be up-regulated by a 
latent gene which is not expressed immediately, such as LMP1 or LMP2. Alternatively, pri-
miR-148a transcription is up-regulated early in transformation and the processing of pri-miR-
148a is delayed until 4 days p.i through an unknown mechanism.  
We showed that miR-148a was highly expressed in GC B cells (centrocytes and centroblasts) 
suggesting that miR-148a may be involved in B cell differentiation. However, miR-148a 
expression profiling of cell lines revealed that miR-148a expression in BL and HL cell lines 
was variable; therefore miR-148a expression is not high in all cell lines with a GC B cell 
phenotype. miR-148a expression in a panel of four NK cell lines and a primary NK sample 
was very low, regardless of EBV status, suggesting that miR-148a expression is not up-
regulated in EBV associated NK lymphomas. 
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Using RNA isolated from paraffin embedded tissue we were able to show miR-148a 
expression in two PTLD, two HL and one T-NHL tissue samples. miR-148a expression 
ranged from 10-30% of the expression seen in an LCL, with the two PTLD samples having 
the highest miR-148a expression. Considering PTLD so closely resembles the phenotype of 
an LCL, the expression of miR-148a would be predicted to be high in these tumours. 
However, we did not have access to a control tissue sample, such as tonsil section, so it is 
difficult to interpret this data. Additionally, the PTLD and HL tumour samples will contain a 
large percentage of reactive lymphocyte infiltrate, therefore the tumour cells themselves will 
only comprise a small fraction of the RNA extracted from these tumour samples. Thus, a 
miR-148a expression of 10-30% of that seen in an LCL may represent a significant 
expression of miR-148a in the tumour cells or a moderate expression of miR-148a in the 
reactive infiltrate. It is worth noting here that we observed a decrease in miR-148a expression 
in one late passage LCL (>100 passages) to approximately two fold greater expression than 
the resting B cells. This result needs to be repeated but it may suggest that miR-148a 
expression may be down-regulated as LCLs become an immortalised cell line with an 
increased tumourogenic phenotype; PTLD tumour cells may therefore not necessarily be 
expected to have high expression of miR-148a. Alternatively, expression of miR-148a is 
important for the initiation of transformation but is not essential for its maintenance as other 
epigenetic and genetic changes take ove the regulation of Bim in these cells [136, 675]. 
The HL tissue samples had higher miR-148a expression than the HL cell lines, which was not 
expected and may reflect the flaw in the experiment (no correct negative control) or it may 
indicate that miR-148a is highly expressed in the reactive infiltrate of HL biopsy material. In-
situ-hybridisation for miR-148a expression on HL tissue samples would establish the 
expression of miR-148a in HL tissue. Collectively, the further characterisation of miR-148a 
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has demonstrated that miR-148a may be involved in B cell differentiation, however, miR-
148a expression profiling does not suggest a role for the up-regulation of this miRNA in 
lymphomagenesis, except possibly in PLTD. 
(d) miR-148a primary target prediction 
To identify gene targets of miR-148a we used a combination of three miRNA target 
prediction programs: miRanda, Target Scan and microT. We have shown that the overlap of 
predicted targets genes is small, with only 183 genes predicted to be miR-148a targets by all 
three programs. This highlights the limitations of the miRNA target prediction programs as 
they produce a large number of false positives and negatives.  
To identify a small subset of the most probable miR-148a target genes we used the scoring 
system of each miRNA target prediction program to generate a list of miR-148a targets within 
the top 10% or 20% score values in each program. 12 genes were identified as miR-148a 
targets with a top 20% scored value in all three programs and these genes included three RNA 
associated proteins: AGO1, AGO2 and FMR1; and two ubiquitin specific proteins, USP6 and 
USP32. It is reasonable to speculate that miR-148a may therefore be involved in the control 
of post-transcriptional gene expression, such as RNAi and possibly mRNA stability.  
The repression of a target gene by a miRNA is often a process which involves a number of 
different miRNAs as multiple miRNAs have been shown to have an additive effect in 
translational repression [499]. To investigate which miR-148a gene targets were also 
predicted to be gene targets of the other 19 miRNAs identified in the Taqman miRNA array 
as up-regulated by EBV infection, we compared the predicted miRNA targets of all 19 
miRNAs. To simplify the analysis and because not all miRNAs had predicted gene targets in 
all three target prediction programs, the analysis was performed using the gene lists form just 
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Target Scan. This analysis revealed that no genes were predicted to be targeted by >13/19 of 
the up-regulated miRNAs. Bim was again identified and was predicted to be targeted by 9/19 
of the miRNAs up-regulated in B cells following EBV infection. This multiple miRNA target 
prediction is flawed in the respect that we compared 19 miRNAs whose expression had not 
been validated as up-regulated by EBV. However, by comparing every combination of 19/19 
miRNAs, down to 2/19 miRNAs, no combination of miRNA comparisons were missed or 
discounted. There will be a high number of false positives with this type of data analysis, but 
as with the other forms of analysis, when compared with multiple sources of information this 
data can still be informative.  
Despite Bim being a candidate miR-148a target we could not show any change in Bim 
expression following transfection of miR-148a inhibitors or mimics into an LCL or DG75 
respectively. It is not surprising that miR-148a inhibition in an LCL did not result in the re-
expression of Bim protein as Bim is reported to be transcriptionally and epigenetically down-
regulated in these cells, therefore, translational repression by one miRNA will be unlikely to 
have a dominant effect [687]. However, there was no detectable increase in DNMT1 protein 
expression following miR-148a inhibition either. It is possible that miR-148a is not a 
significant factor determining DNMT1 expression in LCLs, but it also raises the possibility 
that the miR-148a inhibitors were not sufficient to repress miR-148a function. The luciferase 
reporter which was used to validate the efficacy of the miR-148a inhibitors in an LCL was an 
artificial system which contained a miR-148a binding site with 100% complimentarity to 
miR-148a, rather than the typical imperfect base pairing seen in miRNA:mRNA interactions. 
Thus, the miR-148a reporter may have been more sensitive to miR-148a inhibition than 
authentic miR-148a target genes. Alternative methods of miR-148a inhibtioin may therefore 
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be required for future investigation into miR-148a function, such as miRNA sponges, as 
discussed in section 4.8. 
The over-expression of miR-148a in DG75-BL using miR-148a mimics served to validate 
Bim as a miR-148a target gene. The lack of Bim repression following miR-148a transfection 
could be due the high miR-148a expression in DG75-BL, with similar miR-148a expression 
levels to those seen in centrocytes (figure 4.9). Further increasing miR-148a expression may 
not have any effect on an already saturated miR-148a binding site in the 3’UTR of Bim. This 
is also supported by the lack of DNMT1 protein repression observed in DG75-BL after miR-
148a transfection. Alternatively, Bim may not be a genuine miR-148a target gene as the miR-
148a binding sites predicted in the 3’UTR of Bim have not been validated experimentally 
using luciferase reporters.  
The multiple miRNA target prediction analysis provided an alternative explanation for the 
lack of Bim repression following miR-148a transfection as many miRNAs were also 
predicted to target Bim; thus, Bim regulation by a single miRNA may only be significant in 
the context of the total miRNA expression (cell environment). The multiple miRNA target 
prediction analysis also demonstrated the difficulty in identifying biologically relevant 
miRNA targets. Every bioinformatics analysis performed identified Bim as a candidate miR-
148a target gene, however, the regulation of Bim by miR-148a was unlikely to be a 
significant factor in EBV-mediated transformation for the reasons previously discussed. 
miRNA inhibition and over expression studies coupled with proteomic analysis of gene 
expression in a relevant cell type is the ideal approach to identifying relevant miRNA gene 
targets. Additionally, established cell lines may not be the correct model for determining the 
post-transcriptional regulation of Bim, as these lines may already have established 
mechanisms for maintaining the expression of Bim. It may be that miR-148a regulation of 
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Bim is only relevant during the first few weeks of transformation, or during B cell 
differentiation, and to test this miR-148a over-expression and inhibition in primary B cells 
would be necessary.  
In summary, the results in this chapter suggest that EBV does modulate the host cellular 
miRNA expression during B cell transformation and a subset of these miRNAs also show 
down-regulation in EBV associated lymphomas, and may therefore, be significant to 
transformation and EBV-mediated lymphomagenesis. miR-148a was identified as the only 
miRNA to be up-regulated by EBV and not CD40L stimulation of B cells and this miRNA 
may also be involved in B cell differentiation due to its high expression in GC B cells. The 
function of miR-148a remains to be elucidated; however, miR-148a target prediction analysis 
suggests a potential role for miR-148a in the modulation of RNAi. 
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5. Results Part III 
Cellular gene expression profiling of EBV and CD40L blasts 
 
5.1 Introduction 
In the previous chapter, the miRNA expression profiles of EBV blasts and CD40L blasts were 
compared. This comparison allowed the identification of cellular miRNAs whose expression 
changes were associated with EBV-mediated B cell transformation rather than transient 
activation and proliferation of a resting B cell; however, the role of these cellular miRNAs 
during B cell transformation is still undetermined.  
Cellular gene expression profiling of EBV blasts and CD40L blasts would enable the 
identification of genes whose expression changes are specifically associated with 
transformation, which could be used for two purposes: firstly, for comparison with the 
miRNA expression data from the previous chapter, to identify miRNA target genes regulated 
by EBV. This would enable the contribution of miRNAs to the cellular gene expression 
profile in transformed and cytokine stimulated B cells to be estimated; secondly, to produce a 
novel list of genes whose expression changes may be required for EBV-mediated B cell 
transformation. Investigation into the function of these cellular genes during B cell 
transformation will provide a greater understanding of the mechanism of EBV-mediated B 
cell transformation. 
 
5.2 Cellular gene expression profiling 
To identify cellular genes which may be involved in the transformation of resting B cells by 
EBV, an Affymetrix exon array was performed as described in section 2.11. The miRNA 
Results III 
 
Page 197 
 
array data showed few differences between EBV blasts and LCLs, therefore we excluded the 
LCL from the cellular gene expression profiling. The array was performed in biological 
triplicate on resting B cells, EBV and CD40L blasts 7 days p.i. One of the three biological 
replicates was the same sample set used in the Taqman miRNA array. EBV infection of the 
EBV blasts was confirmed by QPCR for the EBV Cp promoter (figure 5.1). 
The microarray data was analysed to produce two different data sets (i and ii) which could be 
used for separated purposes: (i) gene expression changes relative to resting B cells. This 
analysis was comparable to the miRNA array analysis which provided information on the 
gene expression in the B cells 7 days following EBV infection or CD40L stimulation; thus, 
for miRNA array comparisons, these gene lists were predominantly used. (ii) A direct 
comparison between EBV and CD40L blasts. This analysis was used to identify a small 
subset of genes which showed a statistically significant difference in expression between the 
two different lymphoblasts. These genes therefore represented the genes with the largest 
expression difference between the two blasts, making them the best candidates for functional 
analysis.  
5.2.1 SAM analysis of CD40L blasts and EBV blasts relative to resting B cells 
Significance analysis of microarrays (SAM) [613] was performed on the microarray data by 
bioinformatician Wenbin Wei, as described in section 2.11.2. Briefly, genes were assigned a 
score based on the change in gene expression relative to the standard deviation of repeated 
measurements. This allowed an estimate to be made of the percentage of genes identified by 
chance; termed the false discovery rate (FDR). Stringency can be set according to preference 
and for this analysis we chose highly stringent conditions (minimum fold change of 1.5 and a 
FDR of ≤ 0.05), to reduce the identification of false positive genes.   
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Figure 5.1: EBV promoter usage in the microarray samples. Cp expression by QPCR in three 
biological replicates of resting B cells (B cells d0) either infected with EBV or stimulated 
with CD40L and IL4 and harvested after 7 days. Data is expressed relative to GAPDH 
(assigned a value of 1) and error bars indicate the standard deviation of the QPCR assay. 
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SAM analysis comparing either EBV blasts or CD40L blasts with resting B cells revealed a 
large number of genes which showed a significant (≥1.5 fold, ≤ 0.05 FDR) expression change 
following EBV infection or CD40L stimulation of resting B cells. Relative to resting B cells, 
4123 and 2545 genes were up-regulated by EBV infection or CD40L stimulation respectively, 
and 887 and 330 genes were down-regulated by EBV infection or CD40L stimulation 
respectively. The results of the SAM analysis are summarised in table 19. The degree of 
overlap between the gene expression changes in EBV and CD40L blasts are represented by 
Venn diagrams in figure 5.2. The majority of the gene expression changes in the CD40L 
blasts also occurred in the EBV blasts (83%), illustrating the high degree of similarity in the 
gene expression profiles of these two blasts.  
5.2.2 SAM analysis of CD40L and EBV blasts 
SAM analysis directly comparing EBV day 7 blasts with CD40L day 7 blasts produced a list 
of 61 genes whose expression was significantly different between EBV blasts and CD40L 
blasts (≥ 1.5 fold change, ≤ 0.05 FDR). The data is expressed as a heat map where red 
indicates increased relative expression and blue indicates decreased relative expression (figure 
5.3). The relative expression of the resting B cells was also included in the heat map for 
comparison. The 61 genes differentially expressed between EBV and CD40L are also listed, 
along with fold change, in table 20. 
5.3 Comparative analysis of the miRNA array and cellular gene microarray 
The miRNA and gene expression profiles of CD40L and EBV blasts have been determined 
using the two arrays systems. The question still remains: are any of the genes differentially 
expressed between EBV and CD40L blasts regulated by the differentially expressed miRNAs 
in these two types of lymphoblasts? Answering this question would enable us to determine the  
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A 
 
 
 
B 
 
Figure 5.2: Venn diagrams representing genes A; up-regulated and B; down-regulated by 
EBV and CD40L day 7 blasts relative to resting B cells in a microarray. 
 
 
 
 
 
 
 
 
Table 19: Summarising the gene expression changes in the CD40L vs EBV array. Genes up or down-
regulated by EBV and CD40L blasts relative to resting B cells (>1.5 fold, FDR 0.05). 
 Relative to resting B cells 
Data Set 
Number of genes up 
regulated 
Number of genes 
down-regulated 
EBV d7 blasts 4123 887 
CD40L blasts 2545 350 
Common Genes* 2122 292 
Up-regulated Gene Sets 
Down-regulated Gene Sets 
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    B cells       EBV     CD40L 
Figure 5.3: Heat map generated 
by unsupervised SAM analysis 
comparing EBV day 7 blasts and 
CD40L day 7 blasts. Shown are 
the 61 genes which had >1.5 fold 
and <0.05 FDR differences in 
gene expression between EBV 
and CD40L day 7 blasts. Resting 
B cells are included for visual 
comparison but were not included 
in the unsupervised SAM 
analysis. The colour of each block 
represents the expression of a 
gene relative to the average 
expression of that gene across all 
samples, with red indicating high 
relative expression and blue 
indicating low relative expression.  
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Gene 
Symbol 
Fold Change  
CD40 blasts/EBV 
blasts 
Probability 
of false 
positivity 
NR4A3 12.63 0.00 
IL17RB 9.76 2.90 
QSOX1 8.69 4.08 
DUSP6 8.20 0.00 
MMP12 7.85 0.00 
FCER2 7.19 0.00 
IL4R 6.87 0.00 
TSPAN33 5.99 2.90 
HOMER2 5.98 0.00 
SPINT2 4.89 0.00 
SIRPA 4.29 4.37 
HS3ST1 3.83 0.00 
ITGAL 3.13 4.37 
CENTA2 2.90 0.00 
CTSZ 2.50 4.37 
CD40 2.42 0.00 
TERF2 2.09 4.37 
PPARG 1.98 4.08 
FMNL3 1.93 2.90 
LRRK1 1.69 2.90 
C10orf2 -1.51 4.08 
WDR40A -1.69 2.90 
LDLR -1.93 0.00 
TRIM25 -2.11 0.00 
OASL -2.13 4.08 
PIK3R3 -2.24 0.00 
IGL@ -2.40 4.37 
IGK@ -2.46 0.00 
C3orf37 -2.56 4.37 
CARD6 -2.57 4.08 
FCGR2B -2.61 0.00 
LGALS3BP -2.77 0.00 
ENC1 -2.81 4.08 
ELOVL6 -2.92 0.00 
GPR160 -3.09 0.00 
LY6E -3.23 2.90 
USP18 -3.43 2.90 
IGLV6-57 -3.54 4.08 
PIM2 -3.54 0.00 
P2RX5 -3.60 0.00 
TXNDC5 -3.90 4.08 
NETO2 -3.98 0.00 
Gene 
Symbol 
Fold Change  
CD40 blasts/EBV 
blasts 
Probability 
of false 
positivity 
OAS3 -4.06 4.08 
IL10 -4.07 0.00 
MAP2K6 -4.09 4.08 
MX2 -4.32 2.90 
PLSCR1 -4.45 4.08 
CCL25 -4.50 0.00 
MX1 -4.74 0.00 
CR1 -5.03 2.90 
CD300A -5.71 0.00 
IL12RB2 -6.26 0.00 
CABLES1 -6.34 0.00 
IFI6 -6.84 0.00 
RSAD2 -7.16 0.00 
7A5 -7.17 0.00 
PLAC8 -8.21 4.08 
CHI3L2 -8.88 0.00 
IFI44 -9.52 4.08 
CR2 -13.94 0.00 
IFIT1 -19.37 0.00 
Table 20: Table of genes identified by unpaired 
SAM analysis as differentially regulated 
between EBV and CD40L blasts with a fold 
change >1.5 and a FDR of <0.05 
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extent to which cellular miRNAs are contributing to the cellular gene expression changes 
unique to EBV transformed B cells. However, there are caveats to this type of analysis. 
Firstly, miRNAs predominantly repress gene expression by translational repression, therefore 
most primary miRNA target genes will not be identified on a microarray. Secondly, miRNA 
induced mRNA degradation often produces small changes in transcript expression, which 
may be missed by the stringent conditions of our SAM analysis. Thirdly, miRNA target 
prediction programs will be required for the data comparisons which, as discussed in the 
previous chapter, produce a large number of false positives and negatives, increasing the 
complexity of the analysis. Nevertheless, these comparisons have been successful in previous 
reports [160, 524, 534, 640, 688] and may allow the identification of novel miRNA targets 
relevant to the transformation of resting B cells by EBV. 
We began with a comparison of the microarray data and the miR-148a target prediction 
analysis in chapter 4.6.1, to identify miR-148a target genes down-regulated during B cell 
transformation. We then progressed to a comparison between the global miRNA array data 
and the microarray data, with an emphasis on differentially regulated genes and miRNAs. 
5.3.1 Comparing miR-148a target predictions with the microarray 
miR-148a was identified as significantly up-regulated by EBV infection but not by CD40L 
stimulation of resting B cells. Previously, (section 4.6.1) 183 target genes for miR-148a were 
predicted by three target prediction programs. A comparison between the cellular gene 
expression profile of EBV infected and CD40L stimulated B cells and the 183 miR-148a 
predicted target genes may identify primary miR-148a gene targets regulated by miR-148a 
during B cell transformation. Gene expression changes relative to resting B cells formed the 
majority of the comparisons as this form of microarray analysis was the most comparable to 
the miRNA array analysis.  
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Primary miR-148a targets whose expression was regulated by miR-148a during EBV-
mediated transformation of resting B cells would be expected to be down-regulated following 
EBV infection but not after CD40L stimulation. The miR-148a target prediction and cellular 
gene array data comparison is summarised in table 21. There were 16/750 (2.1%) genes 
down-regulated by EBV compared to resting B cells in the cellular gene expression array 
which were also predicted to be miR-148a targets by the three miRNA target prediction 
programs. Although, 4/16 of these genes were also down-regulated by CD40L, therefore, 
regulation of these genes by miR-148a was unlikely to be responsible for the expression 
changes observed in these four genes (table 22, highlighted in grey). 
BCL2L11 (Bim) and MAFB were 2/12 genes down-regulated by only EBV infection of 
resting B cells (table 22) and they were also predicted to be in the top 10% and 20% score 
values for miR-148a predicted target genes respectively. However, we could not show any 
regulation of Bim protein expression in an established LCL in the previous chapter, 
suggesting that this type of data analysis needs to be treated with caution.  
The significance of 2.1% of the genes down-regulated by EBV being miR-148a predicted 
targets is questionable considering 6/161 (3.7%) genes down-regulated by CD40L were also 
predicted to be miR-148a targets by the three miRNA target prediction programs (SNF1LK, 
ARRDC3, PRNP, MYST2, SNN and HMGB3). Additionally, 31/4018 (0.8%) genes up-
regulated by EBV compared with resting B cells were predicted to be miR-148a targets and 
8/1767 (0.45%) genes up-regulated by CD40L compared with resting B cells were predicted 
to be miR-148a targets.  
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Table 21:  A data comparison between genes altered by EBV infection or CD40L stimulation 
of resting B cells and miR-148a predicted target genes. 6 different analyses were performed 
on the microarray data, comparing EBV or CD40L blasts with either resting B cells or 
directly with each other. A list of 183 genes predicted to be miR-148a targets by 3 
independent target prediction programs (table 13 chapter 4) was compared with the gene lists 
produced by each microarray analysis. The percentage of predicted miR-148a targets from 
each microarray analysis is also displayed.  
 
 
Gene 
Symbol 
Fold Change EBV 
vs d0 B cells 
PRNP -3.87 
BCL2L11 -3.75 
ARRDC3 -2.74 
MMD -2.56 
BACH2 -2.54 
SNN -2.41 
CDC14A -2.13 
MYST2 -2.06 
PHF20 -2.03 
JARID2 -1.97 
DYRK1A -1.94 
BAZ2A -1.88 
SLC2A1 -1.85 
SESTD1 -1.82 
CAMK2A -1.72 
MAFB -1.51 
 
Table 22: 16 genes predicted to be miR-148a targets from 3 independent target prediction 
programs (table 13) which were also identified on a transcriptional array as down-regulated 
by EBV relative to d0 resting B cells. Genes also down-regulated by CD40L 
  
Microarray Analysis 
Number of 
miR-148a targets 
miR-148a targets: 
percentage of total 
Down-regulated - EBV vs d0 B cells 16/750 2.1 
Down-regulated - CD40L vs d0 B cells 6/161 3.7 
Up-regulated - EBV vs d0 B cells 31/4018 0.8 
Up-regulated - CD40L vs d0 B cells 8/1767 0.45 
Up-regulated - EBV vs CD40L 1/41 2.4 
Down-regulated - EBV vs CD40L 0/20 0 
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5.3.1 miRNA array target prediction  
To compare the global miRNA and gene expression arrays, the predicted cellular gene targets 
for each miRNA were obtained; the miRNA predicted gene target list was then directly 
compared with the microarray data (data analysis and results are summarised in figure 5.4). 
The miRNA target prediction program with the least stringent target prediction conditions 
(miRanda, Sanger v5) was used to reduce the number of false negatives. False positives were 
less of a concern in this analysis as we were only focusing our data analysis on 61 genes, 
therefore, the number of false positives would be small enough for removal in future 
validation experiments. For the differentially expressed miRNA and gene array comparison, 
gene targets for the 4 miRNAs whose expression was differentially expressed between 
CD40L blasts and EBV day 7 blasts (miR-148a, miR-95, miR-31, miR-28-5p,) were 
generated using the miRanda target prediction program, and the data was used for comparison 
with the EBV and CD40L blasts cellular gene expression microarray data. 
5.3.3 miRNA and cellular gene expression array comparisons 
Initially, we compared the list of genes from the array which were either commonly up or 
down-regulated by EBV and CD40L, with the miRNAs which were commonly down or up-
regulated by EBV and CD40L. The predicted genes for the 19 miRNAs up-regulated by both 
CD40L and EBV blasts were compared with the 109 genes down-regulated by both CD40L 
and EBV blasts; all of the 19 up-regulated miRNAs were predicted to target at least one of 
31/109 down-regulated genes.  
The predicted gene targets of the 7 miRNAs down-regulated by both EBV and CD40L were 
then compared with the list of 1510 genes up-regulated by both EBV and CD40L; all 7 of the  
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Figure 5.4: Diagram representing the miRNA and gene expression array data comparison. 
miRNAs of interest had their gene targets predicted using the miRanda target prediction 
algorithm. These predicted miRNA gene targets were then compared with the cellular gene 
expression array data, represented in a Venn diagram where blue represents miRNA predicted 
gene targets and green represents genes from the gene expression array. 
  
miRNA Array 
Gene Array 
4 
Differentially 
Regulated miRNAs 
61 
Differentially 
Regulated Genes 
miRNA target prediction 
3537 genes 
3537 61 
miRNA Array     
and 
Gene Array 
Comparison 
19 
Common  
Up-Regulated 
miRNAs 
9153 genes 
109 
Common  
Down-Regulated 
Genes  
1510 
Common  
Up-Regulated 
Genes  
7  
Common 
Down-Regulated 
miRNAs 
4222 genes 
314 
1196 3908 78 9122 
31 
Results III 
 
Page 208 
 
miRNAs were predicted to target 314/1510 of the genes up-regulated on the microarray by 
both EBV and CD40L. 
Next we compared the 61 genes differentially expressed between EBV and CD40L blasts with 
the miRNA array data. The 61 genes differentially expressed between EBV and CD40L blasts 
were split into two groups: those with relatively higher expression in EBV blasts (41genes), 
and those with a relative lower expression in EBV blasts, compared with CD40L blasts (20 
genes). Predicted gene targets for the only up-regulated miRNA (miR-148a) were compared 
with the list of differentially regulated genes which showed lower relative expression in the 
EBV blasts; there were no common genes. There were 3 miRNAs from the miRNA array 
which showed a significant down-regulation in EBV day 7 blasts compared with CD40L day 
7 blasts and these were: miR-95, miR-28-5p and miR-31. The predicted gene targets for these 
three miRNAs were compared with the list of differentially regulated genes which showed 
relatively higher expression in the EBV blasts. Again, there were no common genes, 
indicating that none of the differentially regulated miRNAs regulated the level of transcripts 
of any of the differentially regulated genes.  
The lack of correlation predicted between the differentially regulated genes and miRNAs may 
be due to the small number of genes and miRNAs involved in the comparison. In contrast, the 
comparisons between the commonly regulated genes and miRNAs identified a number of 
predicted miRNA:gene target regulations. This positive result may be due to the large number 
of miRNAs in the commonly up-regulated comparison (19 miRNAs) and the large number of 
genes in the commonly down-regulated miRNA comparison (1510), substantially increasing 
the probability of producing a positive result. Nevertheless, the miRNA and gene expression 
array comparison identified possible gene targets for EBV regulated miRNAs. However, our 
research was focused on the differentially expressed genes and miRNAs, therefore we did not 
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investigate the correlation between the commonly regulated genes and miRNAs any further; 
our research subsequently focused on the genes which were identified on the microarray as 
differentially expressed between EBV and CD40L blasts. 
 
5.4 Analysis of EBV and CD40L blast transcription microarray 
5.4.1 Kegg pathway analysis 
To understand the large number of gene expression changes produced by microarrays, a 
number of programs have been designed to analyse the gene expression changes in the 
context of known signalling pathways or diseases. Kegg (Kyoto encyclopaedia of genes and 
genomes) pathway analysis [689] is one such tool available for this type of analysis. The 
genes which were significantly up or down-regulated following EBV infection or CD40L 
stimulation, relative to resting B cells, were entered into the Kegg analysis tool. The genes 
were then compared with the Homo sapiens reference database and the Kegg pathway 
analysis tool produced a list of cellular signalling pathways which the genes altered in 
response to EBV infection or CD40L stimulation could be grouped into.  
The TLR7 signalling pathway was predicted to be activated by EBV infection and not CD40L 
stimulation, with the following genes up-regulated by EBV infection and not CD40L 
stimulation: IFNα/β receptor, TLR7/8, IRAK4, IRF7, IFNα; these data are summarised in 
figure 5.5. Closer examination of the array data revealed that TLR7 was also up-regulated by 
CD40L stimulation in 2/3 of the samples, although to a lesser extent than in EBV blasts. A 
literature search revealed that EBV manipulates the TLR7 signalling pathway following 
infection of primary B cells [637], which highlights the value of this type of analysis tool. 
Table 23 summarises the Kegg pathway analysis and lists the three most significantly altered  
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Kegg Pathway 
EBV blasts 
Number of 
genes 
Up (↑) or 
Down (↓)  
CD40L blasts 
Number of 
genes 
Up (↑) or 
Down (↓)  
EBV blasts Selected genes 
Up (↑) or Down (↓) 
TLR7/8 
signalling 
↑7 
↓0 
↑4 
↓0 
TLR7/8 
IRAK4 
IRF7 
 
Apoptosis 
↑31 
↓4 
↑16 
↓2 
Fas 
TNFα 
MyD88 
IRAK 
FLIP 
Bid 
Apaf-1 
IAP 
CASP10 
CASP3 DFF45 
BCL2 
BCL-XL 
Bax 
ATM 
CASP8 
NF-қB 
MAPK 
signalling 
↑25 
↓15 
↑16 
↓4 
FAS 
TNF 
ASK1, MKK6 
 p38, MEF2C 
CASF 
MEF2C 
PP2CB 
 
CD14 TRAF6 
TAB2 
MEKK2B  
PP2CA 
RSK2 
FGF 
G12 
RafB 
 
 
Table 23: Summary of the Kegg pathway analysis. Genes up or down-regulated by EBV and 
CD40L relative to resting B cells were entered into the Kegg pathways analysis program. The 
top three pathways predicted to be modulated by EBV are included with the number of genes 
up or down-regulated in each pathway. Genes which were up or down-regulated on the 
microarray by only EBV blasts (not CD40L blasts) are listed. Red genes were up-regualted by 
EBV and green genes were down-regulated by EBV.  
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pathways predicted by the Kegg pathway analysis. The genes whose expression altered in 
only the EBV blasts are listed for each of the three pathways, as well as the number of genes 
altered in each pathway.  
This analysis has revealed that CD40L and EBV blasts both modulate the expression of genes 
in the same pathways, perhaps unsurprisingly considering the similarity of the gene 
expression profiles of these two lymphoblasts. EBV may be predicted to modulate a larger 
number of target genes in the apoptosis and MAPK signalling pathways which may result in 
enhanced MAPK signalling and apoptosis resistance of LCLs. However, the functional 
significance of these gene expression changes requires investigation before conclusions can 
be drawn.  
5.4.2 Tumour suppressor gene analysis 
The process of EBV-mediated B cell transformation is distinct from the process of 
immortalisation required to produce an immortalised LCL. This suggests that additional 
cellular gene expression changes are required following transformation to produce an 
immortalised LCL. Immortalised LCLs, unlike early passage LCLs, show a tumourogenic 
phenotype with the ability to form tumours in nude mice [348], suggesting that the process of 
immortalisation is partially comparable to lymphomagenesis. CD40L blasts do not obtain all 
the necessary gene expression changes to produce an immortalised cell line, suggesting that 
the cellular gene expression changes specific to EBV induced transformation may predispose 
B cells to the additional gene expression changes required for cellular immortalisation. 
Therefore, it is reasonable to propose that some of the cellular genes specific to 
transformation will also be candidate tumours suppressor genes (TSGs) or oncogenes.  
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An analysis was performed to identify whether any of the genes specifically down-regulated 
by EBV were candidate TSGs. A TSG database was created within our department by 
Professor Ciaran Woodman. The TSG database was compiled using a PUBMED literature 
search for the terms: tumor, tumour and suppressor. All abstracts were inspected but only 
genes which showed unambiguous evidence of tumour suppressor activity in cell lines or 
animal models were entered into the database. All gene symbols were then harmonised to 
those on the NCBI database to allow comparison with affymetrix gene expression data (which 
uses NCBI databases gene symbols). Over 800 genes were identified in the literature as 
having expressed tumour suppressor function and these constituted the TSG database. 
A broad comparison between the tumour suppressor database and the microarray data was 
performed which included all 595 genes which were down-regulated by EBV and not by 
CD40L, relative to resting B cells; 45 TSGs were identified (table 24).  
Of the 61 genes differentially expressed between EBV and CD40L blasts, six genes were 
specifically down-regulated in EBV blasts compared with CD40L blasts: NR4A3, DUSP6, 
IL4R, SPINT2, TSPAN33 and CENTA2. Three of these genes were identified as candidate 
TSGs: NR4A3, DUSP6 and SPINT2 (highlighted in yellow, table 24). The function and 
known tumour suppressor activity of these three genes are listed in table 25. 
NR4A1 and NR4A3 were shown to exhibit tumour suppressor function in a mouse knockout 
model but only in double-knockout mice where both genes were deleted [690]. The tumour 
suppressor activity of NR4A3 may therefore depend on the low expression of NR4A1; it was 
therefore important to determine the expression of both of these TSGs.  
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TSG Location 
TLE4 9q21.31 
TP53BP2 1q42.1 
ZEB1 10p11.2 
ARID4A 14q23.1 
BCLAF1 6q22-q23 
CASP8 2q33-q34 
DIRAS1 19p13.3 
EP300 22q13.2 
FOXP1 3p14.1 
GLTSCR2 19q13.3 
MAP3K8 10p11.23 
PLK3 1p34.1 
PTGER4 5p13.1 
XRCC6 22q13.2-q13.31  
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 24: Results of the TSG analysis. Genes down-regulated by EBV (FDR 0.05) and not 
CD40L blasts relative to resting B cells were compared with a list of genes compiled from the 
literature as having shown TGS function in some cell background. Included in the table is 
data from previous arrays performed in the department where germinal centre B cells were 
either infected with EBV or transfected with LMP1.  Genes highlighted in yellow are classed 
as differentially expressed between EBV and CD40L blasts (FDR 0.05%, >1.5 fold) and can 
been seen on the heat map in figure 5.3  
TSG Location 
EGR1 5q23-q31 
SMAD3 18q21.1 
BACH2 6q14.3-q16.1 
BCL2L11 2q13 
DUSP6 12q22-q23 
GGNBP2 17q12  
NR4A1 12q13 
SPINT2 
13q22.2-
13q22.3 
ATF3 1q32.3 
BEX2 Xq22 
CDKN1A 6p21.31 
CREBBP 16p13.3 
CYLD 16q12-q13 
DDX3X Xp11.3-p11.23 
EEF1A1 6q14.1 
FBXL10 12q24.31 
HBP1 7q22-q31 
NR4A3 9q22 
PAQR3 4q21.21 
PFDN5 12q12 
PMAIP1 18q21.32 
RAB37 17q25.1 
RANBP2 2q12.3 
RARA 17q21 
RPS14 5q31-q33 
RPS6KA6  Xq21 
SIRT1 10q21.3 
SKI 1q22-q24 
SOCS3 17q25.3 
TAGLN 11q23.2 
THBS1 6q27 
TLE1 15q22 
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Potential 
TSG 
Alias Function Tumour Association 
DUSP6 
MKP3 
PYST1 
A protein tyrosine phosphatase which 
inactivates MAP kinases with a 
specificity for the ERK family. 
A candidate TSG for 
pancreatic cancer[617, 
691, 692] 
SPINT2 
HAI-2 
KOP 
Membrane protein which acts as an 
inhibitor of hepatocyte growth factor 
activator. 
Acts as a TSG through 
its inhibition of 
hepatocyte growth 
factor activator in 
papillary and clear cell 
renal carcinoma[693] 
and paediatric 
medullablastoma.[694] 
NR4A3 
Nor-1 
MINOR 
CHN 
Is part of the Nur77 (NR4A1) family of 
nuclear steroid receptors and NR4A3 
shows very strong homology with 
NR4A1[695]. NR4A3 has been linked 
with NR4A1 and Bim as mediators of 
negative selection of CD4 and CD8 T 
cells[696] It may be involved in the 
response to forskolin or TPA. Binds to 
the B1A response element. Two 
isoforms exist, α and β. 
Abrogation of NR4A1 
and NR4A3 in mice led 
to the rapid 
development of 
AML[690] 
NR4A1 Nur77 
This orphan nuclear receptor can act as 
a proapoptotic or antiapoptotic protein. 
NR4A1 can bind Bcl2 and convert it 
from a cytoprotective to a 
cytodestructive protein [697].  NR4A1 
been shown to bind EBNA2 in 
fibroblasts which prevents NR4A1 
mediated apoptosis [698]. 
Abrogation of NR4A1 
and NR4A3 in mice led 
to the rapid 
development of 
AML[690] 
 
 
Table 25:  Candidate TSGs with brief known function. Three TSGs down-regulated by EBV 
infection but not CD40L stimulation of resting B cells are listed with brief known function 
(DUSP6, SPINT2 and NR4A3). The additional TSG NR4A1 is included because the tumours 
suppressor function of NR4A3 can depend on loss of NR4A1 expression.  
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5.5 Microarray validations 
To validate the differential expression of genes from the microarray we used custom designed 
Taqman microfluidic cards. These cards allowed singleplex QPCR to be performed for a large 
number of genes (45 genes), plus three endogenous controls for normalisation: B2M, GAPDH 
and PPIA. All Taqman QPCR assays were selected (where possible) to be specific for only 
the gene isotype identified on the microarray. The three biological triplicate microarray 
sample sets and the matched LCL from each biological triplicate were used for the validation 
experiments. The RNA was reverse transcribed using random hexamers and loaded into the 
microfluidic card for QPCR analysis (outlined in section 2.10.4) The data was analysed using 
the ΔΔCt method of analysis [609] and the endogenous control, B2M, was used for 
normalisation as it was the most consistently expressed of the three endogenous controls.  
5.5.1 Selecting genes for validation 
Two genes were included in the array validations as positive controls since their expression 
changes following EBV infection were already established: Bim is down-regulated by EBV 
infection of resting B cells [687, 699] and was included as a positive control for down-
regulation of genes post-EBV infection. BLIMP1 is involved in B cell differentiation and is 
known to be up-regulated following EBV infection of resting B cells [700, 701], and was 
therefore included as a positive control for up-regulated genes post-EBV infection. 
The three differentially expressed candidate TSGs identified in the previous analysis were 
chosen for validation, plus the additional TSG, NR4A1. The remaining 41 genes chosen for 
validation were also from the list of 61 differentially regulated genes and were included for a 
collaborative project.  
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5.5.2 Microarray QPCR validation  
The results of the microarray validation for all 45 genes are represented in a heat map (figure 
5.6) using the ΔCt values as the data output. Blue indicates a lower level of relative 
expression and red indicates a higher level of expression. The QPCR data for the 4 TSGs and 
the two positive controls are presented in figure 5.7. The data is plotted as 20-ΔCt values to 
allow individual data points, and therefore the reproducibility of the data, to be visualised. 
The P values were calculated using a paired analysis of the student T test comparing the EBV 
and CD40L day 7 blasts. The 3 TSGs differentially expressed on the microarray (NR4A3, 
DUSP6 and SPINT2) produced a significant (P= ≤ 0.01) difference in expression between 
EBV and CD40L blasts. The two additional positive control genes (Bim (BCL2L11) and 
BLIMP1 (PRDM1)) both showed the expected changes in gene expression, indicating that the 
microfluidic cards were producing accurate data.  
Validation of NR4A3, NR4A1, DUSP6 and SPINT2 expression at the protein level was 
attempted using western blot but the antibodies for these genes were not sensitive enough to 
detect endogenous protein level and can therefore only be used for over-expression studies.  
 
5.6 Further analysis of TSG expression and regulation by EBV 
To further understand the possible functional significance of the down-regulation of DUSP6, 
SPINT2 and NR4A3, we sought to characterise the expression of these three TSGs in more 
detail and investigate their down-regulation by EBV.  
5.6.1 TSG expression in B cells following LMP1 and gp42 knockout-EBV infection 
The LMP1 knockout virus is a non-transforming virus which causes transient activation and 
proliferation of resting B cells for approximately 10 days before the cells stop proliferating  
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Figure 5.6: Heat map representing the microarray validation by QPCR of 45 genes 
differentially expressed between EBV blasts and CD40L blasts. Data is expressed as 
relative ΔCt values where red represents a relative increase in expression and blue 
represents a relative decrease in expression. P values were calculated using the paired 
student T test, comparing CD40L d7 blasts and EBV d7 blasts. Genes marked with * had 
a P value of ≤ 0.05 and genes marked with ** had a P values of ≤ 0.01 to three decimal 
places. 
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Figure 5.7: Microarray validations of TSGs by QPCR. A; 4 candidate TSGs indentified on 
the microarray as down-regulated by EBV and not CD40L. B; QPCR positive controls, Bim 
and BLIMP1.  P values represent the result of a paired student T test comparing CD40L and 
EBV blasts. 
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and eventually die. If DUSP6, SPINT2 and NR4A3 are involved in the transformation of 
resting B cells, then it would be informative to determine whether or not they are also down-
regulated by a non-transforming mutant LMP1KO EBV. To control for the effect of virus 
binding in the absence of EBV internalisation and expression, we used a gp42 knockout virus 
(described in section 3.3.5).  
B cells were positively selected from two donors and pooled prior to infections, and 7x10
6
 B 
cells were used immediately for RNA extraction to serve as the d0 time point. The wtEBV, 
LMP1KO and Δgp42 viruses were titred (section 2.3.3) and resting B cells were infected at an 
m.o.i of 100 for each virus; cells were harvested 7 days pi. The experiment was repeated twice 
to produce biological triplicate samples sets. 
QPCR for EBV promoter usage (Wp and Cp) and LMP1 expression was performed on all 
samples and demonstrated that there was no EBV promoter usage or LMP1 expression in 
Δgp42 virus infected cells. LMP1KO infected B cells showed both Cp and Wp transcripts but 
no LMP1 expression, whereas the wtEBV infected B cells showed expression of both 
promoter transcripts and LMP1, indicating that all the viruses were functioning as expected 
(figure 5.8). 
The RNA from triplicate biological replicates of: resting B cells (d0), wtEBV infected, 
LMP1KO infected and Δgp42 infected B cells, was reverse transcribed using random 
hexamers and loaded into the custom designed Taqman microfluidic cards for QPCR analysis. 
SPINT2 only showed down-regulation with wtEBV and LMP1KO EBV infections. 
Conversely, the results show that B cells infected with all viruses showed down-regulation of 
DUSP6, NR4A3, and NR4A1. Additionally, Bim and BLIMP1 also showed a down-
regulation and up-regulation following Δgp42 virus infection respectively. It is not possible to  
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Figure 5.8: EBV promoter and latent gene expression by QPCR in B cells infected with 
wtEBV, LMP1KO or Δgp42 EBV. A; Wp. B; Cp, C; L MP1 expression in resting B cells 
(d0) infected with either wt EBV, LMP1KO or a gp42KO virus. ND represents samples 
whose expression was not-determined. Data is expressed relative to an appropriate control. 
Error bars represent the standard deviation of the QPCR. 
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draw conclusions about the non-transforming capacities of the LMP1KO virus when the 
Δgp42 virus infected cells also showed down-regulation of 3/4 of the TSGs.  
The statistical significance of the gene expression changes observed in B cells following 
infection with Δgp42 virus are indicated on each graph (figure 5.9), with 3/6 of the genes 
showing statistically significant changes in gene expression in the Δgp42 infected B cells; 
indicating that the Δgp42 virus can in some instances can produce the same effect on gene 
expression as wtEBV.   
The data presented in figure 5.9 were unexpected, and suggested that several EBV induced 
changes, which were not induced in CD40L blasts, may be initiated by virus binding alone. 
We therefore asked whether this phenomenon was restricted to EBV-regulated TSGs, or was 
more widespread. To ascertain whether the Δgp42 EBV produced the same changes in gene 
expression as the wtEBV in a wider number of genes, the QPCR data for the remaining 41 
genes was analysed. An additional 27 genes showed a change in expression post-infection 
with Δgp42 virus. All but two (PLAC6 and C3orf37) of the additional 27 gene expression 
changes produced by Δgp42 virus mirrored those caused by the wtEBV. A heat map 
representing the ΔCt values produced from this QPCR data is presented in figure 5.10. It is 
clear from this data that the Δgp42 virus does not produce gene expression changes to the 
same extent as the wt or LMP1KO EBV, however, the gene expression changes are great 
enough to prevent the LMP1KO data from being significantly greater, therefore firm 
conclusions from this data cannot be drawn. 
The resting B cells and Δgp42 infected B cells produce the most varied QPCR data, 
presumably due to the heterogeneous condition of the cells; despite this, 11/45 genes assayed  
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Figure 5.9: TSG expression by QPCR in B cells infected with wtEBV, LMP1KO or Δgp42 EBV. 
QPCR data was collected using custom designed Taqman microfluidic cards. Gene expression was 
measured in resting B cells isolated from peripheral blood (B cells d0) and B cells infected with the 
following viruses: wtEBV at 7 days p.i (EBV d7) and 6 weeks p.i (LCL), gp42 knockout virus 
(gp42KO d7) harvested 7 days p.i and an LMP1 knockout virus 7 days p.i (LMP1KO d7). A; 4 
candidate TSGs and B; two positive controls. The statistical significance of the difference in gene 
expression between the virus infecting cells and the resting B cells was calculated using the student T 
test, paired analysis; P values of ≤ 0.05 or ≤ 0.01 are represented by * and ** respectively.  
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Figure 5.10: Heat map representing the results of a QPCR assay on biological triplicate 
samples of B cells (d0) isolated from peripheral blood and infected with either wtEBV 7 days 
p.i (wt) and 6 weeks p.i (LCL), Δgp42 EBV (Δgp42) and LMP1KO EBV (LMP1KO). Data is 
expressed as relative ΔCt values where red represents a relative increase in expression and blue 
represents a relative decrease in expression. P values represent the results of a paired student T 
test comparing resting B cells with Δgp42 EBV infected cells. Genes marked with * had a P 
value of ≤ 0.05 and genes marked with ** had a P values of ≤ 0.01. 
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showed a significant difference in expression between resting B cells and the Δgp42 infected 
B cells by the student T test. Collectively, this suggests that a significant subset of genes 
differentially expressed between EBV and CD40L are also affected by virus binding alone, 
but expression is maintained (or even amplified) in LCLs, indicating additional mechanisms 
for maintaining differential gene expression. 
5.6.2 TSG expression in malignant cell lines 
The expression of the three differentially regulated TSGs, DUSP6, SPINT2 and NR4A3, was 
measured by QPCR in a limited panel of BL cell lines expressing the latency state of the 
original tumour biopsy; latency I. An EBV negative BL cell line (DG75) and an LCL were 
included for comparison. Data is expressed relative to resting B cells. The panel of BL cell 
lines represents only a limited number of cell lines for analysis but were well characterised 
latency I BL cell lines available within our group, the gene expression data from this small 
panel of cell lines cannot therefore be classified as representative of all BL cell lines, a wider 
panel would be required to draw those conclusions. The data shows that DUSP6 and NR4A3 
were both expressed at very low levels in all BL cell lines. DUSP6 expression was elevated in 
Dante when compared to the other BL cell lines; however, this expression was still only 20% 
of that seen in the resting B cells. SPINT2 had variable expression across the cell lines, with 
relative expression ranging from LCL-like levels of 0.01 in Ezema, to expression 8 fold 
greater than resting B cells in Sav (figure 5.11). The SPINT2 expression data suggests that the 
down-regulation of SPINT2 during EBV infection is not relevant to the development of BL, 
whereas the down-regulation of NR4A3 and DUSP6 may contribute to the malignant 
phenotype of BL cells.  
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Figure 5.11: TSG expression by QPCR in BL cell lines. A; DUSP6, B; NR4A3 and C; 
SPINT2 in a panel of BL cell lines and an LCL. Data is expressed relative to resting B cells 
and error bars represent the standard deviation of duplicate QPCR samples. 
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5.7 Functional consequences of re-expression of DUSP6 in LCLs 
DUSP6 is a tyrosine phosphatase which specifically targets the ERK/MAPK pathway by 
removing ERK phosphorylation and therefore preventing ERK activation [702, 703]. The 
down-regulation of DUSP6 may therefore be required for constitutive or enhanced activation 
of MAPK signalling, which is associated with many different cancers [704]. Re-expression of 
DUSP6 in pancreatic cancer cell lines resulted in loss of proliferation and an accumulation of  
cells in the sub G1-phase of the cell-cycle [617]. We therefore sought to investigate the effect 
of ectopic DUSP6 re-expression on the proliferation of LCLs. 
5.7.1 Creating a DUSP6 expressing lentivirus  
To investigate the effect of DUSP6 re-expression in LCLs we created a tetracycline inducible, 
DUSP6 expressing lentivirus. It was important to use an inducible lentivirus system as the re-
expression of a candidate tumour suppressor gene may cause apoptosis or prevent 
proliferation of the LCLs before functional assays can be performed. We chose to use a 
tetracycline inducible lentivirus system kindly donated by Marco Herold [616] for production 
of the DUSP6 lentivirus. Details of the cloning strategy are in chapter 2 section 2.21. Briefly, 
PCR was performed to amplify DUSP6 from a Topo-DUSP6-His expression vector (donated 
by Toru Furukawa [617]). The PCR fragment was ligated into an intermediate vector 
downstream of a tetracycline-inducible promoter. DUSP6 was then excised from the 
intermediate vector, along with the tetracycline inducible promoter, and ligated into the final 
vector. The final vector therefore contained DUSP6 under the control of a tetracycline 
inducible promoter (TREX-P); it also contained eGFP and tetracycline repressor protein 
(hTetR), constitutively expressed from a ubiquitin promoter. A simplified map of the final 
DSUP6 lentiviral vector is shown in figure 5.12. 
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Figure 5.12 Simplified schematic map of the DUSP6 lentiviral vector, FT(DUSP6)UTG. The 
FT(DUSP6)UTG lentivirus was used to generate stable a LCL-DUSP6 cell line with 
tetracycline inducible DUSP6 expression. DUSP6 expression was controlled by a tetracycline 
promoter (TREX-P) while eGFP and the tetracycline repressor protein (hTetR) were 
constitutively expressed from the ubiquitin promoter (ubiquitin-P). 
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Figure 5.13: Western blot and flow cytometry data showing DUSP6 lentivirus transduction 
and gene expression in a LCL. A; Flow cytometry data showing the GFP positivity of an LCL 
transduced with either a CTR-lentivirus or a DUSP6, GFP positive lentivirus. B; Western blot 
for DUSP6 and calregulin expression in 293 cells transfected with a HIS-tagged DUSP6 topo 
vector (D6 Topo), the parental LCL and LCL-DUSP6 harvested 48 hours after culture with 
increasing concentrations of tetracycline to induce DUSP6 expression. C; 293 cells 
transfected with a HIS-tagged DUSP6 topo vector (D6 Topo), the parental LCL and LCL-
CTR and LCL-DUSP6 harvested 48 hours after culture with either no tetracycline (-) or with 
0.5µg/ml of tetracycline.  
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5.7.2 Validating the DUSP6 lentivirus  
To test the tetracycline inducible promoter of the DUSP6 lentivirus in an LCL, 5x10
5
 LCLs 
were transduced with either a DUSP6 lentivirus or a control empty vector lentivirus (CTR), 
and the cells were sorted for GFP. GFP positive cells were then cultured to produce stable cell 
lines; the cell lines were designated LCL-DUSP6 and LCL-CTR (figure 5.13, A). LCL-
DUSP6 and LCL-CTR were plated out to 5x10
6
 cells per well of a 6 well plate and cultured  
for 48 hours at a range of concentrations of tetracycline from 0-1µg/ml. Cells were harvested 
for protein and western blots were performed for DUSP6 and calregulin. DUSP6 expression 
was induced with 50ng/ml of tetracycline, however, DUSP6 expression apparently did not 
increase in a dose dependent manner with further increases in the concentration of 
tetracycline. This indicates that the tetracycline inducible promoter was maximally active in 
50ng/ml of tetracycline, and that a dose responsive increase in DSUP6 expression may be 
seen at concentrations ranging from 5ng/ml-50ng/ml.  
To demonstrate that the control lentivirus did not express DUSP6, LCL-CTR and LCL-
DUSP6 were culture for 48 hours in the presence or absence of 0.5µg/ml of tetracycline. Cells 
were harvested for protein and western blot was performed for DUSP6 and calregulin 
expression. DUSP6 was only expressed in the induced LCL-DUSP6 expressing cell line.  
5.7.3 DUSP6 expression and ERK1/2 phosphorylation in an LCL 
DUSP6 has been shown to specifically de-phosphorylate and inactivate ERK1/2 in cultured 
cells [702]. Ectopic DUSP6 expression in pancreatic cancer cell lines, which contain a gain-
of-function mutation in KRAS and therefore have constitutive ERK phosphorylation, is 
associated with loss of ERK phosphorylation. The re-expression of DUSP6 in an LCL would 
therefore be predicted to prevent ERK phosphorylation in a LCL. Stimulation of a LCL with 
Results III 
 
Page 231 
 
the phorbol ester 12-O-tetradeconoylphorbal-13-acetate (TPA) has been shown to induce 
ERK phosphorylation [705], we investigated the effect of DSUP6 expression on TPA induced 
ERK phosphorylation in a LCL.  
LCL-CTR and LCL-DUSP6 were cultured in the presence and absence of 0.1µg/ml of 
tetracycline for 48 hours to induce DUSP6 expression. Cells were then stimulated with 
20µg/ml of TPA or 1µl of DMSO as a negative control and the cells were harvested after 24 
hours for western blot. The blots were probed for total ERK (ERK1/2), phospho-ERK, 
DUSP6 and calregulin. The data shows no reduction in TPA induced ERK-phosphorylation in 
the presence of DUSP6 in a LCL (figure 5.14). DUSP6 mediated de-phosphorylation of 
ERK1/2 may serve to dampen the ERK signalling by slowing the rate of ERK activation 
rather than preventing it entirely. Measuring ERK phosphorylation 24 hours post-TPA 
stimulation may therefore not detect any decrease in phosphorylation. It is also possible that 
LCLs have several mechanisms to maintain ERK phosphorylation and DUSP6 re-expression 
in established LCLs may therefore not have any effect on ERK1/2 phosphorylation. 
5.7.4 The effect of DUSP6 expression on LCL proliferation  
The tumour suppressor activity of DUSP6 in pancreatic cancer cell lines was partly ascribed 
to its ability to reduce cell proliferation upon re-expression. Pancreatic cancer cell lines were 
unable to complete the cell-cycle following DUSP6 expression, with cells being held in the 
sub-G1 fraction [617]. To determine the effect of DUSP6 re-expression on LCL proliferation, 
LCL-DUSP6 and LCL-CTR were cultured in the presence and absence of 0.5µg/ml of 
tetracycline and cell proliferation was determined by cell counting using a trypan blue 
exclusion assay. The parental LCL (LCL A4) cells were included as an additional control for 
the effect of lentivirus transduction, and were cultured in tetracycline free media. Cells were 
seeded at 0.2 x10
6 
cells per ml in a total of 5ml of media and multiple aliquots were counted   
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Figure 5.14: Western blot analysis of ERK phosphorylation following TPA stimulation of 
LCLs in the presence or absence of DUSP6. Stable cell lines were produced following the 
transduction of an LCL with a tetracycline inducible empty vector (LCL-CTR) or DUSP6 
(LCL-DUSP6) expressing lentivirus. The LCLs were then cultured in the presence or absence 
of tetracycline for 48 hours prior to stimulation with TPA to induce ERK phosphorylation. 
LCLs were harvested 24 hours post-TPA stimulation for western blot analysis. Blots were 
probed for total ERK (ERK 1/2), phospho-ERK, DUSP6 and calregulin as a loading control.    
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Figure 5.15: Trypan blue exclusion assay following DSUP6 re-expression in a LCL. Graphs 
represent the total number of live cells counted in a culture over 7 days. LCL-DUSP6 and 
LCL-CTR were in cultured in the presence (+ tet) or absence (- tet) of 0.5µg/ml of 
tetracycline and the cells. The parental LCL was cultured in the absence of tetracycline as a 
control. 
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daily for 7 days. There was no apparent difference in LCL proliferation in the presence of 
DUSP6. The proliferation of both the induced and un-induced LCL-CTR and LCL-DUSP6 
cell lines was the same (figure 5.15). The parental LCL may have slightly increased rate of 
proliferation than the LCL-CTR and LCL-DSUP6 cell lines; however, this was variable in 
repeat assays and may not be significant.  
A complementary and more sensitive assay to measure LCL proliferation was also performed 
using flow cytometry. GFP positive LCL-CTR and LCL-DUSP6 cells were counted and 
mixed at a 1:1 ratio with the GFP negative parental LCL cell line; the cell lines were cultured 
in the presence or absence of 0.5µg/ml of tetracycline for 7 days. GFP was measured by flow 
cytometry after 7 days to determine whether the GFP positive LCL-DUSP6 cells were out-
competed by the GFP negative LCL due to a decreased rate of proliferation. The results 
presented in figure 5.16 indicate that neither the control, nor the DUSP6 expressing LCLs 
were out-competed by the GFP negative LCLs in the presence or absence of tetracycline. 
Collectively these results suggest that DUSP6 re-expression does not affect the proliferation 
of established LCLs.  
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Figure 5.16: Cell growth assay examining GFP expression by flow cytometry in stable LCL-
DUSP6 or LCL-CTR cell lines either induced or un-induced with tetracycline. LCLs were 
transduced with FT(DUSP6)UTG or a control empty vector plasmid FT(empty)UTG to 
generate LCL-DUSP6 and LCL-CTR cell lines respectively. A; LCL-CTR and LCL-DUSP6 
GFP positive cell lines prior to experiment. B; LCL-CTR or C; LCL-DUSP6 cells were 
mixed with GFP negative LCLs at a ratio of 1:1 (d0). Cells were cultured with or without 
tetracycline and GFP was measured after 7 days as a measure of cell proliferation.  
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Discussion III 
 
The aims of this chapter were twofold: firstly, we aimed to identify transcriptional changes 
which were associated with EBV-mediated B cell transformation; secondly, we sought to 
determine whether there was any correlation between the expression of the cellular miRNAs 
profiled in the previous chapter, and the levels of cellular gene transcripts; whilst from what 
we know of miRNA mode of action, we would not necessarily expect good correlations with 
target transcripts, there are many examples in the literature where this approach has yielded 
results. 
(a) miRNA and cellular gene expression comparison 
(i) miR-148a target prediction analysis and microarray comparison:  The miRNA target 
prediction analysis revealed 12 miR-148a predicted target genes specifically down-regulated 
by EBV infection and not CD40L stimulation of resting B cells. However, we demonstrated 
the transcriptional down-regulation of Bim by CD40L (figure 5.8), and in the previous 
chapter, miR-148a expression was shown not to affect Bim expression in an established LCL. 
This emphasises the caution which is required when comparing mRNA microarray and 
miRNA expression data as many false positive miRNA targets can easily be identified due to 
the limitations of microarray analysis and miRNA target prediction programs.  
Furthermore, there were a similar percentage of miR-148a target genes up and down-
regulated in both CD40L blasts and EBV blasts, and there was a lack of enrichment of miR-
148a targets genes in the EBV down-regulated gene set. This implied that the target prediction 
analysis was producing a significant percentage of false positive in every analysis; for this 
reason, we did not pursue this analysis further.  
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(ii) miRNA array and microarray data comparative analysis: We have shown that 
expression of the 61 differentially regulated genes indentified in the microarray comparing 
EBV and CD40L blasts were not predicted to be targeted by any of the 3 miRNAs which 
showed differential expression between EBV and CD40L blasts 7 days p.i/stimulation. As 
discussed previously, miRNAs negatively regulate gene expression predominantly through 
translational repression, therefore, many of the gene targets of these miRNAs will not be 
detected on a microarray, which may explain the lack of correlation seen between the two 
array sets. Additionally, comparing miRNA and gene expression data using bioinformatic 
prediction of miRNA targets has several caveats, including (i) an assumption that an up-
regulation in miRNA expression will correlate with a decrease in gene expression, which is 
not always the case [480-482] (discussed in section 1.14), and (ii) miRNA target prediction 
programs only scan the 3’UTR of gene targets, therefore, any miRNA target sites in 5’UTRs 
or protein coding regions will be discounted [477, 478]. Nevertheless, miRNA and mRNA 
expression data has been successfully correlated in previous studies [160, 524, 534, 640, 688], 
despite the high number of false positive and negative results inevitably produced from such 
comparisons. 
In contrast, all of the miRNAs commonly up or down-regulated by EBV or CD40L 
stimulation were predicted to target > 20% of the corresponding genes up or down-regulated 
on the microarray. This suggests that the lack of correlation between the differentially 
regulated miRNAs and the differentially regulated genes may be a valid result. However, the 
previous miRNA analysis comparing miR-148a predicted target genes and the microarray 
data would suggest that these comparisons are likely to produce a number of false positives; 
indicating that the lack of false positives in this instance may be due to the small number of 
differentially regulated genes.  
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The commonly up or down-regulated miRNAs were predicted to target one or more gene 
target from the array. This data could have been further refined using multiple miRNA target 
prediction programs to generate a list of the predicted miRNA gene targets which were the 
most probable. This refined gene list could then have been used as a basis for miRNA target 
validation experiments. However, our investigation was focused on the genes and miRNAs 
which were differentially expressed between EBV and CD40L blasts, therefore we did not 
continue with this line of investigation. 
(b) Cellular gene expression in EBV and CD40L blasts 
We had hypothesised that CD40L blasts and EBV blasts would show very similar gene 
expression changes relative to resting B cells; this was confirmed by the two data analyses 
which independently compared EBV and CD40L blasts directly, or with resting B cells.  
When analysing the gene expression data relative to resting B cells, EBV blasts showed 
approximately twice the number of gene expression changes of the CD40L blasts. Therefore, 
there were many gene expression changes (>2000) which occurred in EBV blasts relative to 
resting B cells which were not classified as significant in the CD40L blasts. However, SAM 
analysis comparing the CD40L and EBV blasts directly, identified only 61 genes which were 
significantly differentially expressed between the two types of lymphoblasts. This indicates 
that the majority of the 2000 plus gene expression changes detected in EBV blasts relative to 
resting B cells also occurred in the CD40L blasts, but to a lesser extent.  
Consequently, many of the gene expression changes in the CD40L blasts relative to resting B 
cells, were not great enough to be classified as significant by the stringent conditions (>1.5 
fold, q value 0.05) set for the SAM analysis, although they were large enough to prevent the 
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gene expression difference from being statistically significant when a direct comparison 
between the EBV and CD40L blasts was performed.  
The EBV:CD40L blasts gene expression comparison highlights the effectiveness of the 
CD40L blast control, as without it, we would have needed to identify genes involved in EBV-
mediated B cell transformation from the nearly 5000 gene expression changes observed when 
comparing EBV blasts with resting B cells. 
(c) Tumour suppressor gene analysis and validations 
Using a database compiled through data-mining we have identified three candidate TSGs 
specifically down-regulated in EBV blasts and not in CD40L blasts; DUSP6, NR4A3 and 
SPINT2. We have validated the differential expression of these TSGs using QPCR and have 
shown that they are further down-regulated in the LCL. QPCR analysis also revealed that 
DUSP6 and SPINT2 are slightly up-regulated in CD40L blasts relative to resting B cells, 
enhancing the difference seen in a direct comparison between EBV and CD40L blasts.  
The Kegg pathway analysis was a useful tool for evaluating the gene expression changes in 
the EBV and CD40L blasts relative to resting B cells. The up-regulation of the TLR7 pathway 
was the most striking difference between EBV and CD40L blasts and it is perhaps not 
surprising that virally infected B cells show a stronger TLR activation than mitogen 
stimulated B cells. Nevertheless, TLR stimulation has been shown to enhance the 
proliferation [706] and transformation [707] of naïve B cells, suggesting that the enhanced 
activation of this pathway be EBV may facilitate the transformation process. However, since 
the up-regulation of TLR7 signalling by EBV was already published, we did not investigate 
this observation further.  
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The Kegg pathway analysis also identified apoptosis and MAPK related pathways activated 
by EBV blasts which may contribute to the transformed phenotype of LCLs. Interestingly, 
Nur77 (NR4A1) was listed as one gene down-regulated by both EBV and CD40L in the 
MAPK pathway. NR4A1 is a pro-apoptotic candidate TSG [690, 696], which often functions 
in conjunction with NR4A3. It has been reported that NR4A1 and NR4A3 can be down-
regulated by MAPK signalling [708], suggesting a possible relationship between activated 
MAPK signalling and the down-regulation of these pro-apoptotic TSGs during B cell 
transformation. Furthermore, the down-regulation of the TSGs SPINT2 and DUSP6 has been 
reported to result in increased MAPK signalling [693, 709]; suggesting that not only is the 
MAPK signalling pathway important for B cell transformation, but also that the three TSGs 
down-regulated by EBV may be functionally linked.   
The protein expression of these TSGs cannot be measured using western blot as commercially 
available antibodies are not sensitive enough to detect endogenous protein expression. The 
use of these antibodies in different applications such as immuno-fluorescence or the 
development of new antibodies for these proteins will be required to validate the down-
regulation of the TSGs at the protein level. The transcriptional data alone was convincing 
enough for us to continue our investigation into the genes, although protein validation will be 
required for future work. 
(d) Tumour suppressor gene expression data 
To determine the importance of candidate TSG down-regulation in the transformation 
process, the expression of the three TSGs was measured in B cells infected with the non-
transforming LMP1KO virus and a Δgp42 virus to control for the effect of virus binding. It 
was hoped that this expression data would reveal whether the TSGs were down-regulated by 
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LMP1, and whether the TSG down-regulation occurred in B cells which were not growth 
transformed.  
After confirming the absence of LMP1 expression in LMP1KO virus infected B cells and the 
absence of any EBV promoter usage in Δgp42 virus infected B cells, we showed that the non-
transforming LMP1KO and Δgp42 viruses also down-regulated the expression of NR4A3, 
DUSP6 and NR4A1. This data is comparable to the up-regulation of miR-155 observed 
following Δgp42 virus infection of B cells in chapter 3. The up-regulation of miR-155 by 
Δgp42 virus was interpreted as a response to B cell activation caused by virus binding as 
miR-155 was known to be up-regulated in activated B cells. This interpretation may extend to 
the 31 genes whose expression was also altered following EBV binding.  
In total, 31/45 differentially regulated validated from the microarray also showed altered 
expression following infection with Δgp42 virus. All gene expression changes mirrored those 
of the wtEBV; indicating that virus binding alone can stimulate gene expression changes. The 
LCL expression data demonstrated that these gene expression changes are maintained in the 
LCL, suggesting that they are important for B cell transformation. Consistent with this, EBV 
binding via gp350 to CD21 has been reported to produce changes in cellular gene expression, 
including IL6 production and NF-қB activation [337, 710-713]. CD21 activation has also 
been shown to rescue GC B cell from apoptosis [714], suggesting that the signalling mediated 
by CD21 activation can have significant effect on B cell gene expression. 
 For EBV to successfully transform a resting B cell it may need to rapidly initiate the gene 
expression changes necessary for transformation, to prime the resting B cell for activation and 
transcription of EBV latent genes necessary for EBV-mediated B cell transformation. Virus 
binding and subsequent CD21 mediated signalling may be a method by which EBV initiates 
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the cellular gene expression changes essential for transformation, prior to entering the cell.  
Therefore, the gene expression changes observed in resting B cells infected with Δgp42 virus 
may be required for successful EBV-mediated B cell transformation, an observation which 
warrants further investigation. 
Whilst we were surprised by the number of differentially regulated genes which were 
modulated by EBV binding alone, the fact that these changes continued to be effected in 
LCLs long after the EBV/CD21 complex-mediated signals had expired, suggested that the 
changes were likely to be important for transformation. We therefore asked whether these 
genes were similarly modulated in EBV associated malignancies. The expression of the three 
TSGs was measured in a panel of latency I BL cell lines where we demonstrated that the 
expression of DUSP6 and NR4A3 were almost undetectable, which is consistent with a 
tumour suppressor function for these genes. The expression of SPINT2 was less consistent, 
with expression greater than resting B cells in the majority of the BL cell lines. This suggests 
that the down-regulation of SPINT2 in resting B cells transformation is not necessary for BL 
development. SPINT2 may be up-regulated by the high cMyc expression in BL or may only 
be down-regulated in tumours expressing a less restricted pattern of EBV latency. It is also 
possible that the down-regulation of SPINT2 may be involved in EBV-mediated 
transformation of resting B cells but not EBV associated lymphomagenesis. Further 
characterisation of SPINT2 expression in tumours of EBV associated lymphomas will provide 
insight into the tumour suppressor function of this gene in relation to EBV. 
(e) Re-expression of DUSP6 in an LCL 
DUSP6 is a phosphatase which specifically inactivates ERK1/2 in the MAPK pathway, 
thereby inhibiting MAPK signalling [702]. The re-expression of DUSP6 in pancreatic cell 
lines was shown to induce cell-cycle arrest and sensitise the cells to apoptosis [617]. To 
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examine the role of DUSP6 down-regulation in EBV-mediated growth transformation, a 
lentivirus expressing DUSP6 under the control of a tetracycline responsive promoter was 
successfully created. DUSP6 expression was induced upon the addition of tetracycline but the 
induction did not appear to be dose responsive, although it is possible that the dose responsive 
induction of DUSP6 at lower concentrations of tetracycline is occurring but it cannot be seen 
with the low sensitivity DUSP6 antibody. This poses a potential disadvantage for future work 
using this system as re-expression of DUSP6 to the physiological levels seen in resting B cells 
will not be possible. 
Whilst we had concerns about the physiological relevance of the over-expressed DUSP6, we 
considered that it would be useful to first demonstrate an effect of DUSP6 on LCL phenotype, 
and then validate such effects by reducing the tetracycline concentration to limit the amount 
of DUSP6 expressed. However, induction of DUSP6 expression in LCL-DUSP6 did not 
affect LCL proliferation, in contrast to the affect of DUSP6 re-expression in pancreatic cancer 
cell lines [617]. This difference may represent the difference in cell systems used. MAPK 
signalling is constitutively active in the majority of pancreatic cancer cell lines due to a gain-
of-function mutation in KRAS. ERK phosphorylation in this cell system is therefore central 
for the tumourogenic phenotype of these cells. LCLs appear to have low basal levels of ERK 
phosphorylation (figure 5.14) indicating that constitutive ERK1/2 activation may not be as 
important in these cell lines. Alternatively, LCLs may modulate alternative pathways which 
enable MAPK signalling, introducing a level of redundancy in the MAPK pathway which 
does not exist in pancreatic cell lines; therefore, DUSP6 re-expression in an LCL may not 
result in a loss of ERK phosphorylation.  
Preliminary data investigating the effect of DUSP6 re-expression on ERK phosphorylation 
revealed that DUSP6 cannot reduce ERK phosphorylation 24 hours post-stimulation with 
Discussion III 
 
Page 244 
 
TPA, supporting the hypothesis that DUSP6 re-expressing in an LCL may not prevent ERK 
phosphorylation. A time course assay investigating the effect of DUSP6 re-expression on the 
rate of ERK-phosphorylation might determine the extent to which DUSP6 can modulate the 
activation of this pathway in a LCL. 
The down-regulation of DUSP6 during B cell transformation may be necessary during early 
transformation to stimulate B cell proliferation and protect from apoptosis, but may not be 
essential in an established LCL. An investigation into the effect of DUSP6 re-expression in 
early EBV blasts (7 days p.i) may provide greater insight into the role of this gene during B 
cell transformation. This point is also relevant to the investigation of NR4A3 and SPINT2, 
and future investigation into the function of these candidate TSGs will focus on EBV blasts 
and early passage LCLs.   
There have been conflicting reports regarding the requirement of ERK1/2 activation during 
EBV-mediated transformation [169, 715], although these have used MAPK inhibitors with 
differing specificities, so the role of MAPK signalling during B cell transformation has not 
been definitively shown. Fenton et al [715] showed that MAPK inhibitors prevent phorbol 
ester induced BZLF1 expression, suggesting that the ERK1/2 signalling pathway is involved 
in the control of viral latency. Modulation of the MAPK pathway by EBV may therefore be 
required to enable the virus to regulate viral latency rather than B cell proliferation and 
apoptosis resistance. If so, re-expression of DUSP6 in EBV transformed B cells might render 
them insensitive to certain triggers of the lytic cycle. This could be examined more carefully 
in the Akata-BL cell line which can efficiently be induced into lytic cycle by different 
triggers, including BCR-ligation or phorbal ester treatment [246, 716, 717]. 
In summary, we have identified a subset of 61 genes specifically modulated by EBV infection 
and not CD40L stimulation of resting B cells. Data analysis revealed that none of the 
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differentially regulated genes were predicted to be targeted by any of the differentially 
regulated miRNAs. However, the cellular miRNAs commonly up or down-regulated by EBV 
and CD40L were predicted to target corresponding cellular genes on the microarray 
commonly down or up-regulated by EBV and CD40L; therefore, future investigation into the 
contribution of cellular miRNAs to EBV-mediated B cell transformation may focus on the 
genes and miRNAs which are commonly regulated by EBV and CD40L.  
The expression of 45/61 of the differentially regulated genes was successfully validated and 
included the expression of 3 candidate tumour suppressor genes down-regulated following 
EBV infection. Two of these candidate tumour suppressor genes showed low expression in a 
panel of BL cell lines, consistent with a tumour suppressor function in BL tumours. An 
inducible lentivirus system has enabled the re-expression of these TSGs to be investigated in 
EBV infected B cells. DUSP6 re-expression in an LCL did not affect LCL proliferation and 
highlighted a possible flaw of investing the function of these TSGs in established LCLs. 
Future investigation into the function of the three TSGs in EBV-mediated B cell 
transformation will therefore focus on early stage EBV blasts rather than established LCLs.  
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6. Conclusions and Future Work 
The transformation of resting B cells by EBV requires the modulation of cellular gene 
expression, in some instances these gene expression changes may also contribute to the 
development of EBV associated malignancies. The aim of this work was to investigate the 
role of cellular miRNAs in EBV induced transformation and oncogenesis.  
(a) The regulation of miR-155 by EBV 
The precursor of the oncogenic miR-155 (BIC) was reportedly up-regulated in HL [612] and 
miR-155 expression was shown to be elevated in LCLs [374, 603]. We demonstrated that 
miR-155 expression was up-regulated by a latency III pattern of viral gene expression and by 
induced expression of the viral oncogene LMP1. The investigation into the regulation of miR-
155 by EBV, involved the re-analysis and clarification of  a previously published result which 
apparently demonstrated a processing defect in BL cell lines [375]. Using newly available 
miRNA QPCR assays, we were able to demonstrate that the data in this previous report was 
misinterpreted largely as a result of the limited sensitivity of northern blotting, the only 
technique previously available to measure miRNA expression; emphasising the caution with 
which the literature at that time needed to be interpreted. 
The role of miR-155 in EBV induced cellular transformation was an area of much interest in 
the field, with many reports published regarding the potential role of this miRNA in EBV 
induced cellular transformation and oncogenesis, prompting our research to focus on the 
identification of novel miRNAs modulated by EBV. However, it was not until recently that 
the definitive result was published which demonstrated that miR-155 was essential for LCL 
growth, as miR-155 inhibition in an LCL has been shown to cause cell-cycle arrest and 
spontaneous apoptosis [646]. The cellular gene targets of miR-155 during transformation have 
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still not been identified and miR-155 inhibition was shown not to affect LMP1 or EBNA2 
protein expression [646], therefore, the mechanism by which miR-155 promotes EBV 
mediated transformation remains to be elucidated. The dependence of LCLs on miR-155 
expression demonstrates the importance of miR-155 in B cell transformation and highlights a 
possible weakness in the criteria which we applied to identify novel transformation associated 
miRNAs as miR-155 is strongly up-regulated in both EBV and CD40L blasts. Although not 
tested experimentally, we would predict that proliferation of CD40 blasts would also be 
impaired by inhibition of miR155. 
(b) Cellular miRNAs modulated by EBV during transformation 
It is clear from our results that EBV does modulate the cellular miRNA expression of B cells 
during the process of B cell transformation. These expression changes include the up-
regulation of seven oncogenic miRNAs , including miR-17-92 cluster, miR-21 and miR-155. 
Interestingly, all of the aforementioned oncogenic miRNAs are also up-regulated in 
proliferating B cell blasts, which can only transiently proliferate in culture; therefore the up-
regulation of these miRNAs is not sufficient to induce continuous proliferation or 
transformation of B cells. This led us to focus on the miRNAs which were differentially 
expressed between EBV and CD40L blasts, reasoning that these miRNA and gene expression 
changes may be key to the transformation process. However, in retrospect, this view may 
have been too simplistic for a number of reasons:  
Firstly, miRNAs are known to target genes for degradation in a coordinated manner [499]; 
therefore, it is likely that the simultaneous up-regulation of 7 oncogenic miRNAs will 
contribute to EBV-mediated cellular transformation and oncogenesis even though they are  
regulated by both EBV and CD40L. Indeed, our own multiple target prediction analysis 
revealed that 68 genes were predicted to be targeted by 9 or more of the 19 miRNAs up-
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regulated by EBV infection. Thus, the total miRNA expression profile of a cell is important 
when considering the consequences of miRNA gene expression changes in response to EBV 
infection. The multiple miRNA target prediction analysis has also provided a possible 
explanation for the lack of Bim protein repression we observed following transfection of miR-
148a alone into DG75 as multiple miRNA binding sites functioning in cooperation may be 
required for Bim repression. This analysis has also raised the interesting possibility that 10 
miRNAs up-regulated following EBV infection of B cells (including miR-148a) may 
negatively regulate Bim protein expression early following EBV infection, prior to previously 
described EBV-mediated transcriptional and epigenetic down-regulation (figure 6.1). The 
multiple mechanisms employed by EBV to control the expression of Bim indicate that Bim 
mediated down-regulation is very important for transformation and the repression of Bim 
protein expression early post-infection by cellular miRNAs may aid a transforming B cell 
escape apoptosis before more efficient and stable down-regulation, mediated by EBV latent 
genes, can occur. 
Secondly, during the course of this work it was reported that under specific culture conditions, 
CD40L generated B cell blasts can proliferate indefinitely in culture to produce an 
immortalised cell line [718]. That report raises the possibility that the miRNA and gene 
expression changes induced by CD40L and IL4 can, under certain conditions, produce B cell 
blasts which are phenotypically indistinguishable from an LCL. Consequently, the gene and 
miRNA expression changes induced by both EBV and CD40L blasts may also be important 
for cellular transformation.  Nevertheless, it is still the case that in our experiments we were 
comparing two types of blasts; one which was destined to stop proliferating within weeks, and 
a second which would become transformed. 
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The miRNA array and microarray comparison did not identify any cellular genes which were 
predicted to be regulated by any of the differentially regulated miRNAs. This is most likely 
due to the small number of selected genes and miRNAs involved in the analysis. 
Nevertheless, the analysis of the two array sets did identify possible miRNA target genes 
which were modulated in response to both CD40L stimulation and EBV infection. 
Considering the importance of miR-155 in LCL proliferation and survival, future work aimed 
at elucidating the role of cellular miRNAs in EBV-mediated transformation could include the 
cellular genes and miRNAs regulated by both stimuli. It would be interesting to use the 
multiple miRNA target prediction analysis to identify cellular gene targets predicted by the 
microarray comparison, which are also predicted to be regulated by more than one EBV 
regulated miRNA. This would reduce the number of false positive identifications produced by 
the miRNA and gene expression array comparisons, making the identification of genuine 
miRNA target genes more probable.  
The miRNA array identified 7 miRNAs which were differentially expressed between EBV 
and CD40L blasts. Further characterisation of the expression of the differentially regulated 
miRNAs revealed a down-regulation of miR-95 and miR-199a-3p in the latency I Mutu-BL 
clone relative to the EBV loss Mutu-BL clone. This is an interesting result because latency I 
BL cell lines are more resistant to apoptosis than the EBV loss clones [213, 330], although 
extensive gene expression profiling of EBV positive and EBV loss BL clones could not 
identify any cellular gene expression changes common to all BL clones (unpublished results, 
Boyce, A). The down-regulation of miR-95 and miR-199a-3p in EBV positive clones could 
be confirmed on a greater number of BL cell lines. If miR-95 and miR-199a-3p are down-
regulated in EBV positive BL clones, this would provide a novel opportunity to identify genes 
which confer the apoptosis resistant phenotype to EBV positive clones, which are perhaps 
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modulated post-transcriptionally. To test the effect of these miRNAs on the proliferation and 
apoptosis sensitivity of BL cell lines, a lentivirus system could be used to re-express the 
miRNAs in EBV positive BL clones. Similarly, miRNA function could be inhibited in the 
EBV loss BL clones following transduction with a lentivirus expressing a miRNA sponge 
[719]. 
(c) EBV-mediated down-regulation of tumour suppressor genes 
 Cellular gene expression profiling of CD40L and EBV blasts identified 61 genes 
differentially expressed between the two types of blast. Perhaps unsurprisingly, data mining 
revealed that 13 of these genes were associated with the immune response, such as interferon 
stimulated genes and known antiviral genes. This suggests that a significant number of the 
genes which are differentially expressed between EBV and CD40L may not be aiding 
transformation but simply reflecting the host antiviral response triggered by EBV infection. 
Consistent with this observation, the differentially regulated miRNA, miR-199a-3p, has 
recently been identified as a broadly antiviral miRNA [686]. The modulation of 
approximately half of the differentially regulated genes following infection with a Δgp42 
virus may also be partially explained by the fact that some of the antiviral genes are 
responding to virus binding. Nevertheless, the gene expression changes induced by virus 
binding alone are maintained in an LCL, indicating that they could still be involved in EBV-
mediated growth transformation. Signalling through CD21 has been shown to induce cellular 
gene expression changes in B cells, including NF-қB activation and IL6 production [710, 
713], which may account for some of the gene expression changes observed following virus 
binding. However, NF-қB is also activated by CD40 signalling [720], therefore NF-қB 
activation alone cannot account for the gene expression changes induced by EBV binding. 
The role of virus binding could be investigated using agonistic CD21 antibodies which cause 
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signalling through CD21. Additionally, it would be interesting to determine whether the same 
gene expression changes, such as tumour suppressor gene (TSG) down-regulation, could be 
induced through CD21 stimulation of CD40L blasts, and what effect this would have on 
proliferation and cell survival.  
Three of the six genes specifically down-regulated following EBV infection and not CD40L 
stimulation of resting B cells were candidate TSGs. The function of the three candidate TSGs 
down-regulated by EBV will continue to be investigated using the tetracycline inducible 
lentivirus system. However, for reasons already articulated, future work will not focus 
exclusively on the differentially regulated genes and will aim to incorporate the information 
from the global gene expression changes observed following EBV infection. For example, the 
expression and function of the candidate tumour suppressor gene NR4A1, which is down-
regulated following both EBV infection and CD40L stimulation, will be investigated in 
conjunction with NR4A3, as the down-regulation of both of these genes has been reported to 
be required for tumourogenesis [690].  
Both NR4A1 and NR4A3 are members of the NR4A family of orphan nuclear receptors 
[695]. Analysis of the crystal structure of another member of the NR4A family, NR4A2, 
revealed that the ligand binding domain of NR4A2 was unlikely to bind ligand, indicating that 
the NR4A family of receptors may act as real orphan receptors and function independently of 
ligand binding [721]. The function of the NR4A receptors is believed to be mediated, at least 
in-part, via binding to DNA sequences up-stream of gene transcriptional start sites. Cloning of 
NR4A3 revealed that its DNA and ligand binding domains contain amino acid sequences 
which are homologous to those of NR4A1, suggesting that these two receptors may function 
in a similar manner [722]. This is supported by the observation that transgenic mice with 
Conclusions and Future Work 
 
Page 252 
 
mutations in either NR4A1 or NR4A3 show no phenotype, however, double knockout mice 
develop AML, suggesting a redundancy in function between these two receptors [690, 723]. 
It has been demonstrated that NR4A1 and NR4A3 both translocate from the nucleus to the 
mitochondria following stimulation with ionomycin to induce apoptosis [724]. Additionally, 
over-expression of NR4A1 or NR4A3 causes apoptosis of T cells, suggesting that these two 
receptors modulate the apoptosis pathways in T cells [723]. The mechanism by which NR4A1 
and NR4A3 induce apoptosis in T cells was shown to involve the translocation of these two 
receptors to the mitochondria where they associate with Bcl2, causing exposure of the Bcl2-
BH3 domain, converting Bcl2 from an anti-apoptotic protein to a pro-apoptotic protein [696, 
697, 725]. Bim is an antagonist of Bcl2 [726] and it has been hypothesised that NR4A1 and 
NR4A3 both function in conjunction with Bim to modulate apoptosis in T cells undergoing 
negative selection in vivo [696].  
The role of NR4A3 and NR4A1 down-regulation by EBV could be hypothesised to provide 
an additional mechanism exploited by the virus to evade apoptosis, which may even 
compliment the down-regulation of Bim observed in EBV transformed cells. LMP1 has been 
shown to induce Bcl-2 expression during transformation [727, 728] and EBV selectively 
down-regulates Bim, an antagonist of Bcl-2, suggesting that maintaining Bcl-2 expression is 
important for EBV transformation. If both NR4A1 and NR4A3 are able to convert Bcl-2 to a 
pro-apoptotic gene in B cells then it would be reasonable to predict that the down-regualtion 
of these two genes is also important for transformation, to maintain expression of functional, 
anti-apoptotic Bcl-2 (figure 6.2). In additional to the transcriptional down-regulation of 
NR4A3 and NR4A1 we have demonstrated following EBV infection, it has been reported that 
EBNA2 can directly bind NR4A1 in fibroblast and kidney cell lines, preventing NR4A1 
nuclear export to the mitochondria and consequently NR4A1 mediated apoptosis [698]. It 
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would be interesting to determine whether EBNA2 also binds NR4A3 and whether EBNA2 
sequestration of both genes occurs in B cells. The sequestration of NR4A1 by EBNA2 
suggests that loss of function and expression of NR4A1 and NR4A3 may be an important 
strategy employed by EBV to inhibit apoptosis during B cell transformation. The re-
expression of NR4A1 and NR4A3 would therefore be hypothesised to increase the sensitivity 
of EBV blasts to apoptosis, and this will be investigated using lentiviral expression vectors.  
As lentiviral infection of resting B cells and CD40L blasts is currently very difficult with the 
common vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped lentiviruses which we 
have used to date [729-731], we have obtained a recently described measles glycoprotein 
pseudotyped lentivirus packaging system which has been reported to enable the successful 
transduction of resting B cells and CD40L generated B cell blasts [732]. This will facilitate an 
investigation into the requirement for TSG down-regulation during B cell transformation. B 
cells could be transduced prior to EBV infection, allowing the transformation efficiency of 
TSG expressing (GFP positive) B cells to be compared with non-transduced B cells. 
Furthermore, this would enable the TSG expression to be knocked-down in CD40L blasts, 
following transduction with a siRNA containing lentivirus; allowing the function of the 
candidate TSGs to be comprehensively investigated in B cells.  
In summary, we have shown that EBV modulates cellular gene expression during B cell 
transformation. We have identified a subset of miRNAs and genes which are differentially 
expressed between EBV and CD40L blasts, which may represent genes and miRNAs which 
are specific, and therefore important, to B cell transformation. These include miRNAs which 
are specifically down-regulated in EBV positive BL cell lines relative to EBV loss clones, and 
10 miRNAs which are up-regulated during transformation and which are all predictd to 
negatively regulate Bim expression. In addition, we identified three candidate TSGs which are 
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Figure 6.1: EBV modulation of the pro-apoptotic Bim and NR4A proteins during B cell 
transformation. A cartoon representing the various methods employed by EBV to modulate the 
expression and function of Bim, NR4A1 and NR4A3 following EBV infection of B cells. Bim is 
an antagonist of the pro-survival protein Bcl2 whereas NR4A1 and NR4A3 have been shown to 
convert Bcl2 from a pro-apoptotic to an anti-apoptotic protein, thus, representing two possible 
strategies employed by EBV to enhance cell survival during B cell transformation. (A) Our own 
data has shown that EBV infection of B cells results in the up-regulation of 10 miRNAs which are 
predicted to post-transcriptionally repress Bim expression, providing another possible mechanism 
by which Bim expression is controlled by EBV during transformation. (B) It has also been 
reported that the viral Bcl2 homolog, BHRF1, can bind to and sequester Bim protein, inhibiting 
the apoptotic function of Bim [733]. (C) EBNA3A and EBNA3C have been shown to inhibit the 
transcription of Bim [699] and this down-regulation may be partially mediated via increased 
histone methylation at the Bim promoter during transformation, which in late passage LCLs is 
replaced by CpG island methylation of the Bim promoter [734]. (D) LMP1 and LMP2A have 
been shown to repress the forkhead box class O1 (FoxO1) transcription factor which is known to 
activate the transcription of Bim [735, 736], providing another mechanism by which EBV may 
down-regulate the expression of Bim during transformation. (E) We have demonstrated that the 
pro-apoptotic proteins NR4A1/3 are both down-regualted following EBV infection of B cells. The 
pro-apoptotic function of NR4A1/3 in T cell requires their nuclear export to the mitochondria 
where they bind to Bcl2 and convert it to a pro-apoptotic protein. Thus, NR4A1/3 may also 
function in the induction of apoptosis in B cells. EBNA2 has been reported to bind to NR4A1 
preventing its export to the mitochondria, providing an additional meacnism by which EBV may 
negatively regulate the expression and function of these two pro-apoptotic receptors during 
transformation. 
A 
B 
C 
D 
E 
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down-regulated following EBV infection. In addition, we have also demonstrated that virus 
binding alone induces a significant number of gene expression changes in resting B cells, the 
majority of which are maintained in LCLs, suggesting a possible mechanism where EBV 
stimulates some of the gene expression changes necessary for transformation prior to entering 
the cell.  
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